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General Introduction
Organ transplantation
In the past 60 years, solid organ transplantation is one of the most remarkable and dras-
tic therapeutic achievements in medicine. On December 23, 1954, the first living donor 
kidney transplantation was performed between identical twins1,2. In 1958, successful 
kidney transplantation between non-identical twins was performed3. After the introduc-
tion of immunosuppressive drugs the rate of successful kidney transplantation slowly 
increased during the 1960s4, with not only living donors but also deceased non-related 
donors5. Since kidney transplantation turned out to be feasible, liver transplantation 
was developed some years later6. In 1967, the first successful liver transplantation was 
performed in the United States by Thomas Starzl7. 
Improvements in postoperative outcome made organ transplantation a treatment 
of choice for end-stage organ failure. At present, organ transplantation is a victim of 
its own success. The improved results have increased the number of patients on the 
waiting list for organ transplantation, while numbers of deceased donors have remained 
stable8. Eurotransplant statistics showed that in 20169, 3278 deceased donor kidneys 
have been transplanted and 1338 kidneys from living donors. Besides that, 1528 patients 
received a liver from a deceased donor while 122 patients received a liver from a living 
donor. However, at the end of 2016, still 10476 patients were waiting for a donor kidney 
and 1097 patients were waiting for a liver transplant. In an attempt to overcome this 
discrepancy, not only Donation after Brain Death (DBD) donors are used, but also living 
donors, Donation after Circulatory Death (DCD) donors and extended criteria donors10,11. 
Living donors are healthy during organ procurement and experience minimal warm 
and cold ischemia times, which results in superior long-term graft survival compared 
to DBD- and DCD donors12. DBD donors suffer from hemodynamic instability, hormone 
dysregulation and immunologic reactivity, which contribute to organ damage and af-
fect organ quality13,14. Organs from DCD donors are exposed to a period of hypotension, 
hypoxia and prolonged warm ischemia time. This affects early graft function as well as 
graft survival11,15. Nowadays, the use of extended criteria donors is increasing. Extended 
criteria donors are defined as donors being >60 years old, or aged >50-59 years old with 
≥2 of the following risk factors: history of hypertension, serum creatinine level ≥1.5mg/
dL, or death resulting from a cerebrovascular accident16. The use of DBD-, DCD- and 
extended criteria donors, is associated with more severe ischemia reperfusion injury, 
reducing the organ quality. However, the use of these donors is necessary to overcome 
the gap between organ demand and supply. The pathophysiology that leads to damage 
in DBD- and DCD donors organs is a topic of interest for the development of donor 
specific strategies that might be able to improve post-transplant outcome.
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Ischemia reperfusion injury
During organ transplantation and major surgery, ischemia reperfusion injury (IRI) is 
inevitable and associated with morbidity and mortality17,18. Ischemia is caused by an 
interruption of the blood flow associated with a lack of oxygen and nutrients. This 
results in a decrease of the oxidative metabolism, depletion of ATP and accumulation 
of metabolic products17,19. Reperfusion leads to rewarming, re-oxygenation, and a re-
turn of the aerobic metabolism and the production of ATP. Reperfusion also activates 
an inflammatory response and reactive oxygen species (ROS) are generated in high 
concentrations which rise above the capacity of the antioxidant defence, resulting in 
massive apoptosis17. After IRI, repair and regeneration processes occur together with 
cellular apoptosis, autophagy and necrosis19. 
IRI negatively influences the outcome after transplantation and is a risk factor for 
primary non-function or delayed graft function. IRI is also associated with acute rejec-
tion, and decreased graft and patient survival17,20. Many studies were identified to study 
the mechanisms leading to IRI, and to reduce the impact of IRI on transplant outcome. 
However, at this moment there is no therapy available to prevent or ameliorate IRI. 
Nutritional preconditioning
Dietary restriction (DR) is the reduction in daily calorie and nutrient intake without 
causing malnutrition21,22. A life-long reduction of 30% calorie intake prolongs lifespan, 
increase health span and improve resistance to multiple stressors in a variety of organ-
isms such as yeasts, worms, fruit flies and rodents23. DR was also able to increase lifespan 
in non-human primates, suggesting DR could also work in humans24. Human volunteers 
on a low-calorie diet showed beneficial changes in their physiological and biochemical 
parameters25,26. The energy metabolism generates ROS that causes molecular oxidative 
damage and leads to aging27. DR decreases the rate of ROS production, and increases the 
protection against oxidative stress28. Therefore, DR is a promising strategy to reduce IRI. 
Two weeks of 30% DR had a protective effect on IRI in both kidney and liver29. In addition, 
3 days of fasting induces the same beneficial effects on organ function and improved 
survival22,29,30. The question rises whether the protection of both 2 weeks of 30% DR or 3 
days of fasting is based on the reduction in calorie intake or based on a deficiency of a 
macronutrient (carbohydrates, fat or protein). In fruit flies, long-term protein restriction 
contributed more to lifespan extension than the reduction in carbohydrates31. In fasted 
mice, glucose supplementation did not interfere with the protection against renal IRI30. 
This point towards a protective essential role for one specific (marco)nutrient. However, 
long-term restriction of proteins or 30% DR is not achievable in the clinical setting but 
short-term is. Studies in this thesis focus on the effect of macronutrient- and essential 
amino acid deficient diets on IRI, the length of time on a diet to induce protective ef-
fects and their underlying mechanisms. For implementation in the clinical setting it is 
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important to unravel the underlying mechanism of nutritional preconditioning to be 
able to find a mimetic. 
Mesenchymal stem cells 
Mesenchymal stem cells (MSC) are able to differentiate into cell types other than their 
tissue of origin, secrete growth factors and have immunomodulatory and anti-inflam-
matory properties32,33. Therefore MSC are considered as a potential therapy in organ 
transplantation. Last decades, the effect of MSC in small animal models of hepatic IRI or 
liver regeneration were studied34-39. Results show that MSC have anti-apoptotic and anti-
inflammatory properties and have the potential to reduce hepatic IRI35-37. Moreover, MSC 
have a beneficial effect on liver regeneration after partial hepatectomy34,35,38,39. However, 
the use of MSC in large animal models of IRI showed inconsistent results40,41. It remains 
unclear if and how MSC are able to prevent IRI and/or stimulate regeneration. Besides 
that, only few studies investigated the effect of MSCs in a combined hepatic IRI and 
partial hepatectomy model, while this model is relevant for translation to the clinical 
setting39,42,43. 
Fibulin-4 deficiency 
Previous studies showed that preoperative fasting protects against renal and hepatic IRI 
in a healthy mouse model. We were curious if preoperative fasting also protect against 
renal IRI in a mouse model with aortic wall degeneration that might develop aortic an-
eurysms. Aortic aneurysms are defined as local widening of the artery, several times its 
normal size, and is a cause of morbidity and mortality in the Western world44,45. Rupture 
leads to extensive internal bleeding and is frequently fatal. Of the abdominal aortic an-
eurysms 8-20% are proximal abdominal aortic aneurysms (P-AAA), which are character-
ized by the absence of normal aorta between the upper extent of the aneurysm and the 
renal arteries46,47. During surgical repair of P-AAA the renal arteries are clamped, which 
causes renal IRI47,48. Renal IRI can lead to renal insufficiency, which has been reported 
as the most frequent complication to suprarenal clamping, and occurs in 22% of the 
patients47,49. Renal insufficiency is a major cause of morbidity, can lead to dialysis and is 
associated with prolonged hospitalization50. Besides that, mortality after surgical P-AAA 
repair is reported to be 3-8% compared to 1-5% after elective infrarenal abdominal aortic 
aneurysm repair47,50. Standard endovascular repair (EVAR) is feasible in abdominal aortic 
aneurysms and reduces morbidity and mortality51. However, in patients with P-AAA the 
use of standard EVAR is limited by anatomic restrictions, high costs, and manufacturing 
lead times51,52. Therefore, open surgical repair is still used in patients with P-AAA. 
Aortic aneurysms show destructive extracellular matrix remodelling, apoptosis of 
smooth muscle cells, and inflammatory cell infiltration. Besides gender, age, and life-
style-related risk factors, there is evidence that genetic determinants play a role in the 
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development of aortic aneurysms53. Fibulin-4 is an elastic fiber-associated glycoprotein, 
which plays a role in organization of the extracellular matrix, elasticity and integrity44,54. 
A Fibulin-4 knockout mouse displays embryonic death due to aortic rupture55. In a 
heterozygous Fibulin-4 deficient mouse model, the expression of Fibulin-4 is 2-fold re-
duced compared to wild type mice. This results in aortic wall degeneration, elastic fiber 
fragmentation and significantly more local regions of disorganized extracellular matrix 
and collagen fibers55. The heterozygous Fibulin-4 mouse might be a relevant model to 
learn about the early onset of aortic degeneration and the effect of stressors on blood 
vessel walls. Since renal IRI is inevitable during surgical repair of P-AAA and treatment of 
renal IRI is still unsatisfactory, we used this Fibulin-4 deficient mouse model to explore 
the local and systemic effects of P-AAA repair related renal IRI. Since previous studies 
showed that preoperative fasting protects against renal IRI22, we also investigated the 
effects of preoperative fasting in Fibulin-4 deficient mice.
Aim and outline of the thesis
In the first part we investigated the impact of donor type on transcriptional changes 
that occur after organ retrieval and cold storage in kidneys and livers from living donors, 
DCD and DBD donors. Further studies describe the use of nutritional preconditioning 
and infusion of mesenchymal stem cells as possible treatments to ameliorate IRI. Finally, 
a mouse model with reduced expression of Fibulin-4 was used to study the local and 
systemic effects of renal IRI in short- and long-term. 
A review of the literature on possible treatment options against renal IRI and the trans-
lation from animal experiments towards the clinical setting is described in chapter 2. 
In chapter 3, the impact of living donation, DBD and DCD on transcriptional changes 
that occur after organ retrieval and cold storage in rat kidneys is investigated. Expres-
sion levels of genes indicative of inflammation, cytoprotection, and injury after clini-
cally relevant cold ischemia times were examined. Immunohistochemistry with an early 
apoptotic marker was performed on DBD- and DCD donor kidneys. In chapter 4, the 
expression levels of inflammatory, cytoprotective and injury genes were examined in 
rat livers from living donors, DBD and DCD donors. The numbers of apoptotic cells were 
counted in DBD- and DCD livers after cold preservation. 
In chapter 5, we investigated in a mouse model whether a preoperative macronutri-
ent free diet protects against renal IRI. We studied food intake, body weight, and kidney 
function. To unravel the protective mechanism of the diets with a beneficial effect on 
renal IRI, we created and analysed an unique microarray dataset of different (non-)pro-
tective dietary interventions. In chapter 6, we studied the protective effect of essential 
amino acid deficient diets in a mouse hepatic IRI model. Besides phenotypical data, we 
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used microarray analysis to unravel the specific pathways and/or transcription factors 
involved in inducing the protective state. 
In chapter 7, the effect of intravenous infusion of fat derived mesenchymal stem cells 
in a mouse model of combined hepatic IRI and partial hepatectomy is studied, focus-
sing on liver damage and liver regeneration. In chapter 8, a mouse model with reduced 
expression of Fibulin-4 is used to explore the effect of renal IRI on kidney damage in 
short- and long-term. We also investigated the effect of preoperative fasting on kidney 
damage in the heterozygote Fibulin-4 mouse model. 
Finally, in chapter 9, the findings of this thesis are summarized and discussed, and 
suggestions are made for future research. 
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Abstract
Kidney transplantation is the treatment of choice in patients with end stage renal 
disease. During kidney transplantation ischemia reperfusion injury (IRI) occurs, which 
is a risk factor for acute kidney injury, delayed graft function and acute and chronic 
rejection. Kidneys from living donors show a superior short- and long-term graft survival 
compared with deceased donors. However, the shortage of donor kidneys has resulted 
in expansion of the donor pool by using not only living- and brain death donors but 
also kidneys from donation after cardiac death and from extended criteria donors. These 
grafts are associated with an increased sensitivity to IRI and decreased graft outcome 
due to prolonged ischemia and donor comorbidity. Therefore, preventing or amelio-
rating IRI may improve graft survival. Animal experiments focus on understanding the 
mechanism behind IRI and try to find methods to minimize IRI either before, during 
or after ischemia. This review evaluates the different experimental strategies that have 
been investigated to prevent or ameliorate renal IRI. In addition, we review the current 
state of translation to the clinical setting. Experimental research has contributed to the 
development of strategies to prevent or ameliorate IRI, but promising results in animal 
studies have not yet been successfully translated to clinical use. 
Lost in translation?
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Introduction
Kidney transplantation is the treatment of choice in patients with end stage renal 
disease. Increased prevalence of end stage renal disease, and improved results after 
kidney transplantation have contributed to the increased shortage of donor organs 
and the need to expand the donor pool1,2. Organs from living donors have a superior 
graft survival compared with deceased donors3,4. The superior outcome of living donor 
kidneys is associated with shorter warm and cold ischemia, shorter waiting time for the 
recipient and ‘healthier’ donor kidneys5. Warm ischemia occurs after the blood supply 
has been cut off while the organ is still in the donor. During storage of the donor organ, 
the temperature is reduced to approximately 4oC. During this cold ischemia period, me-
tabolism is significantly reduced which allows for prolonged preservation of the organ 
until transplantation. 
To bridge the growing gap between organ demand and supply, Donation after Circu-
latory Death (DCD) donors6 and extended criteria donors are increasingly being used3-5. 
Donation after Brain Death (DBD) donors are exposed to physiological changes during 
brain death, which may lead to organ damage and inferior graft survival compared to 
living donors7,8. DCD donors do not develop the physiological changes of DBD donors, 
but suffer from prolonged warm ischemia times during cardiac arrest. DCD kidneys have 
an increased incidence of delayed graft function (DGF) of 73% compared to 27% in DBD 
kidneys9, while the rate of acute rejection is similar in both. Despite the higher incidence 
of DGF, DCD kidneys show no differences in long-term graft survival compared with DBD 
kidneys6,10.
Although the use of DCD donors has been increased, the total number of cadaveric 
donors remains stable, while the waiting list continues to grow6,11. Therefore, the num-
ber of extended criteria donors is increasing. Extended criteria donors are defined as 
donors being >60 years old, or aged >50-59 years old with ≥2 of the following risk fac-
tors: history of hypertension, serum creatinine level ≥1.5 mg/dL, or death resulting from 
a cerebrovascular accident12,13. Organs from extended criteria donors are associated 
with a higher incidence of DGF, lower graft survival and suboptimal kidney function13,14. 
Recipients of kidneys procured from extended criteria donors show an 1.7 fold greater 
risk of graft lost compared to recipients with a kidney from an ‘ideal donor’ (10-39 years 
old without hypertension or stroke as a cause of death and a serum creatinine concen-
tration <1.5mg/dL)15. 
Ischemia reperfusion injury (IRI) is an inevitable consequence of kidney transplanta-
tion and has major consequences for graft- and patient survival16-18. Renal IRI is a known 
risk factor for DGF19, acute kidney injury20 and acute and chronic rejection21. Donor type 
is strongly associated with the severity of renal IRI22. DCD donors and extended criteria 
donors are more vulnerable to IRI since donor kidneys suffer from prolonged warm isch-
22
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emia time, increased donor age or comorbidity of the donor13,14. Prevention or reduction 
of IRI could improve graft survival and decrease patient morbidity. 
Renal ischemia reperfusion injury
Renal IRI is unavoidable during transplantation and is a risk factor for DGF19, acute kid-
ney injury18,23 and acute and chronic rejection24,25. Acute kidney injury is associated with 
high morbidity, prolonged hospitalization, and increased mortality20,26. During ischemia 
there is a lack of O2 and nutrients, which results in a decrease of oxidative metabolism, 
accumulation of metabolic waste products and depletion of ATP19,20. Reperfusion leads 
to rewarming, re-oxygenation and a return to aerobic metabolism. However, reactive 
oxygen species are generated which directly injure the cytoskeletal and functional cellu-
lar components19. Normally, antioxidant enzymes may counteract the effects of reactive 
oxygen species, but their protective effect is overwhelmed by the rapid production of 
reactive oxygen species, resulting in tissue injury and cell death27. During reperfusion, 
tissue injury is exacerbated by an inflammatory response, which initiates a cascade of 
deleterious cellular responses18,19. Inflammatory cytokines are up-regulated, and che-
mokines and complement are released, which results in the migration and activation 
of leukocytes. The mechanism underlying IRI is multifactorial. Due to its complexity, 
IRI provides different targets to prevent or ameliorate renal IRI before, during or after 
transplantation23.
Strategies to ameliorate renal IRI
Strategies to reduce renal IRI can be implemented in both donor and recipient, and 
before, during and after transplantation. Treatment of IRI can be focused on scavenging 
reactive oxygen species, reducing inflammation, stimulating cell survival and regenera-
tion, or a combination thereof. Prevention of ischemia is impossible by inducing resis-
tance against ischemia before organ retrieval. Pre-treatment of living donors is feasible, 
provided it does not affect the health and wellbeing of the donor. In post-mortem 
donors the situation is more difficult since these donors are not able to give informed 
consent and ethical issues may rise. During preservation treatment is possible by using 
machine preservation and/or by adding protective agents to the perfusion fluid, pre- or 
post-conditioning is feasible during transplantation. After transplantation, treating the 
recipient, after informed consent, may reduce the damage caused by IRI. In this review, 
we focus on experimental and clinical studies on dietary preconditioning, preservation, 
ischemic pre- and post-conditioning, cell therapy, pharmacological treatment and mi-
croRNAs as intervention strategies to reduce renal IRI. In addition, we review the current 
state of translation to the clinical setting of these interventions (Figure 1). 
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pable of ameliorating renal ischemia reperfusion injury in animal models.
Dietary preconditioning
Dietary restriction is a reduction in food intake without malnutrition, and is associated 
with extended life span, improved metabolic fitness and increased resistance to oxida-
tive stress in a wide range of organisms28-30. In mice, short-term 30% dietary restriction or 
3 days of fasting, reduced kidney damage and dysfunction and improved survival after 
renal IRI30. Short-term dietary restriction and fasting increased expression of cytoprotec-
tive genes and decreased the expression of inflammatory markers30. Food restriction 
leads to a reduction in both calorie and nutrient intake, yet the contribution of calories 
or nutrients to the protective effect on renal IRI is unknown28. Verweij et al.31 showed that 
the benefits of preoperative fasting are not affected by the intake of calories via glucose 
water during fasting from solid food. Subsequently, diets lacking protein or even the es-
sential amino acid tryptophan for 6-14 days resulted in similar protection against renal 
IRI in mice32-34. Therefore, a preoperative calorie restricted diet might be a non-invasive 
way to reduce IRI after human kidney transplantation. Although the beneficial effects of 
a preoperative diet are in apparent conflict with the patients’ nutritional wellbeing35,36, 
several recent clinical studies showed that the human response to dietary restriction is 
similar to that observed in experimental mammalian models37,38. In human living kidney 
donors short-term dietary restriction before surgery is feasible, well tolerated and safe39, 
although the conditions to induce a similar powerful protection against IRI as in mice 
have not been elucidated yet. More clinical research is needed to translate the beneficial 
effect of preoperative diets from animals to humans. 
Preservation
Another option to decrease IRI is to minimize damage caused during ischemia. 
Prolonged cold ischemia time has a strong association with development of DGF19,25, 
but a decrease in cold ischemia time is difficult due to logistics, allocation and organ 
transport. Optimisation of conditions during cold ischemia time is therefore essential. 
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Cold storage solutions were designed to increase organ tolerance and preserve cellular 
integrity during ischemia40,41. Reducing the temperature of the kidney to 4˚C reduces 
enzyme activity, decreases oxygen requirement and lowers metabolism by 58%42. Some 
studies add nutrients or pharmacologically active agents to the preservation solution 
(reviewed in Chatauret et al.43). Cold storage is still considered the gold standard in 
kidney preservation. 
During machine perfusion, the organ is attached to a machine during preservation, 
which pumps preservation solution through the organ. It creates the possibility to main-
tain hemodynamic stimulation, administer nutrients to the kidney and even eliminate 
toxins. A large international prospective randomized controlled trial The Netherlands 
showed the benefits of machine perfusion by reducing the incidence and duration 
of DGF, in DCD kidneys44. Also, machine perfusion of extended criteria donor kidneys 
reduced the rate of DGF45,46, is feasible and safe47. In a meta-analysis, Deng et al.48 com-
pared the transplant outcomes in patients receiving DCD kidneys preserved by machine 
perfusion or by static cold storage. Recipients with a DCD kidney preserved by machine 
perfusion had a decreased incidence of DGF compared to static cold storage. However, 
there is no significant difference between the two groups in incidence of primary non-
function, graft survival or patient survival after one year. 
Hypothermic machine preservation slows down the metabolism of the kidney and 
allows an organ to be stored without oxygen for a short period of time but this process 
also causes cellular damage. Therapeutic agents have been added to the preservation 
solution during hypothermic machine preservation but the hypothermic conditions 
make it difficult for the agent while the metabolism is blocked. Maintaining the kidney 
at a normothermic temperature has many advantages. The kidney is able to regain 
function and can minimize the cold ischemia time. The kidney can be maintained in a 
stable state and it provides the opportunity to add therapeutical agents to a functioning 
organ49. Machine perfusion is one of the therapeutic interventions that is making the 
translation to humans. Randomized controlled trials are now being developed and will 
guide machine perfusion into the clinical arena.
Ischemic Pre-/Post-conditioning
Ischemic conditioning is defined as applying a brief ischemic insult to an organ through 
brief (repetitive) sequences of ischemia and reperfusion before or after an ischemic 
attack to provide resistance against IRI. Ischemic preconditioning (IPC) and ischemic 
post-conditioning (IPoC) were both developed in cardiac research, but may be applied 
in the kidney as well, reviewed in Kierulf-Lassen et al.50
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Ischemic pre-conditioning
In 1986, protection against IRI by IPC was first seen in canine hearts51. Dogs were pre-
conditioned with four repetitive sequences of ischemia and reperfusion each 5 minutes, 
followed by 40 minutes of occlusion. IPC limited infarct size to 25% compared to the 
control group. After these findings many animal experiments have been done to repro-
duce this protective effect in other organs52. In the kidney, IPC induces improved renal 
function and histology after transplantation53.
In remote IPC, the ischemic trigger is not applied locally to the target organ, but on 
another ‘remote’ organ54. Patients undergoing elective coronary artery bypass graft 
surgery underwent remote IPC consisting of three 5-minute cycles of right upper limb 
ischemia directly after anesthesia. Remote IPC reduced serum troponin-T release com-
pared to patients undergoing coronary artery bypass graft surgery without IPC55. 
In a rat model, renal IRI was induced by a right nephrectomy and clamping the left 
renal artery for 60 minutes. Remote IPC was induced by 5-minute cycles of ischemia and 
reperfusion, occluding the right hind limb. The remote IPC groups showed lower levels 
of kidney dysfunction and damage56. In a renal IRI pig model, remote IPC was induced by 
clamping the left iliac artery for 10 minutes, which showed no beneficial effects on renal 
function or histology57. In humans, kidney transplant recipients underwent remote IPC 
and were compared to paired recipients without IPC. Remote IPC was induced by three 
cycles of 5 minutes of brief repetitive ischemia by clamping the exposed external iliac 
artery. Serum creatinine levels were lower in the remote IPC group, while glomerular 
filtration rates were higher during the first 14 days post-transplant. These results suggest 
that remote IPC has beneficial effects on the early recovery of renal function after kidney 
transplantation58. 
Remote preconditioning is a potential therapeutic strategy that can reduce renal IRI, 
and is simple to apply, non-invasive and virtually cost-free, but large multi-center clinical 
trials using remote IPC are needed to improve the level of evidence and implement re-
mote IPC in the clinical setting. Results of a large international prospective randomized 
controlled trial (CONTEXT trial) are eagerly awaited59.
Ischemic post-conditioning
IPoC, defined as rapid, intermittent interruptions of blood flow at the onset of reperfu-
sion can reduce myocardial infarct size in animal models60,61. The use of IPoC in humans 
undergoing cardiac surgery showed better post-operative outcomes62. Similar beneficial 
effects have also been observed in animal models of renal IRI63. IPoC reduced tubular 
necrosis after reperfusion, and attenuated renal dysfunction64. Its observed benefits 
are associated with an enhanced expression level of SOD and inhibition of apoptosis65. 
These effects are seen in different animal species with different index ischemia times 
and different algorithms. Only two studies did not observe a significant difference in 
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renal function, which could be explained by the time points of analyzing renal function, 
which were either too early (2 hours) or too late (12 weeks) after reperfusion66,67. 
Contrary to IPoC, remote IPoc has only been performed in 2 renal IRI rat studies56,68. 
Remote IPoC of the hind limb resulted in significant improvement in renal function 24 
hours after IRI. Sequences of ischemia and reperfusion during the ischemic episode, 
PER-conditioning, was able to reduce renal IRI even further68. As with IPC, the first at-
tempts to translate IPoC into human kidney transplantation are already being done69. 
Unfortunately, the robust beneficial effects as seen in animal experiments, have not 
been observed yet. IPoC is feasible and safe in patients undergoing kidney transplanta-
tion, but the proper algorithm that reduces the incidence of DGF still has to be found69.
Cellular therapy 
Administration of cells to modulate the course of IRI has attracted considerable interest. 
Two cell types in particular, mesenchymal stem cells (MSC), and regulatory T cells (Tregs) 
have been investigated.
MSC are able to differentiate into cell types other than their tissue of origin, are non-
immunogenic, immunosuppressive, able to migrate, secrete growth factors and anti-
apoptotic cytokines70, and might play a role in tissue repair. Due to these characteristics, 
MSC are promising as a cell therapy to reduce renal IRI. In rodent renal IRI models, MSC 
were able to up-regulate the cytoprotective genes HO-1 and SOD71-73, reduce oxidative 
stress and apoptosis71, and improve kidney function71,72,74. Furthermore, kidneys treated 
with MSC showed a stronger regenerative response75.
Subsequently, in large-animal models, MSC failed to reduce cell death and no changes 
in proliferation or cytokine release were found76,77. It might be that the optimal time win-
dow for stem cell therapy is different in large-animal models than in rodents. Another 
problem is poor cell survival of injected MSC. After intravenous injection MSC home 
to the lungs and within 24 hours the majority of MSC die, MSC do not migrate to the 
site of injury and do not contribute to structural renal repair78. This suggests that the 
effect of the MSC might result from paracrine or endocrine effects unrelated to their 
differentiation capacity78-82. 
Early clinical trials have attempted to translate the potential immunosuppressive 
effects of MSC, but results were not convincing. Perico et al.83 were the first to report 
on two patients undergoing living kidney transplantation and receiving an infusion of 
autologous MSC on post-transplant day 7. Serum creatinine levels were increased in 
MSC-treated patients 7 to 14 days after infusion, suggesting dysfunction of the graft. One 
year post-transplantation kidney biopsies showed no signs of rejection. Their conclusion 
was that MSC therapy in kidney transplantation is feasible, although timing, doses and 
immunosuppressive medication may need to be adapted for optimal effect. Reinders 
et al.84 studied the feasibility of autologous MSC administration in kidney transplanta-
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tion recipients and showed it to be feasible and safe, although the study does not allow 
conclusions on efficacy. Peng et al.85 combined MSC with a sparing dose of Tacrolimus 
(50% of standard dose) in living-related kidney transplant recipients. Patients received 
two infusions of MSC, the first directly into the renal artery at the time of transplantation, 
the second intravenously one month later. Results suggest that MSC therapy is safe and 
could reduce the dosage of Tacrolimus. The results of both animal models and clinical 
trials are encouraging, but the low number of randomized controlled trials and small 
numbers of patients make it difficult to draw definitive conclusions and implement MSC 
therapy in transplantation86. 
The knowledge that Tregs have a crucial role in control of autoimmunity and tolerance 
induction in transplantation has made the induction of-, or infusion of Tregs a possible 
treatment for an array of inflammatory conditions, IRI. In humans, intravenous infusion 
of Tregs is not only feasible and safe, but reduced the incidence of graft versus host 
disease in patients with hematologic malignancy that were treated with stem cell trans-
plantation87. Furthermore, after inducing renal IRI in rodents, Tregs are able to suppress 
renal inflammation and preserve renal function88. In a mouse model, Treg deficiency 
resulted in enhanced renal inflammation, acute tubular necrosis and loss of function. 
Suppletion of Tregs protected mice from renal dysfunction and improved survival89. 
Although the use of Tregs as a cellular therapy against renal IRI seems promising, studies 
in humans with renal IRI are lacking. The use of Tregs in humans is troubled by numerous 
challenges. The dose of Tregs needed for therapeutic efficacy is unclear, the isolation of 
pure Tregs is difficult due to the absence of Treg-specific cell surface markers and safety 
is still a topic of concern90. 
Pharmacological treatment 
Although many pharmacological agents are effective in experimental models of IRI and 
acute kidney injury, none of these have successfully been implemented in standard 
clinical care protocols. With few exceptions, most do not enter the clinic. An overview 
of tested pharmacological substances is given by Bajwa et al.91. Of the eight substances 
that might reduce inflammation and reduce cytotoxicity they focused on, only two were 
tested in clinical studies for acute kidney injury (statins and erythropoietin). However, 
in human studies the results on renal IRI induced acute kidney injury are conflicting. 
Retrospective case controlled studies found that statins reduced acute kidney injury in 
patients with contrast-induced nephropathy92,93, whereas a prospective study did not 
find any beneficial effects94. Remarkably, a number of observational studies suggested 
that in the first few weeks and months of starting a statin, statins were associated with 
the early development of acute kidney95. Due to the adverse data and the lack of good 
prospective randomized controlled trials, there is no evidence that statins reduce the 
incidence of acute kidney injury. 
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Preconditioning with erythropoietin protects against IRI in rodents96,97. Encouraged 
by these results erythropoietin was injected intravenously in humans before surgery, 
and was able to reduce the incidence of acute kidney injury in patients who underwent 
a coronary artery bypass98. Xin et al.99 published a meta-analysis including four random-
ized controlled trials that investigated high-dose erythropoietin on graft function after 
kidney transplantation. The results showed that high-dose erythropoietin is able to 
reduce the number of patients with DGF, but these results did not reach significance. 
However, Vlachopanos et al.100 published a meta-analysis to explore the impact of 
recombinant human erythropoietin on DGF in kidneys from deceased donors. Four ran-
domized controlled trials were included and perioperative high-dose recombinant hu-
man erythropoietin was compared with placebo or no therapy. High-dose recombinant 
human erythropoietin did not affect mortality, acute rejection, DGF or kidney function 
4 weeks after transplantation. Remarkably, the systolic blood pressure was significantly 
higher in patients treated with recombinant human erythropoietin. These results ques-
tion the efficacy and safety of high-dose human recombinant erythropoietin in humans. 
Despite the promising results in animal models, translating these findings to the clinic 
is difficult. Variable factors as dosage and time points of injection might be a topic of 
interest for further clinical trials. 
Recently, nonerythropoietic peptides derived from the three-dimensional structure of 
erythropoietin were shown to exert tissue protective properties. It was shown that the 
helix B surface peptide of erythropoietin is responsible for the tissue protective effect 
of erythropoietin and has a much better stability101. In a mouse renal IRI model, helix B 
peptide improved renal function, decreased apoptosis, inflammation and histological 
injury102. Yang et al.103 added the helix B peptide to preservation and reperfusion solu-
tions used to normothermically perfuse porcine kidneys after 20 minutes of warm isch-
emia and 18 hours of cold ischemia. Adding helix B peptide to the reperfusion solution 
improved the renal blood flow, oxygen consumption and urine output during reperfu-
sion and decreased renal tissue damage. Helix B peptide could be the key needed to 
translate the beneficial effects of erythropoietin to human transplantation.
MicroRNA’s
MicroRNA’s are RNA-molecules of 20-25 nucleotides long. They are capable to inhibit 
protein transcription by stimulating degradation of mRNA104. The majority of gene ex-
pression is regulated in this way. A promising quality of microRNA’s is their stability in 
body fluids105, which makes them a good candidate to act as a biomarker or as a thera-
peutical target. One microRNA can inhibit more than 100 genes, so determining the role 
of microRNAs in IRI is difficult. The few studies on microRNAs in renal IRI failed to elucidate 
an unequivocal microRNA-signature106-108. Expression profiling of microRNAs following 
renal IRI in a mouse model showed that nine miRNAs (miR-21, miR-20a, miR-146a, miR-
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199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) are differently expressed 
compared to sham animals108. In vitro studies revealed that miR-21 is expressed in pro-
liferating tubular epithelial cells, and overexpression of miR-21 has a protective effect 
against cell death. This might suggest that miR-21 plays a role in protection against IRI. 
In humans, microRNA expression profiles have been analysed to see if microRNAs may 
predict the outcome after kidney transplantation106,107. In renal biopsies of patients with 
acute rejection, 20 differentially expressed miRNAs were identified106. These expression 
profiles may provide useful information about the outcome after kidney transplantation. 
Unfortunately, research so far has not brought major insights in the role of microRNAs as 
therapeutic target or agent in both animals and humans109. 
Discussion 
The improved results after kidney transplantation and the increased waiting list have 
contributed to the growing gap between organ demand and supply. Extension of the 
donor pool is needed to diminish this gap. Therefore, there has been a shift to the use 
of DCD donors and extended criteria donors. DCD donors have an increased incidence 
of DGF compared to DBD donors, while the rate of acute rejection is similar in both 
groups9,10. Kidneys from extended criteria donors have a higher risk of DGF, lower graft 
survival and suboptimal kidney function13,14. Although renal IRI is inevitable during 
transplantation and has detrimental effects on the outcome, there is no therapy avail-
able. Therefore, finding a method to ameliorate renal IRI is of major interest. 
Renal IRI can be treated before-, during-, and after- transplantation, or a combination 
thereof. When treatment is applied before ischemia, translation of these data is difficult 
since in the human setting, treatment before ischemia would imply treatment of the 
donor. This raises ethical concerns in DCD donors110. During treatment of the living 
donors, the donor must give full consent and treatment should not interfere with the 
donor’s health. An option for treatment of the (living) donor before transplantation 
is dietary preconditioning. Van Ginhoven et al.39 showed that dietary pretreatment of 
living donors is feasible and safe, but the robust effects on reducing IRI as observed in 
mice are lacking. Despite many experimental studies which show beneficial effects on 
an array of treatments and interventions against IRI, translation to humans has not been 
successful111. 
In animal experiments, genetic variability is low and mostly young, healthy, males are 
used. This is obviously not representative for the population that is undergoing kidney 
transplantation and is experiencing renal IRI. Overweight, comorbidities, old age, gen-
der and the use of medication can all interfere with the effects of studied methods to 
ameliorate renal IRI112,113. Another limitation of animal experiments may be the use of 
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warm ischemia models to mimic transplantation induced IRI30,31,71,74. The use of cellular 
therapy is difficult to translate to humans due to the differences between animals and 
humans. More clinical trials are needed to evaluate the effect of both MSC and Tregs. It 
would be of tremendous value to use MSC, or to be able to induce the production of 
Tregs in the recipient to ameliorate renal IRI. 
Besides these translational difficulties, another problem in the treatment of IRI is its 
pathophysiological complexity. Many pathological mechanisms contribute to IRI and 
can be focused on. Studies on IRI treatment are therefore divers, and the probability to 
find a single therapeutical agent is low. Besides that, experimental therapeutical agents 
may induce adverse side effects114-117 or be carcinogenic118,119 which limits their use in 
humans. Another difficulty in translating animal results into humans is the publication 
bias. It is difficult to get an objective overview of the results of experimental therapies 
since there may be a bias towards publication of studies with a positive outcome120. 
Nevertheless, machine perfusion and (remote) ischemic pre- and post-conditioning 
are promising treatment options, which are feasible and safe. Especially machine perfu-
sion induces beneficial effects on kidney function after transplantation in various donor 
types, and large randomized controlled trials are being conducted. The use of machine 
perfusion is actually making the translation to the clinical arena. 
Renal IRI is a highly relevant detrimental consequence of kidney transplantation and 
therefore an important topic in transplantation research. Studying renal IRI is complex 
though, coping with translational difficulties, and multifactorial pathophysiological 
mechanisms. Although animal studies have resulted in promising methods to amelio-
rate renal IRI, we are still lost in translation since only few animal data are finding their 
way into the clinic and improve transplant outcome. This gap in our understanding of 
IRI may be filled in the next years with new data derived from more sophisticated animal 
models and results of large randomized controlled trials.
Lost in translation?
31
References
 1. Klein AS, Messersmith EE, Ratner LE, Kochik R, Baliga PK, Ojo AO. Organ donation and utilization 
in the United States, 1999-2008. Am J Transplant 2010;10:973-86.
 2. Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with 
dialysis in clinically relevant outcomes. Am J Transplant 2011;11:2093-109.
 3. Gjertson DW, Cecka JM. Living unrelated donor kidney transplantation. Kidney Int 2000;58:491-9.
 4. Chkhotua AB, Klein T, Shabtai E, et al. Kidney transplantation from living-unrelated donors: 
comparison of outcome with living-related and cadaveric transplants under current immunosup-
pressive protocols. Urology 2003;62:1002-6.
 5. Sapir-Pichhadze R, Young A, Joseph Kim S. Living donor age and kidney transplant outcomes: an 
assessment of risk across the age continuum. Transpl Int 2013;26:493-501.
 6. Le Dinh H, Weekers L, Bonvoisin C, et al. Delayed graft function does not harm the future of 
donation-after-cardiac death in kidney transplantation. Transplant Proc 2012;44:2795-802.
 7. Schuurs TA, Morariu AM, Ottens PJ, et al. Time-dependent changes in donor brain death related 
processes. Am J Transplant 2006;6:2903-11.
 8. Nijboer WN, Moers C, Leuvenink HG, Ploeg RJ. How important is the duration of the brain death 
period for the outcome in kidney transplantation? Transpl Int 2011;24:14-20.
 9. Nagaraja P, Roberts GW, Stephens M, et al. Influence of delayed graft function and acute rejec-
tion on outcomes after kidney transplantation from donors after cardiac death. Transplantation 
2012;94:1218-23.
 10. Wadei HM, Heckman MG, Rawal B, et al. Comparison of kidney function between donation 
after cardiac death and donation after brain death kidney transplantation. Transplantation 
2013;96:274-81.
 11. 2011. at http://www.eurotransplant.org/cms/mediaobject.php?file=year_20131.pdf.)
 12. Pascual J, Zamora J, Pirsch JD. A systematic review of kidney transplantation from expanded 
criteria donors. Am J Kidney Dis 2008;52:553-86.
 13. Martinez-Vaquera S, Navarro Cabello MD, Lopez-Andreu M, et al. Outcomes in renal transplanta-
tion with expanded-criteria donors. Transplant Proc 2013;45:3595-8.
 14. Balaz P, Rokosny S, Wohlfahrtova M, et al. Identification of expanded-criteria donor kidney grafts 
at lower risk of delayed graft function. Transplantation 2013;96:633-8.
 15. Domagala P, Kwiatkowski A, Perkowska-Ptasinska A, et al. Assessment of kidneys procured from 
expanded criteria donors before transplantation. Transplant Proc 2009;41:2966-9.
 16. Johnson KJ, Weinberg JM. Postischemic renal injury due to oxygen radicals. Curr Opin Nephrol 
Hypertens 1993;2:625-35.
 17. Kusch A, Hoff U, Bubalo G, et al. Novel signalling mechanisms and targets in renal ischaemia and 
reperfusion injury. Acta Physiol (Oxf ) 2013;208:25-40.
 18. Jang HR, Ko GJ, Wasowska BA, Rabb H. The interaction between ischemia-reperfusion and im-
mune responses in the kidney. J Mol Med (Berl) 2009;87:859-64.
 19. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. 
Lancet 2004;364:1814-27.
 20. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 
2011;121:4210-21.
 21. Kosieradzki M, Rowinski W. Ischemia/reperfusion injury in kidney transplantation: mechanisms 
and prevention. Transplant Proc 2008;40:3279-88.
32
Chapter 2
 22. Ali S, Sheerin NS. Biomarkers of acute injury: predicting the long-term outcome after transplanta-
tion. Kidney Int 2013;84:1072-4.
 23. Devarajan P, Mishra J, Supavekin S, Patterson LT, Steven Potter S. Gene expression in early isch-
emic renal injury: clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol 
Genet Metab 2003;80:365-76.
 24. Fletcher JT, Nankivell BJ, Alexander SI. Chronic allograft nephropathy. Pediatr Nephrol 
2009;24:1465-71.
 25. van der Vliet JA, Warle MC. The need to reduce cold ischemia time in kidney transplantation. Curr 
Opin Organ Transplant 2013;18:174-8.
 26. Thurman JM. Triggers of inflammation after renal ischemia/reperfusion. Clin Immunol 2007;123:7-
13.
 27. Castaneda MP, Swiatecka-Urban A, Mitsnefes MM, et al. Activation of mitochondrial apoptotic 
pathways in human renal allografts after ischemiareperfusion injury. Transplantation 2003;76:50-
4.
 28. Robertson LT, Mitchell JR. Benefits of short-term dietary restriction in mammals. Exp Gerontol 
2013.
 29. Gallinetti J, Harputlugil E, Mitchell JR. Amino acid sensing in dietary-restriction-mediated longev-
ity: roles of signal-transducing kinases GCN2 and TOR. Biochem J 2013;449:1-10.
 30. Mitchell JR, Verweij M, Brand K, et al. Short-term dietary restriction and fasting precondition 
against ischemia reperfusion injury in mice. Aging Cell 2010;9:40-53.
 31. Verweij M, van de Ven M, Mitchell JR, et al. Glucose supplementation does not interfere with 
fasting-induced protection against renal ischemia/reperfusion injury in mice. Transplantation 
2011;92:752-8.
 32. Peng W, Robertson L, Gallinetti J, et al. Surgical stress resistance induced by single amino acid 
deprivation requires Gcn2 in mice. Sci Transl Med 2012;4:118ra11.
 33. Mair W, Piper MD, Partridge L. Calories do not explain extension of life span by dietary restriction 
in Drosophila. PLoS Biol 2005;3:e223.
 34. Min KJ, Tatar M. Restriction of amino acids extends lifespan in Drosophila melanogaster. Mech 
Ageing Dev 2006;127:643-6.
 35. Nygren J. The metabolic effects of fasting and surgery. Best Pract Res Clin Anaesthesiol 
2006;20:429-38.
 36. Stuart PC. The evidence base behind modern fasting guidelines. Best Pract Res Clin Anaesthesiol 
2006;20:457-69.
 37. Redman LM, Heilbronn LK, Martin CK, et al. Effect of calorie restriction with or without exercise on 
body composition and fat distribution. J Clin Endocrinol Metab 2007;92:865-72.
 38. Rochon J, Bales CW, Ravussin E, et al. Design and conduct of the CALERIE study: comprehensive 
assessment of the long-term effects of reducing intake of energy. J Gerontol A Biol Sci Med Sci 
2011;66:97-108.
 39. van Ginhoven TM, de Bruin RW, Timmermans M, Mitchell JR, Hoeijmakers JH, Ijzermans JN. Pre-
operative dietary restriction is feasible in live-kidney donors. Clin Transplant 2011;25:486-94.
 40. Hoeger S, Lueg G, Tsagogiorgas C, et al. UW is superior compared with HTK after prolonged 
preservation of renal grafts. J Surg Res 2011;170:e149-57.
 41. Straatsburg IH, Abrahamse SL, Song SW, Hartman RJ, Van Gulik TM. Evaluation of rat liver 
apoptotic and necrotic cell death after cold storage using UW, HTK, and Celsior. Transplantation 
2002;74:458-64.
Lost in translation?
33
 42. Stubenitsky BM, Ametani M, Danielewicz R, Southard JH, Belzer FO. Regeneration of ATP in kidney 
slices after warm ischemia and hypothermic preservation. Transpl Int 1995;8:293-7.
 43. Chatauret N, Thuillier R, Hauet T. Preservation strategies to reduce ischemic injury in kidney trans-
plantation: pharmacological and genetic approaches. Curr Opin Organ Transplant 2011;16:180-7.
 44. Moers C, Smits JM, Maathuis MH, et al. Machine perfusion or cold storage in deceased-donor 
kidney transplantation. N Engl J Med 2009;360:7-19.
 45. Burgos Revilla FJ, Hevia V, Diez V, et al. Machine perfusion: initial results in an expanded criteria 
donor kidney transplant program. Transplant Proc 2015;47:19-22.
 46. Jochmans I, O’Callaghan JM, Pirenne J, Ploeg RJ. Hypothermic machine perfusion of kidneys 
retrieved from standard and high-risk donors. Transpl Int 2015.
 47. Nicholson ML, Hosgood SA. Renal transplantation after ex vivo normothermic perfusion: the first 
clinical study. Am J Transplant 2013;13:1246-52.
 48. Deng R, Gu G, Wang D, et al. Machine perfusion versus cold storage of kidneys derived from 
donation after cardiac death: a meta-analysis. PLoS One 2013;8:e56368.
 49. Hosgood SA, van Heurn E, Nicholson ML. Normothermic machine perfusion of the kidney: better 
conditioning and repair? Transpl Int 2015;28:657-64.
 50. Kierulf-Lassen C, Nieuwenhuijs-Moeke GJ, Krogstrup NV, Oltean M, Jespersen B, Dor FJ. Molecular 
Mechanisms of Renal Ischemic Conditioning Strategies. Eur Surg Res 2015;55:151-83.
 51. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in 
ischemic myocardium. Circulation 1986;74:1124-36.
 52. Candilio L, Malik A, Hausenloy DJ. Protection of organs other than the heart by remote ischemic 
conditioning. J Cardiovasc Med (Hagerstown) 2013;14:193-205.
 53. Wever KE, Menting TP, Rovers M, et al. Ischemic preconditioning in the animal kidney, a systematic 
review and meta-analysis. PLoS One 2012;7:e32296.
 54. Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: ready for prime-time cardioprotection. 
Trends Pharmacol Sci 2008;29:258-67.
 55. Hausenloy DJ, Mwamure PK, Venugopal V, et al. Effect of remote ischaemic preconditioning on 
myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised 
controlled trial. Lancet 2007;370:575-9.
 56. Jiang H, Chen R, Xue S, Zhu H, Sun X, Sun X. Protective effects of three remote ischemic condition-
ing procedures against renal ischemic/reperfusion injury in rat kidneys: a comparative study. Ir J 
Med Sci 2014.
 57. Bedir S, Ma Y, Antonelli J, Cadeddu JA, Gahan JC. Ineffectiveness of Remote Ischemic Renal Pre-
conditioning in a Porcine Solitary-Kidney Model. J Endourol 2015.
 58. Wu J, Feng X, Huang H, et al. Remote ischemic conditioning enhanced the early recovery of renal 
function in recipients after kidney transplantation: a randomized controlled trial. J Surg Res 
2014;188:303-8.
 59. Krogstrup NV, Oltean M, Bibby BM, et al. Remote ischaemic conditioning on recipients of de-
ceased renal transplants, effect on immediate and extended kidney graft function: a multicentre, 
randomised controlled trial protocol (CONTEXT). BMJ Open 2015;5:e007941.
 60. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postcondition-
ing during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ 
Physiol 2003;285:H579-88.
 61. Mykytenko J, Kerendi F, Reeves JG, et al. Long-term inhibition of myocardial infarction by post-
conditioning during reperfusion. Basic Res Cardiol 2007;102:90-100.
34
Chapter 2
 62. Hausenloy DJ, Yellon DM. The therapeutic potential of ischemic conditioning: an update. Nat Rev 
Cardiol 2011;8:619-29.
 63. van den Akker EK, Manintveld OC, Hesselink DA, de Bruin RW, Ijzermans JN, Dor FJ. Protection 
against renal ischemia-reperfusion injury by ischemic postconditioning. Transplantation 
2013;95:1299-305.
 64. Eldaif SM, Deneve JA, Wang NP, et al. Attenuation of renal ischemia-reperfusion injury by postcon-
ditioning involves adenosine receptor and protein kinase C activation. Transpl Int 2010;23:217-26.
 65. Jiang B, Liu X, Chen H, et al. Ischemic postconditioning attenuates renal ischemic/reperfusion 
injury in mongrel dogs. Urology 2010;76:1519 e1-7.
 66. Miklos Z, Kurthy M, Degrell P, et al. Ischaemic postconditioning reduces serum and tubular 
TNF-alpha expression in ischaemic-reperfused kidney in healthy rats. Clin Hemorheol Microcirc 
2012;50:167-78.
 67. Weng X, Shen H, Kuang Y, et al. Ischemic postconditioning inhibits the renal fibrosis induced by 
ischemia-reperfusion injury in rats. Urology 2012;80:484 e1-7.
 68. Kadkhodaee M, Seifi B, Najafi A, Sedaghat Z. First report of the protective effects of remote per- and 
postconditioning on ischemia/reperfusion-induced renal injury. Transplantation 2011;92:e55.
 69. van den Akker EK, Hesselink DA, Manintveld OC, et al. Ischemic postconditioning in human DCD 
kidney transplantation is feasible and appears safe. Transpl Int 2014;27:226-34.
 70. Masoud MS, Anwar SS, Afzal MZ, Mehmood A, Khan SN, Riazuddin S. Pre-conditioned mesenchy-
mal stem cells ameliorate renal ischemic injury in rats by augmented survival and engraftment. J 
Transl Med 2012;10:243.
 71. Chen YT, Sun CK, Lin YC, et al. Adipose-derived mesenchymal stem cell protects kidneys against 
ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J 
Transl Med 2011;9:51.
 72. Zhuo W, Liao L, Xu T, Wu W, Yang S, Tan J. Mesenchymal stem cells ameliorate ischemia-reperfu-
sion-induced renal dysfunction by improving the antioxidant/oxidant balance in the ischemic 
kidney. Urol Int 2011;86:191-6.
 73. Zhuo W, Liao L, Fu Y, et al. Efficiency of endovenous versus arterial administration of mesen-
chymal stem cells for ischemia-reperfusion-induced renal dysfunction in rats. Transplant Proc 
2013;45:503-10.
 74. Cao H, Qian H, Xu W, et al. Mesenchymal stem cells derived from human umbilical cord ameliorate 
ischemia/reperfusion-induced acute renal failure in rats. Biotechnol Lett 2010;32:725-32.
 75. Semedo P, Palasio CG, Oliveira CD, et al. Early modulation of inflammation by mesenchymal stem 
cell after acute kidney injury. Int Immunopharmacol 2009;9:677-82.
 76. Behr L, Hekmati M, Lucchini A, et al. Evaluation of the effect of autologous mesenchymal stem 
cell injection in a large-animal model of bilateral kidney ischaemia reperfusion injury. Cell Prolif 
2009;42:284-97.
 77. Behr L, Hekmati M, Fromont G, et al. Intra renal arterial injection of autologous mesenchymal 
stem cells in an ovine model in the postischemic kidney. Nephron Physiol 2007;107:p65-76.
 78. Hoogduijn MJ, Roemeling-van Rhijn M, Engela AU, et al. Mesenchymal stem cells induce an 
inflammatory response after intravenous infusion. Stem Cells Dev 2013;22:2825-35.
 79. Burst VR, Gillis M, Putsch F, et al. Poor cell survival limits the beneficial impact of mesenchymal 
stem cell transplantation on acute kidney injury. Nephron Exp Nephrol 2010;114:e107-16.
 80. Luo J, Zhao X, Tan Z, Su Z, Meng F, Zhang M. Mesenchymal-like progenitors derived from hu-
man embryonic stem cells promote recovery from acute kidney injury via paracrine actions. 
Cytotherapy 2013;15:649-62.
Lost in translation?
35
 81. Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into 
cardiac myocytes in myocardial infarcts. Nature 2004;428:664-8.
 82. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem 
cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004;428:668-73.
 83. Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney trans-
plantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011;6:412-22.
 84. Reinders ME, de Fijter JW, Roelofs H, et al. Autologous bone marrow-derived mesenchymal 
stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase 
I study. Stem Cells Transl Med 2013;2:107-11.
 85. Peng Y, Ke M, Xu L, et al. Donor-derived mesenchymal stem cells combined with low-dose tacro-
limus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 
2013;95:161-8.
 86. Luk F, de Witte SF, Bramer WM, Baan CC, Hoogduijn MJ. Efficacy of immunotherapy with mesen-
chymal stem cells in man: a systematic review. Expert Rev Clin Immunol 2015;11:617-36.
 87. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults trans-
planted with umbilical cord blood: safety profile and detection kinetics. Blood 2011;117:1061-70.
 88. Kinsey GR, Sharma R, Okusa MD. Regulatory T cells in AKI. J Am Soc Nephrol 2013;24:1720-6.
 89. Kinsey GR, Sharma R, Huang L, et al. Regulatory T cells suppress innate immunity in kidney 
ischemia-reperfusion injury. J Am Soc Nephrol 2009;20:1744-53.
 90. Dijke IE, Hoeppli RE, Ellis T, et al. Discarded Human Thymus Is a Novel Source of Stable and Long-
Lived Therapeutic Regulatory T Cells. Am J Transplant 2015.
 91. Bajwa A, Kinsey GR, Okusa MD. Immune mechanisms and novel pharmacological therapies of 
acute kidney injury. Curr Drug Targets 2009;10:1196-204.
 92. Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. 
Clin Nephrol 2004;62:273-8.
 93. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an 
analysis of contemporary percutaneous interventions. Am J Med 2005;118:843-9.
 94. Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using 
short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angi-
ography (PROMISS) trial--a randomized controlled study. Am Heart J 2008;155:499 e1-8.
 95. Philips B, MacPhee I. Do statins prevent acute kidney injury? Expert Opin Drug Saf 2015;14:1547-
61.
 96. Ishii Y, Sawada T, Murakami T, et al. Renoprotective effect of erythropoietin against ischaemia-
reperfusion injury in a non-human primate model. Nephrol Dial Transplant 2011;26:1157-62.
 97. Zhang J, Zou YR, Zhong X, et al. Erythropoietin pretreatment ameliorates renal ischaemia-
reperfusion injury by activating PI3K/Akt signalling. Nephrology (Carlton) 2015;20:266-72.
 98. Song YR, Lee T, You SJ, et al. Prevention of acute kidney injury by erythropoietin in patients under-
going coronary artery bypass grafting: a pilot study. Am J Nephrol 2009;30:253-60.
 99. Xin H, Ge YZ, Wu R, et al. Effect of high-dose erythropoietin on graft function after kidney trans-
plantation: a meta-analysis of randomized controlled trials. Biomed Pharmacother 2015;69:29-33.
 100. Vlachopanos G, Kassimatis TI, Agrafiotis A. Perioperative administration of high-dose recombi-
nant human erythropoietin for delayed graft function prevention in kidney transplantation: a 
meta-analysis. Transpl Int 2015;28:330-40.
 101. Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the 
tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 2008;105:10925-30.
36
Chapter 2
 102. Yang C, Xu Z, Zhao Z, et al. A novel proteolysis-resistant cyclic helix B peptide ameliorates kidney 
ischemia reperfusion injury. Biochim Biophys Acta 2014;1842:2306-17.
 103. Yang C. Cyclic helix B peptide in preservation solution and autologous blood perfusate amelio-
rates ichemia-reperfusion injury in isolated porcine kidneys. Transplantation Direct 2015.
 104. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
 105. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem 
2010;56:1733-41.
 106. Sui W, Dai Y, Huang Y, Lan H, Yan Q, Huang H. Microarray analysis of MicroRNA expression in acute 
rejection after renal transplantation. Transpl Immunol 2008;19:81-5.
 107. Anglicheau D, Sharma VK, Ding R, et al. MicroRNA expression profiles predictive of human renal 
allograft status. Proc Natl Acad Sci U S A 2009;106:5330-5.
 108. Godwin JG, Ge X, Stephan K, Jurisch A, Tullius SG, Iacomini J. Identification of a microRNA signa-
ture of renal ischemia reperfusion injury. Proc Natl Acad Sci U S A 2010;107:14339-44.
 109. van den Akker EK, Dor FJ, JN IJ, de Bruin RW. MicroRNAs in Kidney Transplantation: Living up to 
Their Expectations? J Transplant 2015;2015:354826.
 110. Rowinski W, Paczek L. Transplantation ethics: are we approaching the crossroads? Transplant Proc 
2012;44:2171-2.
 111. Sachs DH. Tolerance: of mice and men. J Clin Invest 2003;111:1819-21.
 112. Sachdeva M, Sunday S, Israel E, et al. Obesity as a barrier to living kidney donation: a center-based 
analysis. Clin Transplant 2013.
 113. Hourmant M, Lerat L, Karam G. Donation from old living donors: how safe is it? Nephrol Dial 
Transplant 2013;28:2010-4.
 114. Chapman JR, Nankivell BJ. Nephrotoxicity of ciclosporin A: short-term gain, long-term pain? 
Nephrol Dial Transplant 2006;21:2060-3.
 115. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of 
chronic allograft nephropathy. N Engl J Med 2003;349:2326-33.
 116. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor 
nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004;78:557-65.
 117. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients 
of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011;377:837-
47.
 118. Ponticelli C. Herpes viruses and tumours in kidney transplant recipients. The role of immunosup-
pression. Nephrol Dial Transplant 2011;26:1769-75.
 119. Carroll RP, Ramsay HM, Fryer AA, Hawley CM, Nicol DL, Harden PN. Incidence and prediction of 
nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Austra-
lia. Am J Kidney Dis 2003;41:676-83.
 120. ter Riet G, Korevaar DA, Leenaars M, et al. Publication bias in laboratory animal research: a survey 
on magnitude, drivers, consequences and potential solutions. PLoS One 2012;7:e43404.


Chapter 3
A comparison of inflammatory, 
cytoprotective and injury gene 
expression profiles in kidneys 
from brain death and cardiac 
death donors
Tanja C. Saat, Denis Susa, Henk P. Roest, Niels F.M. Kok, Sandra van den Engel,  
Jan N.M. IJzermans, Ron W.F. de Bruin
Transplantation
40
Chapter 3
Abstract
The superior long-term survival of kidneys from Living Donors (LD) compared to kidneys 
from Donation after Brain Death (DBD) and Donation after Circulatory Death (DCD) is 
now well established. However, comparative studies on transcriptional changes that 
occur at organ retrieval, and during and after cold ischemia (CI) are sparse. Using a rat 
model, we used qRT-PCR to examine expression levels of inflammatory, cytoprotective 
and injury genes at different time points after organ retrieval. Cleaved caspase-3, was 
used to evaluate early apoptosis in DCD- and DBD kidneys. Immediately after retrieval 
we found massive up-regulation of pro-inflammatory genes IL-1β, IL-6, TNF-α, MCP-1, P-
selectin and E-selectin in DBD- compared to LD- and DCD kidneys. A significant increase 
in the expression of injury markers Kim-1, and p21, and the cytoprotective gene HO-1 
accompanied this. Bax was up-regulated in DCD kidneys, and Bcl-2 was down-regulated 
in DBD kidneys. After 2 hours of CI in the LD group and 18 hours in the DBD and DCD 
groups, gene expression levels were similar to those found after retrieval. During 18 
hours of cold storage expression levels of these genes did not change. In DCD- and DBD 
kidneys, early apoptosis increased after CI. The gene expression profile in DBD kidneys 
represents an inflammatory and injury response to brain death. In contrast, DCD kidneys 
show only mild up-regulation of inflammatory and injury genes. These results may imply 
why delayed graft function in DCD kidneys does not have the deleterious effect it has 
in DBD kidneys.
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Introduction
The superior long-term survival of kidney transplants from Living Donors (LD) compared 
to Donation after Brain Death (DBD) or Donation after Circulatory Death (DCD) donors 
are now well established1-3. LD are healthy during organ procurement, and retrieved 
kidneys are exposed to minimal warm and cold ischemia (CI) times. DBD donors suffer 
from hemodynamic instability, hormone dysregulation and immunologic reactiv-
ity, which contribute to organ damage and inferior post-transplant function and graft 
survival compared to LD4-8. Organs from DCD donors do not develop the physiological 
changes of DBD donors, but are exposed to prolonged warm ischemia times (WIT), 
which increase the incidence of delayed graft function (DGF). In addition, organs from 
both post-mortem groups are exposed to prolonged CI compared to LD9,10. Although 
there is no difference in the incidence or severity of acute rejection between DBD- and 
DCD kidneys, DCD donors have a 73% chance of DGF compared to 27% in DBD kidneys11. 
However, the long-term graft survival of renal transplants of DCD- is similar to those 
from DBD donors11-15. Improved technology and an increasing gap between supply and 
demand for donor organs have prompted an increased use of organs from both LD and 
DCD donors4,16. 
The pathophysiology that leads to organ damage following brain death is relatively 
well established5,17-19, and strategies to protect the organs of a DBD donor are emerg-
ing20-23. In contrast, experimental studies on the changes that occur in organs from DCD 
donors are sparse24. A drawback in clinical studies that compare peri-operative gene 
expression patterns during transplantation is that they are confined to a relatively small 
time-span, and a limited number of time-points. Usually “t=0 biopsies” are obtained at 
the end of the cold storage period, followed by a post-reperfusion biopsy 30-60 minutes 
after reperfusion of the graft19. These time-points are not able to take into account the 
major pathophysiological perturbances that occur during the periods of brain death, 
cardiac arrest, organ retrieval and the subsequent cold storage period. Experimental 
studies have tried to overcome these limitations by studying gene expression at explan-
tation, but have mainly focused on DBD donors25,26. 
The aim of this study therefore was to compare expression levels of genes indicative 
of inflammation (IL-6, IL-1α, TNF-α, MCP-1, E-selectin, P-selectin, TLR4, HMGB1), cytopro-
tection (HO-1) and injury (HIF-1α, VEGF, Bax, Bcl-2, p21, Kim-1) at the time of kidney 
retrieval, after clinically relevant CI times and over a time-course during cold storage. 
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Materials and Methods
Experimental design 
The experimental protocol was approved by the Animal Experiments Committee under 
the Dutch National Experiments on Animals Act and complied with the 1986 directive 
86/609/EC of the Council of Europe. Male Brown Norway rats of 12-14 weeks old, weigh-
ing 250–300g, were purchased from Harlan-CPB (The Netherlands). Rats were randomly 
assigned to a LD, DBD or DCD group (n=7/group). The LD group served as control for 
both post-mortem groups. 
After kidney retrieval, samples were stored in University of Wisconsin (UW) solution; 
time-point 0 samples were directly snap frozen in nitrogen. At 2, 4, 6, 12 and 18 hours 
the kidneys were collected and snap frozen until further use. Gene expression levels af-
ter retrieval were measured in time-point 0 samples. To measure expression levels after 
clinically relevant CI; 2 hours of CI was used for LD and 18 hours of CI for the post-mortem 
donors. mRNA expression levels were examined by qRT-PCR. For immunohistochemistry 
DCD- and DBD kidneys were used directly after retrieval and after 18 hours of CI.
Experimental models 
Animals were anesthetized with isoflurane. After intubation, anaesthesia was maintained 
using a mixture of N2O/O2/2% isoflurane. Animals were pressure control ventilated on a 
Siemens Servo 900C ventilator with 14 cm H2O PIP, 4 cm H2O PEEP with a frequency of 
40 breaths per minute.
In the DBD group a frontolateral trepanation was made and a balloon catheter (Fog-
arty Arterial Embolectomy Catheter: 5F, BaxterHealthcare Co.) was introduced in the 
extradural space and slowly inflated, causing a gradually increasing intra-cranial pres-
sure27. Herniation of the brainstem and DBD was confirmed by dilated and fixed pupils, 
the absence of corneal reflexes, and an apnoea test. Brain dead animals received ventila-
tion but no further anaesthesia. Intra-arterial pressure was continuously monitored via 
a PE50 catheter placed in the carotid artery. Only rats with stable mean arterial pressure 
(MAP > 80 mm Hg) during the 6 hours of brain death were included in the experiment. 
After 6 hours both kidneys were removed, flushed with PBS and stored in UW solution 
at 4oC.
In the DCD group the animals were catheterised using a PE50 catheter placed in the 
carotid artery, and both kidneys were exposed via a midline incision that was then 
temporarily closed with a few sutures until retrieval of the kidneys. Cardiac arrest was 
induced by isoflurane overdose and lasted 20 minutes, starting when the blood pressure 
had dropped to 5-7 mm Hg, the time commonly needed before starting with cold stor-
age of DCD donor kidneys. The DCD donors are type III, controlled; waiting for cardiac 
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arrest, of the Maastricht criteria28. In the LD group, nephrectomy was performed after 
one hour of mechanical ventilation. 
mRNA expression analysis
Kidney sections were homogenized in 1.0 ml Trizol (Invitrogen). Total RNA was isolated 
according to the manufacturer’s guidelines, precipitated, and subsequently dissolved in 
DEPC-treated water. RNA concentration was determined using a Nanodrop ND-1000 UV-
VIS spectrophotometer. For cDNA synthesis M-MLV Reverse Transcriptase (Invitrogen) 
was used according to the manufacturer’s protocol with 250ng of random hexamers 
(Promega) and RNAseOUT (Invitrogen). All temperature-dependent steps were per-
formed using a Biometra T-gradient cycler (Biometra Gmbh). cDNA samples were stored 
at -20°C. Quantitative real-time PCR was performed using a BioRad Icycler with SYBR 
Green incorporation. Each sample was tested in duplo, two times. ∆Ct values of genes of 
interest were calculated as described by Pfaffl et al.29 using β-actin as a reference gene. 
∆Ct values were normalized to the average ∆Ct of the LD. LD kidneys 2 hours after CI 
were used comparison for the post-mortem kidneys after 18 hours of CI, and the respec-
tive time-points in the time-course. The fold increase was calculated using the Pfaffl 
equation: 2∆∆ Ct. Results are expressed as mean ± SEM.
Primers 
Inflammation (IL-6, IL-1α, TNF-α, MCP-1, E-selectin, P-selectin, TLR4, HMGB1), cytoprotec-
tion (HO-1) and injury (HIF-1α, VEGF, Bax, Bcl-2, p21, Kim-1)
Primers indicative for inflammation are TLR4, HMGB1, IL-1β, IL-6, TNF-α, MCP-1, P-
selectin and E-selectin. Primers indicative for cytoprotection are HO-1, VEGF and HIF-1α. 
Kim-1, p21, Bax and Bcl-2 were used as markers indicative for kidney injury. Used primers 
are shown in Table 1. 
Immunohistochemistry
Frozen sections, 5µm-thick, were stained with a polyclonal antibody against CC3 
(Asp175; Cell Signaling), an early apoptotic marker. CC3 was diluted 1:300 and visualized 
with a horseradish peroxidase-conjugated secondary antibody (dilution 1:500, goat-
anti-rabbit IgG/HRP, DAKO, Denmark). Slides were scored at a magnification of 200x by 2 
independent observers blinded to the treatment. Results are expressed as mean ± SEM. 
Statistical Analysis 
Data were analysed using a Kruskal Wallis ANOVA, followed by a Mann-Whitney–U test. 
Analysis was performed using SPSSv20.0. A p value ≤0.05 was considered statistically 
significant.
44
Chapter 3
Table 1. Primers used for qRT-PCR.
Housekeeping Gene Forward Primer Reverse Primer
β-actin ‘5-gacccagatcatgtttgagacc-3’ ‘5-gatgggcacagtgtgggtgac-3’
Inflammatory Genes Forward Primer Reverse Primer
IL-1β ‘5-gaggctgacagaccccaaaaga-3’ ‘5-tccacagccacaatgagtgaca-3’
IL-6 ‘5-gtctcgagcccaccaggaac-3’ ‘5-agggaaggcagtggctgtca-3’
TNF-α ‘5-gaccctcacactcagatcatcttct-3’ ‘5-tgctacgacgtgggctacg-3’
MCP-1 ‘5-gccatcagcccacaggtgtt-3’ ‘5-gggacactggctgcttgtga-3’
P-selectin ‘5-aagatggtcagcgcctccac-3’ ‘5-atcgaaccgatgggacagga-3’
E-selectin ‘5-cccacatgtgcaggggtaca-3’ ‘5-tggcccactgcaactcatgt-3’
TLR4 ‘5-tccgctggttgcagaaaatg-3’ ‘5-tcccagccagatgcaagaga-3’
HMGB1 ‘5-ccgccaagctgaaggagaag-3’ ‘5-ccctttttcgctgcatcagg-3’
Cytoprotective Genes Forward Primer Reverse Primer
HO-1 ‘5-tttcagaagggtcaggtgtcca-3’ ‘5-agtagagcggggcatagactgg-3’
p21 ‘5-ccacagcgatatcgagacactca-3’ ‘5-acagacgacggcatactttgctc-3’
Injury Genes Forward Primer Reverse Primer
HIF-1α ‘5-agtcagcaacgtggaaggtgc-3’ ‘5-acaaatcagcaccaagcacgtc-3’
VEGF ‘5-tgcactggaccctggctttac-3’ ‘5-ttctgctccccttctgtcgtg-3’
Bax ‘5-tgctgatggcaacttcaactgg-3’ ‘5-tggttctgatcagctcgggca-3’
Bcl-2 ‘5-acatcgccctgtggatgactg-3’ ‘5-gcatgctggggccatatagttc-3’
Kim-1 ‘5-ccacagcgatatcgagacactca-3’ ‘5-acagacgacggcatactttgctc-3’
Results
Expression of pro-inflammatory, cytoprotective and injury genes after retrieval
Directly after retrieval, pro-inflammatory genes showed a significant increase in DBD- 
compared to LD kidneys (Figure 1). Intrarenal IL-1β mRNA levels were increased in 
DBD- (13.7-fold, p=0.032) versus LD kidneys. IL-6 expression was massively increased in 
the DBD- compared to the LD kidneys (417-fold, p=0.003). TNF-α and MCP-1 (not shown) 
were increased (4.7-fold, p=0.004) and (81-fold, p=0.015), respectively. In DCD kidneys 
MCP-1, IL-1β and IL-6 were not significantly different compared to LD, while TNF-α 
was slightly but significantly lower (p=0.003). Expression of the adhesion molecules 
P-selectin and E-selectin was highly elevated in DBD-, but not in DCD kidneys (not 
shown). Cytoprotective gene HO-1 was highly up-regulated in DBD- compared to LD 
kidneys (36.7-fold, p=0.004), whereas no difference was found between the DCD and LD 
group. Neither HIF-1a, nor VEGF expression was significantly influenced by DBD or DCD 
compared to LD. The anti-apoptotic gene Bax (not shown) and pro-apoptotic Bcl-2 (not 
shown) showed no significant differences between the groups. Cell-cyle inhibitor p21 
was significantly elevated in both DBD- (5.0-fold, p=0.032) and DCD kidneys (1.6-fold, 
Gene expression profi les in kidneys from DBD- and DCD donors
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Figure 1. mRNA expression levels of genes indicative of inflammation, cytoprotection, and kidney injury were 
determined by qRT-PCR directly after retrieval of the kidneys in living donors (LD), donation after circulatory 
death (DCD,) and brain death (DBD) donors. To compare the individual expression levels of each animal, ∆Ct 
values were normalized to the average ∆Ct of the LD group at time point 0. Subsequently the fold increase was 
calculated using 2∆∆Ct. Results are expressed as mean ± SEM of seven animals per group. *p<0.05, **p<0.01 
compared to LD. 
Figure 1. mRNA expression levels of genes indicative of infl ammation, cytoprotection, and kidney injury 
were determined by qRT-PCR directly after retrieval of the kidneys in living donors (LD), donation after 
circulatory death (DCD) and donation after brain death (DBD) donors. To compare the individual expres-
sion levels of each animal, ∆Ct values were normalized to the average ∆Ct of the LD group at time point 0. 
S bsequently the fold increas  was c lculated using 2∆∆Ct. Results are x ressed as mean ± SEM of seven 
animals per group. *p<0.05, **p<0.01 compared to LD.
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p=0.007). These changes were accompanied by a significant up-regulation of kidney 
injury marker Kim-1 in DBD (48-fold, p=0.021).
Gene expression levels after clinically relevant cold ischemia times
Next, we investigated the expression levels after CI relevant to human kidney transplan-
tation. LD kidneys were analysed after 2 hours of CI, and the DBD and DCD groups after 
18 hours of CI30,31. 
Compared to LD, IL-1β, IL-6, TNF-a and MCP-1 were increased in DBD kidneys (43-fold, 
p=0.003; 997-fold, p=0.003; 9.7-fold, p=0.003 and 115-fold, p=0.004). IL-1β and IL-6 were 
increased in DCD kidneys but to a lesser extend (2.3-fold, p=0.004; 10-fold, p=0.003). 
TNF-α and MCP-1 showed no significant difference in expression between DCD and 
LD kidneys. P-selectin was significantly increased in DBD- (129-fold, p=0.003) and DCD 
kidneys (2.9-fold, p=0.008). E-selectin was increased in DBD kidneys (64-fold, p=0.003). 
TLR4 expression was elevated in DBD- (4.4-fold, p=0.037), but not in DCD kidneys. 
HMGB1 was not significantly different. 
After DBD, HO-1 was up-regulated (21-fold, p=0.001), while in the DCD donors HO-1 
was slightly but significantly lower compared to the LD (p=0.014). Neither HIF-1a, 
nor VEGF expression was significantly influenced by DBD or DCD. Bax was expressed 
higher in the DCD compared to the LD kidney (1.3-fold, p=0.016). Bcl-2 was lower in 
DBD- compared to LD kidneys (0.7-fold, p=0.032). Expression of p21 was higher in both 
DBD- and DCD donors, (9.1-fold, p=0.003) and (2.5-fold, p=0.003), as compared to LD. 
In DBD donors Kim-1 was increased (319-fold, p=0.003), whereas in DCD donors it was 
slightly increased (5.3-fold, p=0.010).
Gene expression profiles during an 18 hour cold storage period
To address whether changes in gene-expression would occur during cold storage of 
the kidneys, gene expression of HO-1, HIF-1α, Bax, Bcl-2, TLR4, HMGB1 and VEGF (not 
shown) were examined after 0, 2, 4, 6, 12 and 18 hours of cold storage (Figure 2). Gene 
expression levels did not significantly change after retrieval and during cold storage of 
the kidney grafts. These data show that biological processes in the donor are the main 
determinants of gene expression in the graft prior to transplantation.
Apoptosis during cold storage
DCD- and DBD kidneys collected directly after retrieval and after 18 hours of CI were 
stained for cleaved caspase-3 (CC3) (Figure 3). In DCD kidneys, the average number 
of apoptotic cells increased after 18 hours of Ci compared with kidneys directly after 
retrieval (p<0.01). DBD kidneys showed a similar trend.
Gene expression profiles in kidneys from DBD- and DCD donors
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Figure 2. Gene expression profiles in kidneys remain stable during cold preservation. mRNA expression levels of 
HO-1, HIF-1α, Bax, Bcl-2, TLR-4 and HMGB1 were determined directly after retrieval of kidneys from the donor, 
and at 2, 4, 6, 12, and 18 hours of cold preservation in kidneys of living donors (LD), donation after circulatory 
death (DCD,) and brain death (DBD) donors. To compare the individual expression levels of each animal, ∆Ct 
values were normalized to the average ∆Ct of the LD group at the respective time points. Subsequently the fold 
increase was calculated using 2∆∆Ct. Results are expressed as mean ± SEM of seven animals per group. 
 
 
 
 
 
 
 
 
Figure 2. Gene expression profiles in kidneys remain stable during cold preservation. mRNA expression 
levels of HO-1, HIF-1α, Bax, Bcl-2, TLR-4 and HMGB1 were determined directly after retrieval of kidneys from 
the donor, and at 2, 4, 6, 12, and 18 hours of cold preservation in kidneys of living donors (LD), donation 
after circulatory death (DCD,) and brain death (DBD) donors. To compare the individual expression levels of 
each animal, ∆Ct v lues were normalize  to th  average ∆Ct of the LD group at the respective time points. 
Subsequently the fold increase was calculated using 2∆∆Ct. Results are expressed as mean ± SEM of seven 
animals per group.
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Discussion
To better understand the relative contributions of brain death, prolonged WIT and CI 
in DBD- and DCD donors, we studied expression profiles of genes representative of in-
flammation, cytoprotection, and injury. Directly after kidney retrieval, pro-inflammatory 
genes showed a massive up-regulation in DBD- compared to LD- and DCD kidneys. 
A significant increase in the expression of Kim-1 and p21, and cytoprotective gene 
HO-1 accompanied this. After clinically relevant CI times, the gene expression profiles 
remained stable. The high levels of pro-inflammatory and injury genes in DBD donors 
are in contrast with the clinically high incidence of DGF in DCD- compared to DBD 
donors. Induction of pro-inflammatory and injury genes alone might not be sufficient 
to induce DGF and influence short-term graft outcome. Other factors could play an 
import role in the incidence of DGF and post-transplant outcome32, since DCD kidneys 
showed cellular changes during CI. In the clinical setting the average WIT in DCD donors 
is approximately 20 minutes33. Although the prolonged WIT in organs from DCD donors 
is considered the main reason for the increased incidence of DGF in these grafts, the 
deterioration in organ quality induced by 20 minutes of WIT in this study is not reflected 
by changes in gene expression. During cold preservation, hypothermia and the lack of 
oxygen preclude the transcription of DNA into mRNA. The use of preservation fluids 
preserves cellular integrity and may prevent breakdown of RNA, and this may explain 
the stable mRNA levels during cold preservation34-37. 
The most striking finding in our study is the difference between DBD- and DCD donors 
in renal transcription of inflammatory markers such as IL-1β, IL-6, MCP-1, and E-selectin. 
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Figure 3. Early apoptosis was analysed using a cleaved caspase-3 staining in DCD- and DBD kidneys after 
retrieval and after 18 hours of cold ischemia. Directly after retrieval DCD kidneys showed less apoptotic cells 
compared with DCD kidneys after 18 hours of cold preservation. DBD kidneys show a similar trend. *p<0.01 
compared with time-point 0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Early apoptosis was analysed using a cleaved caspase-3 staining in DCD- and DBD kidneys after 
retrieval and after 18 hours of cold ischemia. Directly after retrieval DCD kidneys showed less apoptotic 
cells compared with DCD kidneys after 18 hours of cold preservation. DBD kidneys show a similar trend. 
*p<0.01 compared with time-point 0.
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High levels of inflammatory cytokines in the donor are associated with decreased graft 
survival26,38,39. The high levels of IL-6 in serum of DBD donors are thought to be due to 
production in the injured brain and subsequent leakage through the disrupted blood-
brain barrier17,40. We show that it is likely that the kidney itself significantly contributes 
to systemic IL-6 levels, and systemic inflammation observed during brain death. This 
inflammation resulted in kidney injury, as shown by the up-regulation of Kim-1. In DCD 
kidneys, expression of IL-1β, IL-6 and P-selectin was significantly up-regulated compared 
to LD but to a much lesser extent than in DBD donors. 
TLR4 expression was significantly up-regulated in DBD donors. The important role of 
TLR4 in mediating renal ischemia reperfusion injury has been shown both in animal 
models and after human transplantation41,42. HMGB1 has been identified as ligand for 
TLR4 present on tubular epithelial cells, and is involved in the cellular signalling through 
TLR4, which leads to production of pro-inflammatory cytokines41. HMGB1 secretion is 
stimulated by IL-1β, and by stressed cells or cells undergoing necrosis43,44. Up-regulation 
of both TLR4 and HMGB1 have been observed following reperfusion, and targeting both 
may diminish ischemic injury42. Although we found up-regulation of many cytokines 
that can be induced by TLR4 activation, such as TNF-α and MCP-1, we found low levels 
of HMGB1, which might suggest that it is not involved in the systemic inflammatory 
response observed during DBD in our model, or that low levels of HMGB1 are able to 
activate TLR4. In addition, TLR4 can also be activated by other alarmins43. 
Compared to the severe inflammatory response induced during 6 hours of brain 
death, 20 minutes of WIT in our DCD model induced only mild changes, which are 
almost indistinguishable from the transcriptional changes found after LD. Since the 
duration of the asystolic period in DCD donors determines the severity of the damage to 
the kidney24, it is likely that 20 minutes of asystole used in our study is not sufficient to 
induce massive up-regulation of pro-inflammatory gene expression. In addition, human 
DCD donors may suffer from other injuries, which influence the inflammatory response. 
Because of the higher incidence of DGF in DCD donors9,10,45, it has even been suggested 
that DGF in DCD kidneys predisposes for favourable graft outcome46. The absence of 
overt inflammatory changes and significantly lower Kim-1 expression in our study may 
explain why the impact of DGF is reduced in DCD kidneys.
We found a significant up-regulation of HO-1 in DBD donors at the time of retrieval, 
which remained stable during 18 hours of CI. Several studies describe that over-
expression of HO-1 protects kidney transplants against the deleterious consequences 
of ischemic injury47-49. In LD elevated HO-1 expression in the transplant had a protective 
effect on renal ischemia reperfusion injury25,50. In contrast, the increased levels of HO-1 
in DBD kidneys did not prevent renal damage. This suggests that DBD causes renal 
damage to such an extent that HO-1 expression is insufficient, and may be viewed as a 
marker of injury25. 
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Both HIF-1α, and VEGF itself were not significantly up-regulated in DBD donors. This 
implies that during 6 hours of brain dead, the inflammatory response coincides with 
up-regulation of HO-1, not VEGF. Interestingly, p21 was also strongly induced in both 
post-mortem donors. p21 binds stoichiometrically to PCNA and inhibits its action in 
DNA replication, is a key regulator of proliferation following renal ischemic injury51. 
We previously showed that there is a critical, temporal balance between the expres-
sion levels of p21 and proliferation in the regenerating tubular compartment following 
ischemia52. The up-regulation of p21, like HO-1, in our model may be envisioned as 
indicator of damage, and the lower induction in DCD kidneys may give an advantage 
following transplantation, when proliferation of the damaged tubular compartment is 
warranted51,52.
The pro-apoptotic gene Bax was slightly, but significantly elevated in DCD- versus 
LD kidneys. Expression of the anti-apoptotic gene Bcl-2 was down-regulated in DBD- 
compared to LD kidneys. These results suggest that induction of apoptosis may be 
due to Bax induction during cardiac death, whereas down-regulation of Bcl-2 may be 
responsible in DBD donors. We showed that in both post-mortem donors the number 
of apoptotic cells increases between retrieval and 18 hours of cold storage. Despite the 
stable gene expression levels, there are cellular changes during cold storage resulting in 
a higher rate of apoptosis, which may account for the deteriorating graft quality during 
prolonged CI. 
Our data strongly support pre-treatment of the DBD donor as a promising strategy to 
improve graft function and survival. Indeed, low dose dopamine pre-treatment of the 
donor before kidney transplantation results in a better post-operative kidney function 
and reduces the incidence of DGF21. To reduce the effect of inflammatory cytokines, pre-
treatment with methylprednisolone has been used in deceased donors, which resulted 
in a better outcome after human liver transplantation20. Besides this, induction of sup-
raphysiological levels of the cytoprotective gene HO-1 in DBD donors has a beneficial 
effect on graft function after transplantation47. Our study is limited by the use of healthy, 
young rats without co-morbidity. In this study, we focused on the influence of CI in dif-
ferent donor types. In future study, the use of a transplantation model is required to 
explore the effect of reperfusion injury. Extensive histology could give insight at cellular 
level. 
Although rodent models of DBD, DCD and LD are unable to capture the full complex-
ity of human donors they are a tool to dissect the relative contributions of brain death 
and ischemia to pre-transplant organ damage. Here, we show a massive up-regulation 
of inflammatory, injury, and cytoprotective genes in DBD kidneys, but not in LD- or 
DCD kidneys at the time of graft retrieval, which remains stable during preservation. 
The difference between DBD- and DCD donors in inflammatory gene expression may 
Gene expression profiles in kidneys from DBD- and DCD donors
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underlie the better outcome after DGF in DCD kidneys53, and lends further support to 
the anti-inflammatory treatment of DBD donors20,21. 
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Abstract
Liver transplantation (LT) is the only life-saving treatment for patients with end-stage liver 
disease. The increase in patients has prompted the use of not only Donation after Brain 
Death (DBD) donors but also Living Donors (LD) and Donation after Circulatory Death 
(DCD) donors. Donor-type affects early graft function and graft survival as evidenced 
by an increased risk of developing Ischemic Type Biliary Lesions and higher risk of graft 
loss in DCD- as compared to DBD grafts. Using a rat model, we used qRT-PCR to examine 
expression levels of pro-inflammatory, cytoprotective and injury genes and determined 
apoptosis in DCD- and DBD livers at different time-points after retrieval. After retrieval, 
early mediators of inflammation MCP-1, HMGB1 and TLR4 were increased in DCD livers, 
whereas the pro-inflammatory genes IL-6, IL-1β, TNF-α, P-selectin and E-selectin were 
massively up-regulated in DBD- compared to LD livers. HO-1 was increased in both post-
mortem groups. After cold ischemia, DCD livers showed increased levels of MCP-1, TLR4 
and HMGB1, whereas expression of pro-inflammatory genes in DBD liver remained high. 
During 12 hours of cold storage, expression levels remained stable except HIF-1α and 
HMGB1. DCD livers showed higher number of apoptotic cells compared with DBD livers. 
Compared to livers from LD, DCD livers showed only mild up-regulation of inflammatory 
markers, but increased levels of MCP-1, HMGB1 and TLR4, and more apoptotic cells. In 
contrast, DBD livers showed a massive inflammatory response. These differences in tis-
sue injury and inflammatory response might be relevant for the outcome after LT. 
Gene expression profiles of livers from DBD- and DCD donors
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Introduction
Liver transplantation (LT) is the only curative treatment for patients with end-stage liver 
disease. Over the years the outcome after LT has been improved, and this has resulted 
in more patients eligible for a LT. LT is limited due to the shortage of liver grafts and the 
increase in patients on the waiting list1,2. In an attempt to overcome this discrepancy, the 
donor pool is being enlarged by using not only Donation after Brain Death (DBD) donors 
but also Living Donors (LD) and non-heart-beating donors also known as Donation after 
Circulatory Death (DCD) donors3,4. 
LD livers are retrieved from healthy people and have experienced minimal warm 
and cold ischemia, which results in decreased inflammation in the transplanted liver5. 
Experience with LD transplantation procedure plays an important role in graft and re-
cipient survival and influences the risk of surgical complications for the donor5. Organs 
from DBD donors suffer from physiological perturbations like severe hemodynamic 
changes, hormonal changes, electrolyte imbalances, pulmonary changes, hypothermia 
and inflammation which can contribute to organ damage and inferior post-transplant 
outcome6-10. In DCD donors, death is based on irreversible loss of cardio-pulmonary 
function. Thus, in contrast to organs from DBD donors, organs from DCD donors are 
exposed to a period of hypotension, hypoxia and prolonged warm ischemia time, which 
affects early graft function as well as graft survival11-13. DCD liver grafts have an almost 
11 times increased risk of developing Ischemic Type Biliary Lesions and 1.85 higher risk 
of graft loss as compared to DBD grafts12,14, leading to a higher number of graft failures, 
re-transplantations and decreased patient survival11,13. 
The process of brain death is relatively well described in literature6,7,9 and strategies to 
optimize the organ quality of brain death donors are emerging15,16. In contrast, experi-
mental studies comparing perioperative gene expression profiles in liver grafts from LD, 
DBD- and DCD donors are sparse. Studies are limited to a small number of time points, 
and a relatively small time span10, and focused on results after transplantation. Usually 
‘t=0 biopsies’ are obtained at the end of the cold storage period, and are unable to take 
into account the major pathophysiological perturbation that occur during brain death, 
cardiac arrest, recovery of organs and the cold storage period. Comparative studies in 
organs from LD, DBD- and DCD donors are currently lacking, and the molecular mecha-
nisms that may account for the differences in transplant outcome are unclear15,16. 
The aim of this study therefore was to compare gene expression profiles of inflamma-
tory, cytoprotective and injury genes in livers from LD, DBD- and DCD donors at the time 
of retrieval, after clinically relevant cold ischemia times, and over a time-course during 
cold storage.
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Materials and methods
Experimental design
The experimental protocol was approved by the Animal Experiments Committee under 
the Dutch National Experiments on Animals Act and complied with the 1986 directive 
86/609/EC of the Council of Europe. Male Brown Norway rats of 12-14 weeks old, weigh-
ing 250–300g, were purchased from Harlan-CPB (Austerlitz, The Netherlands). Rats were 
randomly assigned to a LD, DCD or DBD group (n=7/group). The LD group served as 
control for both post-mortem groups. After explantation, livers were stored in Univer-
sity of Wisconsin (UW) solution. At 0, 2, 4, 6 and 12 hours the liver tissue samples were 
collected and snap frozen in liquid nitrogen until further use. mRNA expression levels 
in LD, DBD and DCD livers were examined by qRT-PCR and compared at, and between 
different preservation times. Time-point 0 was defined as the time directly after retrieval. 
Clinically relevant cold ischemia times were defined as 2 hours in the LD group and 12 
hours in the DBD and DCD groups. During cold storage mRNA expression levels were 
determined at 0, 2, 4, 6 and 12 hours. In each group mRNA expression levels were com-
pared with the previous time-point to determine possible changes during cold storage. 
For immunohistochemistry DCD- and DBD livers were used directly after retrieval and 
after 12 hours of cold ischemia and stained with cleaved caspase-3.
Experimental models
Animals were anesthetized with isoflurane. After intubation, anesthesia was maintained 
using a mixture of N2O/O2/2% isoflurane. Animals were pressure control ventilated on a 
Siemens Servo 900C ventilator (Maqet Critical Care AB, Solna, Sweden) with 14 cm H2O 
PIP, 4 cm H2O PEEP with a frequency of 40 breaths per minute. In the DBD group a fron-
tolateral trepanation was made and a balloon catheter (Fogarty Arterial Embolectomy 
Catheter: 5F, Baxter Healthcare Co., Irvine, Ca, USA) was introduced in the extradural 
space and slowly inflated, causing a gradually increasing intra-cranial pressure17. Hernia-
tion of the brainstem and brain death was confirmed by dilated and fixed pupils, the 
absence of corneal reflexes, and an apnoea test. DBD animals received ventilation but 
no further anaesthesia. Intra-arterial pressure was continuously monitored via a PE50 
catheter placed in the carotid artery. Only rats with stable mean arterial pressure (MAP 
> 80 mm Hg) during the 6 hours of brain death were included in the experiment. After 
6 hours the liver was removed, flushed with PBS and stored in UW solution at 4oC. In the 
DCD group cardiac arrest was induced by isoflurane overdose. The cardiac arrest period 
started when the blood pressure had dropped to 5-7 mm Hg, and lasted 20 minutes, the 
time commonly needed before starting with cold storage of the liver. The DCD donors 
are type III of the Maastricht criteria18. In the LD group, livers were collected after one 
hour of mechanical ventilation using an N2O/O2/2% isoflurane mixture. 
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mRNA expression analysis
Liver sections were homogenized for 30 seconds using a pro 200 homogenizer equipped 
(PRO scientific inc., Oxford, CT) in 1.0 ml Trizol (Invitrogen, The Netherlands). Total RNA 
was isolated according to the manufacturer’s guidelines of Trizol (Invitrogen), precipi-
tated, and subsequently dissolved in DEPC-treated water. RNA concentration was deter-
mined using a Nanodrop ND-1000 UV-VIS spectrophotometer (Nanodrop technologies, 
Wilmington, DE) and stored at -80°C until further use. 
For cDNA synthesis, approximately 1 mg of total RNA was used as template for first-
strand cDNA synthesis using M-MLV Reverse Transcriptase (Invitrogen) according to the 
manufacturer’s protocol with 250 ng of random hexamers (Promega, The Netherlands) 
as a starting point for reversed transcription and 40 IU RNAseOUT (Invitrogen) to prevent 
RNA degradation. All temperature-dependent steps were performed using a Biometra 
T-gradient cycler (Biometra Gmbh, Göttingen, Germany). cDNA samples were stored at 
-20°C.
Genes
As genes indicative for inflammation we used TLR4, HMGB1, IL-1β, IL-6, TNF-α, MCP-1, 
P-selectin and E-selectin. To assess cytoprotection we measured HO-1, VEGF, and HIF-α. 
P21, a cell cycle inhibitor, and the apoptosis markers Bax and Bcl-2 were used as a mark-
ers indicative for liver injury. Primers used to amplify the genes of interest were obtained 
from Sigma, the Netherlands, Table 1. 
qRT-PCR analysis 
For quantitative analysis of transcription, 0.33 μl of cDNA was amplified using a BioRad 
Icycler (Bio-Rad laboratories). Reaction mixtures of 25 μl contain cDNA, 5 μmol of each 
primer, 0.5 U Platinum Taq (Invitrogen), 1.5 mM MgCl2, 0.2 mM dNTP each, and 0.075 μl 
of a 200x stock SYBR Green I solution (Sigma). Cycling conditions consisted of 3 minutes 
activation at 95°C, 40 cycles of 15” 95°C, 30” 60°C, and 30” 72°C, followed by 1’ 95°C and 1’ 
65°C. Samples were subsequently subjected to a melt curve analysis with a temperature 
range of 60-94.5°C to verify amplified products.
∆Ct values of genes of interest were calculated as described by Pfaffl19 using β-actin as 
a reference gene. To compare all individual expression levels of each animal, ∆Ct values 
were normalized to the average ∆Ct of the LD group. The LD group at 0 hour was used 
in the 0 hour comparison (Figure 2A, 2B), the LD group at 2 hours was used in the 2 
hour versus 12 hour comparison (Figure 1A, 1B), and the respective time points in the 
time course (Figure 3). Subsequently the fold increase was calculated using the Pfaffl 
equation: 2∆∆ Ct. Results are expressed as mean ± SEM.
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Table 1. Primers used for qRT-PCR.
Housekeeping Gene Forward Primer Reverse Primer
β-actin ‘5-gacccagatcatgtttgagacc-3’ ‘5-gatgggcacagtgtgggtgac-3’
Inflammatory Genes Forward Primer Reverse Primer
IL-1β ‘5-gaggctgacagaccccaaaaga-3’ ‘5-tccacagccacaatgagtgaca-3’
IL-6 ‘5-gtctcgagcccaccaggaac-3’ ‘5-agggaaggcagtggctgtca-3’
TNF-α ‘5-gaccctcacactcagatcatcttct-3’ ‘5-tgctacgacgtgggctacg-3’
MCP-1 ‘5-gccatcagcccacaggtgtt-3’ ‘5-gggacactggctgcttgtga-3’
P-selectin ‘5-aagatggtcagcgcctccac-3’ ‘5-atcgaaccgatgggacagga-3’
E-selectin ‘5-cccacatgtgcaggggtaca-3’ ‘5-tggcccactgcaactcatgt-3’
TLR4 ‘5-tccgctggttgcagaaaatg-3’ ‘5-tcccagccagatgcaagaga-3’
HMGB1 ‘5-ccgccaagctgaaggagaag-3’ ‘5-ccctttttcgctgcatcagg-3’
Cytoprotective Genes Forward Primer Reverse Primer
HO-1 ‘5-tttcagaagggtcaggtgtcca-3’ ‘5-agtagagcggggcatagactgg-3’
p21 ‘5-ccacagcgatatcgagacactca-3’ ‘5-acagacgacggcatactttgctc-3’
Injury Genes Forward Primer Reverse Primer
HIF-1α ‘5-agtcagcaacgtggaaggtgc-3’ ‘5-acaaatcagcaccaagcacgtc-3’
VEGF ‘5-tgcactggaccctggctttac-3’ ‘5-ttctgctccccttctgtcgtg-3’
Bax ‘5-tgctgatggcaacttcaactgg-3’ ‘5-tggttctgatcagctcgggca-3’
Bcl-2 ‘5-acatcgccctgtggatgactg-3’ ‘5-gcatgctggggccatatagttc-3’
Immunohistochemistry
Frozen sections, 5µm-thick, were stained with a polyclonal antibody against cleaved 
caspase-3 (Asp175; Cell Signaling), an early apoptotic marker. Cleaved caspase-3 was 
diluted 1:300 and visualized with a horseradish peroxidase-conjugated secondary 
antibody (dilution 1:500, goat-anti-rabbit IgG/HRP, DAKO, Denmark). The number of 
positive cells was determined in 10 high power fields at a magnification of 200x by 2 
independent observers blinded to the treatment. 
Statistical Analysis 
Data were analysed using a Kruskal Wallis ANOVA, followed by a Mann-Whitney–U test. 
Analysis was performed using SPSS v20.0 for Windows. A p value ≤0.05 was considered 
statistically significant.
Results
Gene expression profiles directly after retrieval
To study changes in gene expression levels between the moment of liver graft procure-
ment and the end of the cold storage period, we analysed gene expression levels at 
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the time of retrieval of the livers (t=0) (Figure 1A). In DBD livers, the pro-inflammatory 
genes IL-1β, IL-6 and TNF-α were 14.8-fold (p=0.003), 326.5-fold (p=0.003), and 22.5-fold 
(p=0.004) increased compared with LD livers. P-selectin (41.7-fold, p=0.004) and E-selec-
tin (12.9-fold, p=0.037) were also increased in DBD livers, whereas TLR4 expression was 
decreased (p=0.001). In DCD livers, only HMGB1 was significantly increased (p=0.009) 
compared to LD livers. HO-1 was increased in both post-mortem groups, 5.6-fold in DCD 
(p=0.021) and 12.6 fold in DBD livers (p=0.003) compared with the LD group (Figure 
1B). In DCD livers, HIF-1α was 2.6-fold increased. VEGF was 0.3 fold down-regulated in 
DBD livers (p=0.004). In DBD livers, Pro-apoptotic Bax was decreased 0.5-fold (p=0.021) 
whereas anti-apoptotic Bcl-2 expression was unchanged. In DCD livers Bax expression 
was not altered, but Bcl-2 showed a 6.9-fold increase (p=0.001). Cell cycle inhibitor p21 
showed no significant difference. 
In conclusion, compared to LD, DCD livers showed only mild up-regulation of inflam-
matory markers, but increased levels of MCP-1, HMGB1 and TLR4, and more apoptotic 
cells. DBD livers showed a massive up-regulation of pro-inflammatory, cytoprotective 
and injury genes.
Gene expression profiles after cold ischemia
Following 12 hours of cold ischemia, expression levels of the pro-inflammatory genes 
IL-1β, IL-6 and TNF-α, and P-selectin and E-selectin, largely reflected those found directly 
after recovery in DBD livers (Figure 2A). In DCD livers, only IL-6 expression was slightly 
but significantly increased (4.6-fold,p=0.018) compared to LD livers. While there was 
no difference after recovery, MCP-1 was increased 30.8-fold (p=0.016) in the DCD- but 
slightly down-regulated in DBD livers (p=0.017). E-selectin was increased in DCD livers 
4.1-fold (p=0.011). HMGB1 expression showed a similar trend as TLR4 in DCD livers. DBD 
livers showed a down-regulation of TLR4 (p=0.008), which is comparable with the results 
found after recovery. 
In DBD livers HO-1 was 16.9-fold (p=0.021) increased, while DCD livers showed no 
significant difference compared to LD livers (Figure 2B). HIF-1α showed no significant 
changes in the post-mortem livers. VEGF and Bax showed a decrease of 0.2-fold (p=0.008) 
and 0.4-fold (p=0.006) respectively in the DBD livers. In DCD livers, Bcl-2 showed an 
up-regulation of 4.6-fold (p=0.009). In both post-mortem groups, p21 up-regulation 
reflected that at recovery, but reached significance after 12 hours of cold preservation. 
These data show that biological processes in the different donors are a major determi-
nant of gene expression in the graft prior to transplantation.
Gene expression profiles during 12 hours of cold storage 
Since the expression levels of some genes changed between the time of recovery of the 
organ and the end of the cold storage period, we addressed when changes in gene-
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Figure 1A. Gene expression profiles of inflammatory genes directly after recovery. DBD livers showed an up-
regulation of the inflammatory genes compared to the LD. DCD livers showed mild inflammation but an up-
regulation of HMGB1 compared to LD livers. mRNA expression levels were determined by qRT-PCR directly after 
recovery of the liver. To compare the individual expression levels of each animal, ∆Ct values were normalized to 
Figure 1A. Gene expression profiles of inflammatory genes directly after recovery. DBD livers showed an 
up-regulation of the inflammatory genes compared to the LD. DCD livers showed mild inflammation but 
an up-regulation of HMGB1 compared to LD livers. mRNA expression levels were determined by qRT-PCR 
directly after recovery of the liver. To compare the individual expression levels of each animal, ∆Ct values
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expression would occur during cold storage. Gene expression of HO-1, HIF-1α, Bcl-2, 
Bax, VEGF (not shown), TLR4 and HMGB1 were examined after 0, 2, 4, 6 and 12 hours of 
cold ischemia (Figure 3). 
In LD livers all the expression levels remained stable during cold preservation. In both 
post-mortem groups, HO-1, VEGF (not shown), and Bax mRNA expression levels did 
Figure 4.1 continued
were normalized to the average ∆Ct of the LD group at time point 0. Subsequently the fold increase was cal-
culated using 2∆∆Ct. Results are expressed as mean ± SEM (n=7/group). *p≤0.05, **p≤0.01 compared to LD.
the average ∆Ct of the LD group at time point 0. Subsequently the fold increase was calculated using 2∆∆Ct. 
Results are expressed as mean ± SEM (n=7/group). *p≤0.05, **p≤0.01 compared to LD. 
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Figure 1B. Expression levels of cytoprotective genes directly after recovery. HO-1 was up-regulated in both DBD- 
and DCD donors compared to LD. HIF1-α was up-regulated in the DCD livers compared to LD livers. VEGF was 
down-regulated in DBD donors compared to LD. In DBD livers, Bax was decreased whereas Bcl-2 expression 
was unchanged. In DCD livers, Bax expression was not altered, but Bcl-2 showed an increase. Results are 
expressed as mean ± SEM (n=7/ group). *p≤0.05, **p≤0.01 compared to LD. 
 
Figure 1B. Expression levels of cytoprotective genes directly after recovery. HO-1 was up-regulated in both 
DBD- and DCD donors compared to LD. HIF1-α was up-regulated in the DCD livers compared to LD livers. 
VEGF was down-regulated in DBD donors compared to LD. In DBD livers, Bax was decreased whereas Bcl-2 
expression was unchanged. In DCD livers, Bax expression was not altered, but Bcl-2 showed an increase. 
Results are expressed as mean ± SEM (n=7/ group). *p≤0.05, **p≤0.01 compared to LD.
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Figure 2A. Gene expression profiles of inflammatory genes in the liver after clinically relevant CI times. mRNA 
expression levels of genes indicative of inflammation were determined by qRT-PCR after 2 hours of CI in LD, and 
after 12 hours of CI in DBD- and DCD donors. DBD donors showed an up-regulation of the inflammatory genes in 
DBD livers, while DCD livers showed mild inflammation compared to LD. Interestingly, MCP-1 was increased in 
the DCD- but slightly down-regulated in DBD- compared to LD livers. To compare the individual expression levels 
of each animal, ∆Ct values were normalized to the average ∆Ct of the LD group at 2 hours. Subsequently the fold 
Figure 2A. Gene expression profiles of inflammatory genes in the liver after clinically relevant CI times. 
mRNA expression levels of genes indicative of inflammation were determined by qRT-PCR after 2 hours of 
CI in LD, and after 12 hours of CI in DBD- and DCD donors. DBD donors showed an up-regulation of the in-
flammatory genes in DBD livers, while DCD l vers showed mild inflammation compared to LD. Interestingly, 
MCP-1 was i creased in the DCD- but slightly down-regulate  in DBD- compared to LD livers. To compare 
the individual expression levels of each animal, ∆Ct values were normalized to the average ∆Ct of the LD 
group at 2 hours. Subsequently the fold increase was calculated using 2∆∆Ct. Results are expressed as mean 
± SEM (n=7/group). *p≤0.05, **p≤0.01 compared to LD.
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increase was calculated using 2∆∆Ct. Results are expressed as mean ± SEM (n=7/group). *p≤0.05, **p≤0.01 
compared to LD. 
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Figure 2B. Gene expression profiles of cytoprotective and injury genes in the liver after CI times. Expression of 
the cytoprotective gene HO-1 was increased in DBD livers compared to LD livers. mRNA expression levels of 
genes indicative of inflammation were determined by qRT-PCR after 2 hours of CI in LD, and after 12 hours of CI 
in DBD- and DCD donors. Results are expressed as mean ± SEM (n=7/group). *p≤0.05, **p≤0.01 compared to 
LD.  
 
Figure 2B. Gene expression profiles of cytoprotective and injury genes in the liver after CI times. Expression 
of the cytoprotective gene HO-1 was increased in DBD livers compared to LD livers. mRNA expression levels 
of g nes indicative of inflammati n were determin d by qRT-PCR after 2 hours of CI in LD, and after 12 
hours of CI in DBD- and DCD donors. Results are expressed as mean ± SEM (n=7/group). *p≤0.05, **p≤0.01 
compared to LD. 
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Figure 3. Gene expression profiles during 12 hours of cold storage. Expression levels of HO-1, HIF-1α, Bcl-2, 
Bax, TLR4 and HMGB1 were determined directly after liver resection, and at 2, 4, 6 and 12 hours of cold 
preservation in LD-, DCD- and DBD livers. Gene expression levels of HO-1, Bax and VEGF remain stable during 
cold preservation in LD-, DCD- and DBD livers. In LD livers all the expression levels remain stable during cold 
preservation. In DCD livers HIF-1α and HMGB1 showed a decrease in expression levels after 2 hours of cold 
storage. Bcl-2 showed a decrease after 6 hours of cold storage. In DBD livers HIF-1α and HMGB1 showed mild 
changes. To compare the individual expression levels of each animal, ∆Ct values were normalized to the average 
∆Ct of the LD group at the respective time points. Subsequently the fold increase was calculated using 2∆∆Ct. 
Results are expressed as mean ± SEM (n=7/group). *p≤0.05, **p≤0.01 compared to LD.  
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Bax, TLR4 and HMGB1 were determined directly after liver resection, and at 2, 4, 6 and 12 hours of cold pres-
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lated using 2∆∆Ct. Results are expressed as mean ± SEM (n=7/group). *p≤0.05, **p≤0.01 compared to LD. 
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not signifi cantly change between recovery of the organ and 12 hours of cold ischemia. 
HIF-1α showed a signifi cant decrease in DCD- (p=0.004) and DBD livers (p=0.018) be-
tween 0 and 2 hours of cold storage, but remained stable thereafter. In DCD livers, Bcl-2 
expression levels showed a decreasing trend between 0 and 6 hours (p=0.018) of cold 
ischemia. In both DCD- and DBD livers TLR4 levels showed no signifi cant diff erence over 
time. In both post-mortem groups HMGB1 levels showed a similar trend. HMGB1 levels 
were signifi cantly increased after 2 hours of cold preservation in both DCD- (p=0.035) 
and DBD livers (p=0.002), returned to levels measured at retrieval, and remained stable 
thereafter. In conclusion, during cold storage, gene expression profi les remain stable in 
LD livers, while in DCD- and DBD livers HIF-1α, Bcl-2 and HMGB1 expression levels show 
mild changes.
Apoptosis during cold storage
DCD- and DBD livers collected directly after retrieval and after 12 hours of cold storage 
were stained for cleaved caspase-3 (Figure 4). In DCD livers the number of apoptotic cells 
is approximately 4 times higher directly after retrieval compared to DBD livers (p<0.05). 
In both DCD- and DBD livers the number of apoptotic cells found directly after retrieval 
does not change during cold preservation. 
Discussion
Our study shows a diff erential gene expression profi le between livers retrieved from 
DBD- versus DCD donors. Livers from DCD donors show only mild up-regulation of 
infl ammatory genes, but increased expression levels of MCP-1, TLR4, and HMGB1 
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Figure 4. Early apoptosis as determined by cleaved caspase-3 staining in DCD- and DBD livers directly after 
retrieval and after 12 hours of cold ischemia. DCD livers show significant more apoptotic cells directly after 
retrieval and after cold ischemia compared with DBD livers. Results are expressed as mean ± SEM (*p<0.05). 
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Figure 5. Proposed model for the differential kinetics of the inflammatory response in DCD versus DBD donors. 
HMGB1, secreted by necrotic cells, is a ligand for TLR4, which activates NFκβ and induces the transcription of 
inflammatory genes. During brain death there is sufficient time to mount this inflammatory response in the donor, 
whereas in DCD donors this response might still be in an early phase and may reach its full magnitude only after 
transplantation of the liver. 
 
Figure 4. Early apoptosis as determined 
by cleaved caspase-3 staining in DCD- and 
DBD livers directly after retrieval and after 
12 hours of cold ischemia. DCD livers show 
signifi cant more apoptotic cells directly 
after retrieval and after cold ischemia 
compared with DBD livers. Results are ex-
pressed as mean ± SEM (*p<0.05).
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directly after recovery. In contrast, DBD donors show a massive up-regulation of pro-
inflammatory, cytoprotective and injury genes. During 12 hours of cold storage, mRNA 
gene expression profiles remain stable in LD livers, while DCD- and DBD livers show 
mild changes in mRNA expression of HIF-1α, Bcl-2 and HMGB1 during cold ischemia. 
Despite the lower expression of inflammatory genes in DCD- compared to DBD livers, 
the outcomes after DCD liver transplantation are inferior to those using DBD livers20. 
DCD donors show an increased rate of biliary complications1,12,13, higher post-transplant 
morbidity and inferior graft survival3,21. 
The most striking finding in our study is the differential expression of inflammatory 
genes such as HMGB1, TLR4, MCP-1 IL-1β, IL-6, and TNF-α between DCD- and DBD livers. 
HMGB1 and TLR4 were highly expressed at the time of recovery and after cold preserva-
tion in DCD- but not in DBD livers. HMGB1 is a nuclear transcription factor that can be 
released from necrotic cells and has been identified as a ligand for TLR422. During he-
patic ischemia reperfusion injury (IRI) it acts as a central mediator of TLR4 dependent23-25 
production of pro-inflammatory cytokines26. Although HMGB1 can be passively released 
by necrotic cells22, it may also be mobilized and released in response to hypoxia23. The 
prolonged warm ischemia time in DCD livers might be the reason why HMGB1 is up-
regulated at procurement. HMGB1 levels correlate more with markers of overall graft 
damage such as aminotransferase than levels of individual cytokines such as TNF-α or 
IL-625. 
MCP-1, or CCL-2, is produced by activated hepatocytes27, cholangiocytes and portal 
fibroblasts28. After binding to the cognate receptor CCR2, MCP-1 attracts monocytes 
and dendritic cells to sites of tissue injury, and is able to induce apoptosis. MCP-1 is 
considered an early mediator of inflammation29, and is implicated in hepatic fibrosis30. 
Over-expression of MCP-1 in the liver leads to inflammation and injury, while MCP-1 
deficient mice are protected against toxic liver injury and oxidative stress31. In humans 
high levels of MCP-1 early after transplantation are associated with poor early graft func-
tion after LT32 and it has been suggested that MCP-1 contributes to the development of 
biliary atresia33. The differential expression of early versus late markers of inflammation 
suggests that the kinetics of injury and inflammation differ between DBD- and DCD 
livers. During 6 hours of brain death in our model, there is sufficient time to mount an 
inflammatory response7-9, whereas in DCD donors (20 minutes of cardiac arrest) this 
response might still be in an early phase and may reach its full magnitude only after 
transplantation (Figure 5). 
High levels of inflammatory cytokines and adhesion molecules in DBD livers are asso-
ciated with the physiological changes that occur during brain death. These changes lead 
to organ damage and higher rates of primary non-function post-transplant compared 
with LD livers6-9. The disrupted blood-brain barrier in DBD donors might contribute 
to the high levels of inflammatory cytokines in DBD donors, since the ischemic brain 
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Figure 4. Early apoptosis as determined by cleaved caspase-3 staining in DCD- and DBD livers directly after 
retrieval and after 12 hours of cold ischemia. DCD livers show significant more apoptotic cells directly after 
retrieval and after cold ischemia compared with DBD livers. Results are expressed as mean ± SEM (*p<0.05). 
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Figure 5. Proposed model for the differential kinetics of the inflammatory response in DCD versus DBD donors. 
HMGB1, secreted by necrotic cells, is a ligand for TLR4, which activates NFκβ and induces the transcription of 
inflammatory genes. During brain death there is sufficient time to mount this inflammatory response in the donor, 
whereas in DCD donors this response might still be in an early phase and may reach its full magnitude only after 
transplantation of the liver. 
 
Figure 5. Proposed model for the diff erential kinetics of the infl ammatory response in DCD versus DBD 
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scription of infl ammatory enes. During brain death there is suffi  cient time to mount this infl ammat ry 
response in the don r, whereas in DCD donors this response might still be in an early phase a d may reach 
its full m gnitude only after transplantation of the liver.
releases infl ammatory mediators, which provokes a systemic infl ammatory response7,34. 
Here we show that it is likely that the liver itself contributes to systemic levels of infl am-
matory cytokines and systemic infl ammation during brain death as well9. 
The cytoprotective gene HO-1 was signifi cantly up-regulated in both post-mortem 
groups at the time of procurement, and remained stable during 12 hours of cold pres-
ervation. Over-expression of HO-1 in the liver interferes with infl ammation, oxidative 
stress and apoptosis35, and results in better outcomes after IRI36,37. The protection af-
forded by physiological over-expression of HO-1 in DBD livers is likely insuffi  cient38, but 
could be further elaborated in experimental studies. In DCD livers HIF-1α, the transcrip-
tion factor inducing the production of VEGF, and VEGF are increased at time of retrieval 
compared to LD livers. DBD livers showed no signifi cant diff erence in HIF-1α expression, 
and decreased VEGF expression. The data suggest that during the warm anoxic phase 
of DCD donation HIF-1α and subsequent VEGF are rapidly induced. Interestingly, the 
cyclin-dependent kinase inhibitor p21 was also strongly induced in both post-mortem 
groups. By binding to PCNA and inhibiting its action in DNA replication, p21 is a key 
regulator of proliferation. Previously we showed that there is a critical, temporal balance 
between the expression levels of p21 and proliferation of the tubular compartment after 
renal ischemia39,40. The up-regulation of p21, like HO-1, in our study may be an indicator 
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of liver damage. The pro-apoptotic gene Bax and the anti-apoptotic gene Bcl-2 are in-
volved in apoptosis of endothelial cells and hepatocytes after warm- and cold ischemia 
during LT41. The Bax/Bcl-2 ratio shows at the genetic level if there is a pro-apoptotic or 
anti-apoptotic state. Compared to LD livers, DCD livers showed a Bax/Bcl-2 ratio at ex-
plantation of 0.23 and after cold storage of 0.25. In DBD livers the Bax/Bcl2 ratio was 1.18 
and after cold storage of 0.53. It is unlikely that these minor differences bear biological 
significance. 
During 12 hours of cold storage, in both DBD- and DCD livers significant differences 
were found in gene expression level of HIF-1α and HMGB1. The use of UW-solution may 
reduce apoptosis and hence prevent degradation of RNA42, whereas the lack of oxygen 
during cold preservation precludes the transcription of DNA into mRNA. This might 
explain why, for most genes, mRNA levels remain stable during cold preservation. After 
excluding technical reasons as cause for the changes in expression levels in the DBD- 
and DCD group, these differences in results might be explained by the poorer quality of 
the post-mortem organs. However, a plausible mechanism for the observed changes is 
currently lacking. Cleaved caspase-3 staining showed that DCD livers have significantly 
higher numbers of early apoptotic cells compared with DBD livers at graft retrieval. 
In both DBD- and DCD livers, these numbers do not change during cold storage. The 
higher numbers of apoptotic cells might explain why DCD livers have a worse outcome 
after LT, despite the lower expression levels of inflammatory and injury genes. 
Our study is limited by the use of experimental models of DBD, DCD and LD, which 
are unable to capture the full complexity of human donors that differ in age, sex and 
co-morbidity. Nevertheless, they are a tool to dissect the relative contributions of 
brain death and ischemia to pre-transplant organ damage. We used whole tissue ho-
mogenates and not specifically looked at the biliary tree. Especially DCD donor livers 
suffer from biliary complications, compared with DBD donor livers43-45. Nevertheless, the 
differential expression levels of inflammatory genes suggest a different postoperative 
course, which may be related to the different postoperative outcomes. 
In conclusion, using these models, we show an increase in MCP-1, HMGB1 and TLR4 
expression in DCD donors, and a massive up-regulation of inflammatory, cytoprotec-
tive, and injury genes in liver transplants from DBD donors, but not from living-, or DCD 
donors at the time of liver procurement. This suggests that the kinetics of injury and 
inflammatory processes might be different, as outlined in Figure 5, and may be relevant 
for the different rates and types of complications and graft outcome, and guide more 
effective early treatment of the recipient based on donor type. 
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Abstract
During kidney transplantation, ischemiareperfusion injury (IRI) induces oxidative stress. 
Short-term preoperative 30% dietary restriction (DR) and 3-day fasting protect against 
renal IRI. We investigated the contribution of macronutrients to this protection on both 
phenotypical and transcriptional levels.
Male C57BL/6 mice were fed control food ad libitum, underwent two weeks of 30% 
DR, 3-day fasting, or received a protein-, carbohydrate- or fat-free diet for various peri-
ods of time. After completion of each diet, renal gene expression was investigated using 
microarrays. After induction of renal IRI by clamping the renal pedicles, animals were 
monitored seven days postoperatively for signs of IRI. 
In addition to 3-day fasting and two weeks 30% DR, three days of a protein-free diet 
protected against renal IRI as well, whereas the other diets did not. Gene expression 
patterns significantly overlapped between all diets except the fat-free diet. Detailed 
meta-analysis showed involvement of nuclear receptor signaling via transcription fac-
tors, including FOXO3, HNF4A and HMGA1. 
In conclusion, three days of protein-free diet is sufficient to induce protection against 
renal IRI similar to 3-day fasting and two weeks of 30% DR. The elucidated network of 
common protective pathways and transcription factors further improves our mechanis-
tic insight into the increased stress resistance induced by short-term DR. 
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Introduction
Dietary restriction (DR) is a reduction in food intake without malnutrition1. Long-term 
DR is known to extend lifespan, increase overall health and improve resistance to mul-
tiple stressors in a wide variety of organisms1-5. Although the effect of DR on human 
lifespan is unknown, studies demonstrate a favorable impact on metabolic parameters 
associated with long-term health6-8. In addition, DR has been shown to protect against 
acute stressors including toxic chemotherapy9, paracetamol intoxication10, and oxidative 
stress induced by ischemia reperfusion injury (IRI)1,11,12. In clinical kidney transplantation, 
renal IRI is a major risk factor for organ damage which may result in acute kidney injury13, 
primary non-function14, delayed graft function15, and acute and chronic rejection16 of 
the graft. After kidney retrieval, cessation of the blood flow (ischemia) leads to hypoxia, 
nutrient deprivation, and accumulation of metabolic waste products15,16. Reperfusion 
of the ischemic kidney promotes the generation of reactive oxygen species, triggers 
apoptotic cell death, and promotes the activation of an inflammatory response resulting 
in profound tissue injury17. Prevention or amelioration of renal IRI could increase graft 
quality, and prolong graft survival. Unfortunately, no effective treatment to reduce or 
prevent IRI is currently available.
Using renal IRI as a model, we previously demonstrated that the benefits of DR on IRI 
are induced rapidly: two and four weeks of 30% preoperative DR as well as three days of 
fasting reduce renal injury and strongly improve survival and kidney function after renal 
IRI in mice1,12. Hence, DR is a potential intervention for living kidney donors to reduce 
IRI and improve the transplantation success rate. Whether the protective effect of short- 
and long-term DR is based on the reduction of calories per se, or specific nutrients, was 
first investigated in fruit flies, in which long-term protein restriction contributed more to 
lifespan extension than a reduction in carbohydrates18. In mice, glucose supplementa-
tion did not interfere with fasting-induced protection against renal IRI, which also points 
towards a role for specific (macro-)nutrients in inducing acute stress resistance11. 
In this study, we investigated the role of specific macronutrients in inducing resistance 
against renal IRI by unrestricted feeding of protein-, carbohydrate-, and fat free diets. 
We showed that the absence of protein for three days is sufficient to induce resistance 
against renal IRI and revealed common pathways and transcription factors that are 
implicated in the protective effect of calorie restriction, induced by two weeks of 30% 
DR, three days of fasting, and protein restriction.
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Materials and Methods
Study design
Sample size calculation of our previous study was based on a 25% decrease of serum 
urea levels at time point 24 hours after renal IRI, with a standard deviation (SD) of 20% 
and a power of 0.81,11. These experiments demonstrated that our renal IRI model was 
feasible and stable, and we therefore reduced the number of mice to six mice per group 
in the dietary intervention groups. Primary endpoint of this study was kidney function 
24 hours after surgery, measured via serum urea concentrations. Secondary endpoints 
of this study were mortality rate in the first seven days after surgery and changes in gene 
expression profiles measured directly after each dietary intervention. Experimental data 
of two weeks 30% DR and three days of fasting groups were previously obtained. Animals 
were euthanized and excluded from the experiment if their body weight decreased ≥ 
20% of their preoperative weight or if they developed a moribund phenotype, including 
ruffled fur, hunched body posture, hypothermia, and decreased activity11,12. 
Animals
C57BL/6 male mice, 10-12 weeks old (20-25 grams), were obtained from Harlan, the 
Netherlands. Animals were housed in individually ventilated cages (3-4 animals/cage) 
under standard conditions. All mice had ad libitum (AL) food and water (acidified with 
HCl to a pH of 2.4-2.7) except where noted. All experiments were performed with the ap-
proval of the Animal Experiments Committee of the Erasmus University Medical Center, 
Rotterdam, the Netherlands under the Dutch National Experiments on Animals Act and 
according to the ARRIVE Guidelines, Animal Research: Reporting of In Vivo Experiments19. 
Diets and experimental design
The control chow for the fasting and dietary restriction groups was obtained from Spe-
cial Diet Services (SDS, Witham, UK). All other diets were purchased from Research Diets, 
Inc. (New Brunswick, NJ, USA). The macronutrient composition and energy content of 
all diets are shown in Table S1. The control diet differed from the standard chow given 
(Special Diet Services, SDS) in the protein source, which consisted of lactic casein protein 
in case of control diet, while the SDS control consisted of crude protein. These two con-
trol diets are designated as “Control” and “SDS” throughout the manuscript.
Long-term dietary intervention
Upon arrival, mice were allowed ad libitum (AL) access to the SDS chow for seven days. 
At the start of the dietary intervention period, all mice were transferred to clean cages 
at 4:00 pm. Mice were randomly divided into a group with 30% DR (n=5) or AL access 
to a carbohydrate-free (CHO-free) diet (n=6) or a fat-free diet (n=6) for 14 days, or a 
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protein-free diet (n=6) for 10 days (Figure S1). Mice in the control group for DR had AL 
access to the control SDS chow (n=10). The control group for CHO-free and fat-free had 
AL access to control type I diet (n=12). The effect of food intake was measured using 
pair-fed (PFed) control groups. Pair-feeding of each group was accomplished by giving 
the PFed groups the identical isocaloric amount of the control diet as the mice on the 
experimental diet had consumed the day before. The CHO-free, fat-free and protein-free 
diets were PFed in this manner (n=6/group). Mice with 30% DR were given 70% of the 
normal daily intake of mice on the control diet, which was administered once daily at 
4:00 pm. Since the phenotypical effects of two weeks 30% DR were reported previously, 
microarray analysis was used as the only outcome for this group1.
Short-term dietary intervention
Upon arrival, the same procedure was followed as for the long-term experiment. Mice 
were randomly divided into groups with AL access to control diet (n=4), a protein-free 
diet (n=6 per group) for three days or 30% DR for three days (n=6), or into groups with 
AL access to SDS chow or fasting for three days (n=5 per group). Since the phenotypical 
effects of three days fasting were reported previously, transcriptome analysis was the 
only parameter for this group1. For a graphical overview of the experimental setup see 
Figure S1. 
Dietary intake and body weight
Food intake and body weight were measured daily. To determine calorie intake, the daily 
food intake was corrected for the variation in the energy content (per gram of food) in 
the diets as follows: food intake per mouse times the number of calories per gram of 
food. Change in body weight was addressed in percentages calculated by dividing the 
body weight measurements during the dietary intervention through body weight at 
onset of the intervention period times 100. 
Surgical procedure
Following each dietary intervention, bilateral renal IRI was induced as previously de-
scribed1. In brief, mice were anaesthetized via inhalation of isoflurane (5% isoflurane ini-
tially followed by 2-2.5% with oxygen for maintenance). Via midline abdominal incisions, 
the renal arteries and veins were exposed followed by occlusion of both renal pedicles 
for 37 minutes using non-traumatic vascular clamps. Purple discoloration of the kidneys 
confirmed ischemia macroscopically, while reperfusion was established when the color 
of both kidneys normalized after removal of the clamps. The incision was closed with 
5/0 sutures in two layers. Following closure, mice received 0.5 ml PBS subcutaneously 
to compensation for fluid loss. The morning after surgery, another identical dose of PBS 
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was given. Mice intended for microarray analysis were sacrificed immediately after the 
dietary intervention, without induction of renal IRI. 
Kidney function
Kidney function was determined as previously described by measuring serum urea lev-
els in blood samples, collected via retro-orbital puncture while mice were anesthetized, 
before (T=0) and day 1 (T=1) after induction of renal IRI1. 
Immuno-blotting
Mouse kidney extracts from 9 different intervention diets were prepared by sonification 
with Soniprep 150 2-3 times 30 seconds on ice in Laemmli buffer (135 mM Tris-HCl pH 
6.8, 4.5% SDS, 22.5% glycerol), supplemented with complete protease inhibitors and 
PhosSTOP phosphates inhibitors (Roche Diagnostics, Indianapolis, IN, USA) After sonifi-
cation, lysates were centrifuged at 4 degrees Celsius for 10 minutes. Protein concentra-
tions were measured using the BCA Protein Assay Kit (Pierce Biotechnology, Rockford, 
USA). 25µg protein was loaded on a NuPAGE 10% Bis-Tris Gel (Life Technologies LTD, 
Paisley, UK) and transferred to a PVDF Hybond-P (GE-Healthcare Life Sciences, Uppsala, 
Sweden) transfer membrane. Immunoblotting was performed with antibodies directed 
against S6 (#2217S Lot5; 1:1.000) and Phospho-S6 (Ser240/244; #2215 Lot14; 1:500) 
(Cell Signaling Technology, Danvers, MA, USA). Blotting membranes were incubated 
with primary antibodies overnight at 4 degrees Celsius, before they were washed and 
incubated with 1:5000 diluted secondary anti-rabbit-IgG-HRP antibody (GE-Healthcare 
Life Sciences). Detection was performed by enhanced chemiluminescence using the 
ECL 2 Western Blotting Substrate (Pierce Biotechnology). Levels of S6 and Phospho-S6 
were semi-quantified using the ImageJ software package and S6-phospho /S6-total 
ratios relative to the control diet were calculated and differences between groups were 
assessed with a t-test (http://rsb.info.nih.gov/ij/index.html). Β-Actin was used as loading 
control (Sigma; A5441 Lot064M4789V; 1:25.000).
Microarrays
The duration of dietary interventions that were used to study gene expression profiles 
was three days for all diets with exception of 30% DR, which was given for two weeks. 
Kidneys were obtained directly after each intervention and were snap frozen in liquid 
nitrogen until further analyses. An overview of the dietary interventions, the groups of 
mice and numbers used for phenotypical and transcriptional endpoints are summarized 
in Table S2. Total RNA was extracted using QIAzol lysis Reagent and miRNAeasy Mini Kits 
(QIAGEN, Hilden, Germany), following Qiagen protocol. Addition of wash buffers RPE and 
RWT (QIAGEN) was done mechanically by using the QIAcube (QIAGEN, Hilden, Germany) 
via the miRNAeasy program. Isolated RNA was and stored at -80°C. The concentration 
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of RNA was measured by Nanodrop (Thermo Fisher Scientific™, Breda, the Netherlands) 
and RNA quality was assessed using the 2100 Bio-Analyzer (Agilent Technologies, Am-
stelveen, the Netherlands) according to manufacturer’s instructions. The RNA quality 
was expressed as the RNA integrity number (RIN, range 0-10). RIN values of included 
samples ranged between 6.6 and 8.5. Hybridization to Affymetrix HT MG-430 PM Array 
Plates was performed at the Microarray Department of the University of Amsterdam 
(the Netherlands), according to Affymetrix protocols. Four to six biological replicates 
were used for each group. Quality control and normalization were performed using the 
pipeline at the www.arrayanalysis.org website (Maastricht University, the Netherlands)20. 
Normalization was done via the Robust Multichip Average (RMA) algorithm21. Due to a 
range in hybridization dates between fasting and the other diets (i.e. September 2011 
versus August 2012), normalization of the data for fasted animals and their controls was 
done separately. Normalization output consisted of data for 45,141 probes, with several 
probes corresponding to the same Gene ID. Complete raw and normalized microarray 
data and their MIAME compliant metadata have been deposited at the Gene expression 
Omnibus (GEO) database GEO GSE65656 (www.ncbi.nlm.nih.gov/geo). After normaliza-
tion, outliers were found in the control SDS (control 30% DR), the 3-day fasting and 3-day 
fat-free diet groups, defined as a deviation in array-array intensity correlations, principal 
component analysis and cluster dendograms. These outliers were excluded from further 
analyses (Table S2). 
Statistical analysis
Data are expressed as means ± standard error of the mean (SEM). Statistical analyses 
were performed using SPSS (version 21.0) and GraphPad Prism (version 5.0). Differences 
in serum urea concentrations were compared by Mann-Whitney U tests, food intake via 
the paired t-test and survival rates were analyzed by Log-rank tests. A p-value of <0.05 
was considered significant. Microarray analyses were performed using the free software 
package R (R foundation). Gene expression data were compared using the Linear Mod-
els for Microarray Data (limma) method with correction for multiple testing using the 
false discovery rate (FDR) according to Benjamini and Hochberg22. Fold changes were 
expressed as the geometric mean per diet group against the corresponding ad libitum 
fed control group. Cutoff values for a significant difference were put at FDR <5% with 
fold change ≥1.5. The enrichment factor (EF) was calculated via the formula: EF=nAB/
((nA×nB)/nC), where nA is the number of differentially expressed probe sets (DEPS) in 
experimental group A, nB the number of DEPS in experimental group B, nC the number 
of total genes in the microarray, and nAB the number of common DEPS between nA 
and nB. Data integration of microarrays hybridized in different dates was performed 
with meta-analysis. The methodology applied was combining rank orders. It is a non-
parametric approach based on rank orders. The R package RankProd implemented in 
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INMEX was used. In summary, for each dataset, the fold changes (FC) were calculated for 
all possible pairwise comparisons. The ranks of the fold changes within each comparison 
were used to calculate the rank product for each gene. To assess the null distribution of 
the rank product within each data set, a permutation test was performed. The process 
was repeated several times to compute the P-value and false discovery rate (FDR) as-
sociated with each gene. A gene was selected as differentially expressed if it had an 
FDR <5% and an absolute combined FC ≥1.5. Functional annotation and analyses were 
performed using Ingenuity software (http://www.ingenuity.com/products/ipa). The 
prediction inhibition or activation of the upstream transcription regulators is calculated 
via de statistical z-score based on the observed gene expression changes in our dataset. 
Calculating the z-score reduces the chance of significant predictions based on random 
data (http://ingenuity.force.com/ipa/articles/Feature_Description/Upstream-Regulator-
Analysis). Cutoff values for a significant activation or inhibition were met with a z-score 
of ≥ 2 or ≤-2, respectively.
Results
Absence of dietary protein induces protection against renal IRI 
To determine the effect of short-term macronutrient deficiency on renal IRI, we provided 
10-day, 14-day or 3-day regimens of protein-free, carbohydrate (CHO)-free and fat-free 
diets before inducing renal IRI. As previously shown, mice that were fed a protein-free 
diet for six or 14 days tend to voluntarily decrease their food intake as compared to 
animals that were fed a normal diet23. We indeed found that mice fed a protein-free 
diet for 10 days decreased their dietary food intake by approximately 30% (Figure 
S2A), resulting in significant body weight loss up until 20% on day 10 (Figure S2B). The 
reduction in food intake and body weight was less substantial in mice fed a CHO-free 
diet for 14 days. A fat-free diet for 14 days led to a small increase in body weight. Only 
the protein-free diet improved survival (Figure S2C) and kidney function (Figure S2D) 
following renal IRI. However, due to the reduction in food intake and body weight, the 
effect of the absence of protein per se could not be disentangled from the effect of 
calorie restriction. 
Subsequently, to separate the effect of the absence of protein from calorie restriction, 
mice were fed a protein-free diet for three consecutive days. We first showed that survival 
and kidney function of mice receiving 30% DR for three days did not differ from mice fed 
ad libitum (Figure 1A, B). Mice fed the protein-free diet for three days had significantly 
improved survival (Figure 1C) and kidney function compared to control mice (P<0.05) 
(Figure 1D). The energy intake during the 3-day protein-free dietary intervention was 
decreased, but did not significantly differ from the intake of animals fed the control 
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diet for three days (P=0.13) (Figure 1E). Body weight of mice on the protein free diet 
decreased by 9%, while body weight of mice that were fed a control diet did not change. 
Mice receiving 30% DR for three days lost about 8% of their body weight (Figure 1F). 
Common gene expression profiles between macronutrient-free diets, fasting 
and DR 
To examine, in an unbiased manner, the transcriptomic response of the kidney, microar-
ray analysis was performed on 45,141 probe sets in kidney samples after three days of 
Chapter 5: A signature of renal stress resistance induced by short-term dietary restriction, fasting, and 
protein restriction 
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Figure 1. A protein-free diet protects against renal IRI. (A) Three days of 30% DR did not protect against renal 
IRI. (B) Serum urea levels before and at day one after renal IRI did not differ between mice fed ad libitum (AL) for 
three days of 30% DR and a control diet. (C) Three days of protein-free diet improved survival compared with AL 
fed controls. (D) Serum urea levels of AL fed protein-free mice were significantly better compared to AL fed 
control mice (P<0.05). (E) Three days of protein-free diet resulted in 30% calorie restriction. (F) Mice fed a 
protein-free diet or a 30% DR diet for three days lost significantly more body weight than mice fed the control diet. 
Body weight changes did not differ between the protein-free diet and 3-day 30% DR. AL Control = ad libitum fed 
SDS chow, Control = control diet for the macronutrient diets, protein free = ad libitum fed protein-free diet. *P 
<0.05. 
 
Figure 1. A protein-free diet protects against renal IRI. (A) Three days of 30% DR did not protect against 
renal IRI. (B) Serum urea levels before and one day after renal IRI did not differ between mice fed ad libitum 
(AL) or three days of 30% DR. (C) Three days of protein-free diet improved survival compared with AL fed 
controls. (D) Serum urea levels of AL fed protein-free mice were significantly lower compared to AL fed 
control mice (P<0.05). (E) Three days of protein-free diet resulted in 30% calorie restriction. (F) Mice fed a 
protein-free diet or a 30% DR diet for three days lost significantly more body weight than mice fed the con-
trol diet. Body weight changes did not differ between the protein-free diet and 3-day 30% DR. AL Control 
= ad libitum fed SDS chow, Control = co trol diet for th  macronutrient diets, protein free = ad libitum fed 
protein-free diet. *P <0.05.
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fasting, three days and two weeks of 30% DR, three days of protein-, fat- or CHO-free 
diet, each compared to its corresponding AL fed control group. As the three days of 
fasting on the one hand and two weeks 30% DR and 3-day 30% DR on the other hand 
were each performed as individual cohorts using their own control group, we had three 
different control groups for all interventions combined. No significant differences in 
gene expression profiles were observed between the different control diets (data not 
shown). The highest number of significantly differentially expressed probe sets (DEPS) 
was found after three days of fasting, namely 2,604, of which 1,268 were up- and 1,336 
down-regulated. Two weeks of 30% DR gave rise to a five times lower number: 492 DEPS, 
of which 265 were up-regulated and 227 were down-regulated. Three days of protein-
free diet induced 391 DEPS, with 230 probe sets up- and 161 down-regulated. Of the 
non-protective diets, the 3-day fat-free diet did not induce any DEPS when compared to 
control diet fed mice, while three days of a CHO-free diet induced 1,717 DEPS containing 
613 up- and 1,104 down-regulated sets. Three days of 30% DR resulted in 454 DEPS, of 
which 284 up- and 170 down-regulated.
Several analytic approaches were performed to compare the transcriptomic response 
between all diets. First, a comparison was made based on the number of overlapping 
DEPS and the corresponding significance of the overlap (Table 1). Based on the maxi-
mum relative overlap, the 3-day protein-free diet and 3-day fasting demonstrated the 
most resemblance to each other with 222 DEPS in common, corresponding to 53.3% 
relative overlap. Two-weeks 30% DR showed 45.9% relative overlap with three days of 
fasting, with 247 DEPS in common. To compare the significance of these overlapping 
fractions, the enrichment factors (EF) with corresponding p-values were calculated. 
Comparison of the two identically modified diets differing only in intervention time, 
namely 3-days 30% DR and two weeks 30% DR, resulted in the highest EF with a 39 
times higher number of DEPS in common than would have been expected by chance 
(Table 1). Comparison of the 3-day protein-free diet with 3-day 30% DR resulted in an 
EF of 29. All enrichments were significant, with values lower than 8.66E-48, suggest-
ing a significant common transcriptomic response between dietary interventions with 
the exception of a 3-day fat-free diet. As directionality of the DEPS was not accounted 
for in this comparison, we explored dendographic heat maps. Since the 3-day fasting 
dataset was hybridized on a different date, the date of hybridization caused a stronger 
effect than the biological signal (Figure S3). It was therefore not possible to integrate 
all complete datasets in one informative heat map analysis. As a solution, we assumed 
three days of fasting to represent the widest transcriptomic protective response, and 
all data sets were limited to its highest number of 2,604 DEPS. The resulting heat map 
(Figure 2A) shows that the majority of the DEPS have similar directionalities, with the 
lowest expression levels in the fat-free diet. The horizontal dendogram, based on the 
(dis)similarity between expression data for probe sets, shows that three days of fasting 
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portrays the largest differences with the other groups. However, this was an assump-
tion, since the heat map is based on the probe sets differentially regulated after three 
days of fasting. Compared to three days of fasting, a 3-day CHO-free diet is the least 
clustered with the other dietary groups. The 3-day protein-free diet clusters closely with 
the non-protective 3-day fat-free diet, based on the number of probe sets as well as 
the expression levels. Three days 30% DR had a similar cluster pattern as two weeks of 
30% DR. Subsequently, the same set of 2,604 DEPS significantly regulated after fasting 
compared to AL fed controls, was used for a principal component analysis (PCA) among 
the macronutrient free diets, two weeks-, and three days 30% DR and their control diets 
(Figure 2B). 
Samples from the control diets and the 3-day fat-free diet cluster together, with high 
overlap and corresponding directionality between the groups. With a large distance on 
the principal component (PC) 2 axis, a similar clustering was seen among the 3-day 30% 
DR and two weeks 30% DR samples. The protein-free diet had its own cluster, separated 
on both PC axes from the other groups. The 3-day CHO-free diet resembled the DR diets, 
but showed no overlap with these diets and showed a large dissimilarity to the other 
groups. To compare the transcriptomic responses between all dietary interventions, all 
DEPS were visualized in a Venn diagram (Figure 3A). This revealed a total of 40 overlap-
ping DEPS in the three protective diets, while 30 overlapping DEPS were also present in 
the non-protective CHO-free diet. The genes corresponding to the 70 DEPS in common 
Table 1. Comparison of the overlapping DEPS between the five dietary interventions and their corre-
sponding P-value and enrichment factor 
Comparison Overlapping 
DEPS
Relative 
overlap (%)*
Enrichment 
factor
P-value
Protein-free vs. Fasting 222 53.3 9.8 5.27E-169
2wks 30% DR vs. Fasting 247 45.9 8.7 8.88E-171
3d 30% DR vs. Fasting 208 42.0 8.7 3.12E-156
2wks 30% DR vs. 3d 30% DR 195 28.1 39.4 3.44E-270
Protein-free vs. CHO-free 113 24.9 6.0 5.84E-55
Fasting vs. CHO-free 584 23.7 5.9 3.73E-300
2wks 30% DR vs. CHO-free 122 20.4 8.2 5.71E-76
3d 30% DR vs. CHO-free 107 19.6 5.8 8.66E-48
Protein-free vs. 3d 30% DR 116 18.5 29.5 2.22E-138
Protein-free vs. 2wks 30% DR 95 15.2 22.3 1.15E-99
The highest percentage of relative overlap was found between three days of protein-free diet and 
two weeks of 30% DR. The enrichment factor indicates the number of times the overlapping DEPS
is higher than expected by chance. All diets showed a significantly overlapping number of DEPS, 
as shown by the corresponding p-values in the last column. *Relative overlap is calculated by 
the number of DEPS in common between the two groups, divided by the total number of unique 
DEPS across both groups, relative to the theoretical maximum overlap according to this formula. 
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are listed in Table S3. Comparing 3-day 30% DR with the protective diets, a similar pat-
tern was observed; only 15 DEPS overlapped in the three protective diets, while 47 DEPS 
were also present in the non-protective 3-day 30% DR diet (Figure 3B). However, both 
numbers of overlapping genes appeared too small to perform pathway analysis with 
the aim to find a common denominator of protection against renal IRI, and therefore an 
alternative approximation for analysis was used.
Pathway analyses and transcription factor analyses
To explore the biological value of these transcriptomic responses, we used an individual 
approximation to identify significantly enriched pathways. The highest enriched path-
ways after the different dietary interventions were ranked by their –log p-value and 
summarized in Table S4. No clear pattern in overlapping pathways between all diets, or 
between the protective diets and the non-protective CHO-free diet, was observed. One 
 
Figure 2. Heat map and PCA plots of directional and cluster patterns in all dietary interventions based on the 
differentially expressed probe sets (DEPS) after three days of fasting compared to its control group. (A) The 
majority of the DEPS in the kidney after three days of fasting showed the same directionality in the other dietary 
interventions. The 3-day CHO-free diet was the least clustered with the other diets, followed by two weeks 30% 
DR and a 3-day protein-free diet. The fat-free diet, showing no significant DEPS, clustered together with a 3-day 
protein-free diet. Red= up-regulation, blue = down-regulation, white = no change. CHO-free = carbohydrate-free. 
(B) Principal component analysis (PCA) plot, based on the 2604 significantly regulated probe sets after three 
days fasting compared to the control diet fed animals. Both two weeks 30% DR and three days of 30% DR diet 
clustered close to each other based on the DEPS found after three days of fasting. The two control diets, control 
and SDS diet, clustered together with the non-protective fat-free diet. Three days of CHO-free diet positioned 
closely to two weeks and three days of 30% DR, but did not overlap with these diets. The protein-free diet had its 
own cluster, separated from the other groups on both PC axes.  
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pathway that emerged was the NRF2-mediated oxidative stress response pathway, since 
this pathway was activated by four out of five dietary interventions (Table S4).
To further identify a common protective response and dissect it from the response of 
the non-protective CHO-free diet, a more comprehensive meta-analytic approximation 
was used. A combining rank orders methodology was implemented to prevent bias of 
the results based on outliers as well as the stronger transcriptomic response after three 
days of fasting24. By eliminating all significant probe sets induced by the CHO-free diet 
in this meta-analysis, only 140 DEPS remained. Pathway analysis revealed no significant 
pathways (data not shown). Theorizing that the protective response might be partially 
overlapping with the response of the non-protective CHO-free diet, we repeated the 
meta-analysis with the three protective diets and the CHO-free diet into the approxima-
tion, thus not excluding the 3-day CHO-free diet. This meta-analysis yielded 640 DEPS. 
The majority of these DEPS in common showed a similar fold change and directionality 
among the three protective dietary interventions. 
A pathway analysis of these DEPS demonstrated regulation of nuclear receptor signal-
ing as well as inhibition of cellular stress and injury and biosynthesis pathways amongst 
the top 10 overrepresented pathway categories (Table 2). Adding the 3-day 30% DR diet 
in the meta-analysis yielded 279 DEPS. No significant enriched pathways emerged. The 
10 highest enriched pathways are depicted in Table S5. To further explore the regulated 
 
Figure 3. Venn diagram of multiple dietary interventions combined. (A) Venn diagram showing the number of 
DEPS after three days of fasting, two weeks 30% DR, three days of protein-free diet, three days of CHO-free diet, 
and their overlap with each diet. Thirty DEPS are differentially regulated in all four diets including the non-
protective CHO-free (centre). The protective diets have 70 DEPS in common, of which 40 of those in common 
with the CHO-free diet are excluded (lower right). (B) Venn diagram showing the number of DEPS after three 
days of fasting, three days of a protein-free diet, two weeks and three days of 30% DR with their overlap. Forty-
seven DEPS are differentially regulated in all fours diets (centre). A total of 15 DEPS were overlapping between 
the three protective diets. 
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Figure 4. Relative S6 phosphorylation signals in kidney after various diet interventions. The ratio of 
phosphorylated S6 over total S6 was significantly lower after three days of fasting compared to its control diet. All 
other dietary interventions showed a large variation in phosphorylation levels that did not reach statistical 
significance.  
 
 
 
Figure 3. Venn diagram of multiple dietary interventions combined. (A) Venn diagram showing the num-
ber of DEPS after three days of fasting, two we ks 30% DR, three days of protein-free diet, three days of 
CHO-free diet, and their overlap with each diet. Thirty DEPS are differentially regulated in all four diets in-
cluding the non-protective CHO-free (centre). The protective diets have 70 DEPS in common, of which 40 of 
those in common with the CHO-free diet are excluded (lower right). (B) Venn diagram showing the number 
of DEPS after three days of fasting, three days of a protein-free diet, two weeks and three days of 30% DR 
with their overlap. Forty-seven DEPS are differentially regulated in all fours diets (centre). A total of 15 DEPS 
were overlapping between the three protective diets.
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DEPS and pathways in relation to the protective response against renal IRI, we exam-
ined the involvement of upstream transcription factors (TFs) in the DEPS that emerged 
from the meta-analysis. In the meta-analysis, 16 TFs were identified of which 12 were 
predicted to be activated and six inhibited (Table 3). Critical denominators might be TFs 
showing the same directionality in the protective diets, but are oppositely directed or 
not regulated in the non-protective CHO-free diet. The TFs complying with these criteria, 
in descending order of absolute z-score, were forkhead box O3 (FOXO3), heat shock fac-
tor protein 1 (HSF1), and high mobility group AT-hook 1 (HMGA1). 
Furthermore, hepatocyte nuclear factor 4-alpha (HNF4α) was highly activated in the 
protective diets, but only minimally in the non-protective CHO-free diet. Also, sterol 
regulatory element-binding transcription factor 1 (SREBF1) and 2 (SREBF2) were signifi-
cantly down-regulated after three days of fasting and in the protein-free diet, activated 
in the CHO-free diet but not regulated after two weeks 30% DR. The non-protective 
3-day 30% DR diet showed similar results as the protective diets, since all TFs after three 
Table 2. Overview of the top 10 overrepresented canonical pathways in the meta-analysis ranked by their 
–log P-value. 
Meta-analysis 
Canonical Pathway Pathway Category P-value Genes Ratio Z-score
LXR/RXR Activation Nuclear Receptor Signaling 7.24E-09 16/121 (13.2%) +0.302
FXR/RXR Activation Nuclear Receptor Signaling 3.63E-06 13/127 (10.2%) N/A
LPS/IL-1 Mediated Inhibition of RXR 
Function
Nuclear Receptor Signaling 2.24E-05 16/219 (7.3%) -2.646
Superpathway of Cholesterol 
Biosynthesis
Fatty Acids and Lipids 
Biosynthesis, Sterol Biosynthesis
2.40E-05 6/28 (21.4%) N/A
NRF2-mediated Oxidative Stress 
Response
Cellular Stress and Injury 3.72E-05 14/180 (7.8%) -1.000
Aryl Hydrocarbon Receptor 
Signaling
Cell Cycle Regulation; Apoptosis; 
Xenobiotic Metabolism, Nuclear 
Receptor Signaling
5.13E-05 12/140 (8.6%) +1.633
PXR/RXR Activation Nuclear Receptor Signaling 9.12E-05 8/67 (11.9%) N/A
Intrinsic Prothrombin Activation 
Pathway
Cardiovascular Signaling; Cellular 
Stress and Injury
3.47E-03 5/29 (17.2%) N/A
Superpathway of 
Geranylgeranyldiphosphate 
Biosynthesis I
Cofactors, Prosthetic Groups and 
Electron Carriers Biosynthesis
3.98E-03 4/17 (23.5%) N/A
Aldosterone Signaling in Epithelial 
Cells
Cardiovascular Signaling; Nuclear 
Receptor Signaling
4.57E-03 11/152 (7.2%) N/A
The top 10 overrepresented pathways derived from the 640 DEPS in common between three days of fast-
ing, two weeks 30% DR, three days of a protein-free diet and three days of a carbohydrate-free diet. These 
pathways are mostly involved in regulation of nuclear receptor signalling (five out of 10), biosynthesis sig-
nalling (two out of 10) and cellular stress and injury (two out of 10). 
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days of 30% DR were similarly regulated as after three days of fasting, two weeks 30% DR 
and the three days of protein-free diet. 
The validity of these findings was further examined by determining mRNA expression 
levels. The expression levels of FOXO1 were significantly higher after all diets except the 
fat-free diet (Figure S4A), while FOXO3 was significantly up-regulated in all diets except 
after two weeks of 30% DR (Figure S4B). FOXO4 was only significantly up-regulated after 
three days of protein-free and three days of CHO-free diet (Figure S4C). HNF4α was not 
significantly regulated after any of the dietary interventions (Figure S4D). The mRNA 
expression level of down-regulated transcription factor SREBF1 was only significantly 
down-regulated after three days of fasting (Figure S4E), while SREBF2 was significantly 
down-regulated after three days of fasting and three days of protein-free diet (Figure 
S4F). 
Table 3. List of upstream transcription factors after meta-analysis with corresponding z-scores in the dif-
ferent dietary interventions.
Dietary intervention 
Transcription Factor
Meta-
analysis
3-day 
fasting
2 weeks 
30% DR
Protein-
free
CHO-
free
3-day 
30%DR 
SMAD7 – SMAD family member 7 +2.890 +0.718 -0.128 +2.466 N/A N/A
* FOXO3 - Forkhead box O3 +2.729 +3.303 +1.042 +1.701 -0.314 +1.893
FOXO1 - Forkhead box O1 +2.692 +1.599 -0.109 +0.269 -1.850 +0.360
* HNF4α – Hepatocyte nuclear factor 4 alpha +2.462 +2.122 +1.179 +2.089 +0.109 +1.327
MYCN – v-myc avian myelocytomatosis viral 
oncogene +2.414 +1.982 N/A +1.245 -2.464 +1.091
CLOCK – Circadian Locomotor output Cycles 
Kaput +2.373 +1.980 +1.119 N/A +1.940 +1.925
* HMGA1 – High mobility group AT-hook 1 +2.051 +1.432 +2.177 +0.356 N/A +0.785
MED1 – Mediator complex subunit 1 +2.008 +2.058 N/A N/A +0.102 N/A
SPDEF – SAM pointed domain containing ETS 
transcription factor +2.000 +2.170 N/A +1.000 N/A N/A
LYL1 – Lymphoblastic leukemia associated 
hematopoiesis regulator 1 +2.000 +2.000 N/A N/A N/A +1.982
SIM1 – Single-minded homolog 1 +2.000 +0.557 N/A N/A N/A N/A
ARNT2 – Aryl hydrocarbon receptor nuclear 
translocator 2 +2.000 +0.557 N/A N/A N/A N/A
GLI1 – GLI family zinc finger 1 -2.183 N/A N/A +0.057 N/A N/A
* HSF1 – Heat shock factor protein 1 -2.697 -1.659 -2.653 -2.376 +0.462 -0.451
SREBF2 - Sterol regulatory element-binding 
transcription factor 2 -2.923 -3.420 N/A -0.243 +0.660 N/A
SREBF1 - Sterol regulatory element-binding 
transcription factor 1 -3.889 -2.794 N/A -1.304 +1.229 -0.779
Upstream regulator analysis of the DEPS found in common after three days of fasting, two weeks 30% DR 
and three days of protein-free diet (meta-analysis) revealed 16 transcription factors (TFs) significantly regu-
lated, of which 12 were activated and four were inhibited. Highest activated TFs were SMAD7 and FOXO3. 
*TFs of interest that are not or oppositely regulated in the non-protective CHO-free diet. 
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Target pathways possibly involved in the protective effect of renal IRI 
Various pathways have been proposed to be involved in the protective response against 
renal IRI induced by DR and protein restriction. One of these is the eukaryotic transla-
tion factor 2 (eIF2α) signaling pathway, in which eIF2α is phosphorylated by the general 
control nonderepressible 2 (Gcn2) kinase, thereby inhibiting initiation of translation23. 
The role of Gcn2 and the eIF2α pathway is subject of debate, and the relevance of this 
pathway still needs to be elucidated23,25. Our microarray analyses showed a significant 
up-regulation of eIF2α transcription factor only after three days of fasting, while the GCN2 
gene and other target genes of the eIF2α pathway were not significantly differentially 
regulated after any of the dietary interventions. The mammalian Target of Rapamycin 
(mTOR) signaling pathway mediates between growth factors, hormones and nutrients 
to regulate essential cellular functions including survival and protein translation. Inhibi-
tion of the mTOR pathway has been demonstrated to increase lifespan in various animal 
species26,27 mTOR is part of mTOR complex 1 (mTORC1), a nutrient sensor complex that 
is involved in induction of oxidative stress resistance28. We found a down-regulation of 
mTOR after two weeks 30% DR (-0.6; P<0.01) and three days of a protein-free diet (-1.7; 
P<0.001), while MTORC1 (-1.6; P<0.01) and mTOR (-0.6; P<0.001) were down-regulated 
after three days of fasting. Both non-protective diets 3-day CHO-free (+0.8; P<0.01) and 
3-day 30% DR (+1.3; P<0.001) showed an up-regulation of mTOR. mTOR activity was 
examined at protein level by examining ribosomal protein S6 phosphorylation through 
immunoblotting in kidney extracts from all intervention and control groups. S6 is a 
downstream target of mTOR through S6 kinase29. Compared to the corresponding 
control group, three days of fasting showed a significant two-fold increase in relative 
ribosomal protein S6 phosphorylation (Figure 4). In the other dietary interventions, a 
large variation in phosphorylation levels was observed which did not reach statistical 
significance. 
 
Figure 3. Venn diagram of multiple dietary interventions combined. (A) Venn diagram showing the number of 
DEPS after three days of fasting, two weeks 30% DR, three days of protein-free diet, three days of CHO-free diet, 
and their overlap with each diet. Thirty DEPS are differentially regulated in all four diets including the non-
protective CHO-free (centre). The protective diets have 70 DEPS in common, of which 40 of those in common 
with the CHO-free diet are excluded (lower right). (B) Venn diagram showing the number of DEPS after three 
days of fasting, three days of a protein-free diet, two weeks and three days of 30% DR with their overlap. Forty-
seven DEPS are differentially regulated in all fours diets (centre). A total of 15 DEPS were overlapping between 
the three protective diets. 
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Figure 4. Relative S6 phosphorylation signals in kidney after various diet interventions. The ratio of 
phosphorylated S6 over total S6 was significantly lower after three days of fasting compared to its control diet. All 
other dietary interventions showed a large variation in phosphorylation levels that did not reach statistical 
significance.  
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Discussion
Since the discovery of the beneficial effects of short-term dietary restriction (DR) on stress 
resistance, optimizing its duration and content to eventually lead to a clinical applicable 
DR regimen has been an important part of the body of literature about DR2,11,23. Previ-
ously we have shown that two and four weeks of 30% DR as well as three days of fasting 
decreased morbidity and mortality, and improved kidney function in a murine renal IRI 
model1,12. In the present study, we show that a protein-free diet administered for only 
three days is sufficient to induce similar protection, whereas fat- and carbohydrate-free 
diets did not. Initially, we attempted longer periods of diet interventions, but found that 
mice fed a protein-free diet during 10 days applied self-restriction of approximately 30% 
of their normal intake (Figure S2). Therefore, the possible beneficial effects of calorie and 
protein restriction on kidney function and survival were indistinguishable. In a recent 
publication, Peng et al.23 found that mice fed a protein-free diet for six days restricted 
calorie intake. However, they stated that corrected for body weight, their calorie intake 
was similar to that of ad libitum fed mice. It is unknown whether six days of 30% DR 
induces protection against IRI, therefore a distinction between protein restriction and 
calorie restriction is still difficult to make. We showed that three days of 30% DR does not 
induce protection against renal IRI, and therefore we could disentangle the effects of 
calorie and protein restriction per se (Figure 1). A protein-free diet, given for three days 
induced protection whereas both a CHO-free and fat-free diet given for three or 14 days 
did not protect against renal IRI (Figure S2). A recent publication by Solon-Biet et al.20 
showed that the ratio of proteins and carbohydrates rather than DR per se influenced 
the lifespan of mice as well as metabolic parameters such as insulin and lipids. Since 
proteins fully substituted the carbohydrates in our CHO-free diet, and carbohydrates 
fully substituted the proteins in our protein-free diet, these diets further emphasize the 
importance of the ratio between proteins and carbohydrates (Table S1). 
Although the beneficial effects of both long-term and short-term DR have been ac-
knowledged, the mechanisms underlying DR are still subject of investigation. Various 
pathways, factors and genes have been proposed to play a central role in the protective 
effects30, but attempts to validate these yielded conflicting results31-34. We produced 
extensive expression datasets of diets proven to be either protective or not protective 
against renal IRI. Gene expression profiles of the non-protective CHO-free diet showed 
a considerable overlap with gene expression profiles of protective diets, namely three 
days of fasting, two weeks 30% DR and three days of protein-free diet (Figure 3). A PCA 
plot demonstrated the partial different directionality of gene expression in the CHO-free 
diet compared to the other dietary interventions. The 3-day 30% DR diet also showed 
considerable overlap with the protective diets, mainly with two weeks 30% DR, and a 
partially different but also partially overlapping directionality in response. These find-
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ings could either indicate that overlapping probe sets and pathways are not involved in 
the induction of protection against renal IRI, or that they may require additional changes 
in other probe sets to induce this effect. Particularly, the striking similarity between 
three days and two weeks 30% DR suggests that three days is sufficient to activate a 
transcriptomic response which is not yet sufficient to induce phenotypical protection. 
In addition, the non-protective fat-free diet showed strong similarity with the protective 
3-day protein-free diet, but with gene expression levels that were lower. These results 
indicate that the directionality, the number of probe sets and the expression levels are 
of importance in order to induce protection against renal IRI. To provide structure in 
the infinite amount of data generated by microarray analysis, we used meta-analytic 
approximations to specify for overlapping pathways and factors in all diets. A specific 
meta-analysis in which the DEPS were oppositely regulated in the protective diets ver-
sus the non-protective CHO-free diet, resulted in only 160 DEPS and yielded no addi-
tional pathways of interest compared to a meta-analysis including the CHO-free diet. 
In this meta-analysis several TFs, including FOXO3 and HNF4α, remained significantly 
up-regulated in the protective diets whilst not or oppositely regulated in the CHO-free 
diet (data not shown). 
Activation of nuclear receptor signaling pathways dominated the top 10 overrepre-
sented pathways after three days of fasting, two weeks of 30% DR and three days of 
protein-free diet (Table 2). Specific retinoid receptors, including the retinoid X receptor 
(RXR), the pregnane X receptor (PXR) and the peroxisome proliferator-activated receptor 
(PPAR)35, were also prominently up-regulated in our analysis, pointing towards a pivotal 
role for nuclear receptor signaling. 
Nuclear receptors are transcription factors that can be activated by steroid hormones 
and lipid-soluble agents, such as the retinoid acids (RAs)36. Administration of RAs 
induces many of the beneficial effects observed after DR. DR is able to ameliorate age-
related insulin resistance and degenerative brain diseases, and similar results have been 
described after treatment with RAs37-39. Both DR and administration of RAs are able to 
protect from ischemic stroke in the brain40-42. Signaling pathways activated by the inter-
action between RAs and nuclear receptors have also been considered to have tumor-, 
and immune suppressive effects, just as DR9,36,43. 
Involvement of nuclear receptor signaling is further supported by the upstream TF 
analysis (Table 3), since the majority of the activated or inhibited TF could be directly 
or indirectly linked to the activation of nuclear receptors. The activated TFs in all protec-
tive diets that were oppositely or not regulated in the non-protective CHO-free diet are 
FOXO3, HNF4α, HMGA1 and HSF1. A role for each of these four TFs in increased stress 
resistance has been previously observed. For example, FOXO3 phosphorylation via the 
c-Jun N-terminal kinase -pathway results in its nuclear inclusion and activation of vari-
ous processes involved in cellular stress resistance, biosynthesis, cell cycle regulation as 
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well as apoptosis and autophagy44,45. A fasting-induced interaction, mediated by insulin 
signaling, with members of the FOXO family and RXR has been described as well46. 
HMGA1 is a downstream target of the insulin receptor pathway and could function as 
an important nuclear factor mediating the binding of FOXO proteins to other nuclear 
receptors, including the retinoid nuclear receptor family and thereby regulating insulin 
target genes47. 
HNF4α is a nuclear TF that is involved in the development as well as in the metabo-
lism of mainly the liver and kidney48. Up-regulation of HNF4α occurs via co-stimulation 
of LXR and FXR and usually depends on the presence of low levels of stressors, such 
as interleukin-1 and tumor necrosis factor alpha. Transcriptional activity of HNF4α 
 is also regulated indirectly by insulin through the action of FOXO148. Activation of HNF4α
 results in inhibition of the activity of metabolic sensors, including SREBF and the mam-
malian target of Rapamycin (mTOR)49,50. This leads to down-regulation of metabolism, in 
particular cholesterol metabolism, and may contribute to increased stress resistance via 
the down-regulation of mTOR50,51. We showed that the activity of mTOR, as determined 
by the phosphorylation of the ribosomal protein S6, was significantly down-regulated 
after three days of fasting. A trend towards lower phosphorylation levels was seen after 
the other two protective diets: two weeks 30% DR and a 3-day protein-free diet. These 
data indicate that mTOR may play an important role in the protection against IRI, which 
may vary according to the type of nutrient deprivation that is offered.
Another pathway involved in nutrient sensing is GCN2, of which eIF2α is an important 
downstream target. GCN2 becomes transcriptionally activated by deprivation of amino 
acids and phosphorylates eIF2α, which leads to the activation of pathways involved in 
stress resistance. We did not find transcriptional regulation of the GCN2 gene in any 
of the three protective diets. Although our data do not preclude posttranscriptional 
regulation of this pathway, they corroborate with those of Robertson et al.52, who ob-
served that GCN2 signaling was not required for protection against renal IRI by protein 
restriction.
In summary, we demonstrated that three days of a protein-free diet in mice protects 
against renal IRI, similar to two weeks of 30% DR and three days of fasting. Comparative 
transcriptional analysis of kidney tissue following these dietary interventions demon-
strated a significant overlap in differentially expressed genes and pathways, which are 
involved in resistance against oxidative damage induced by renal IRI. A meta-analysis 
of pathways and TFs indicates that DR up-regulates at least four TFs that activate a 
transcriptional response, which, in turn, increases nuclear receptor signaling dependent 
and independent cellular stress resistance. However, our attempt to understand the 
beneficial effects of different dietary restriction regimens on renal IRI by transcriptome 
analysis suggests that pivotal molecular changes also occur beyond the transcriptional 
level, and that additional ‘omics” analyses, including proteomics are needed to come to 
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a complete understanding. Therefore, more research is warranted to further elucidate 
the role of these pathways in the induction of acute stress resistance by short-term DR, 
which may ultimately lead to “dietary restriction mimetic” therapeutic strategies that 
exploit the benefits of dietary restriction in humans. 
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Figure S1. Schematic overview of the experimental design. 
 
Figure S1. Schematic overview of the experimental design. After an acclimation period for all groups of 7 
days on SDS chow, the long-term experiments started with diets given for either 10- or 14 days. At day -3 relative 
to induction of ischemia-reperfusion injury (IRI) the short-term dietary intervention and gene expression profiling 
experiments were started. At day 0, animals used for transcriptomic profiling were sacrificed for further analyses. 
In the other groups, blood collection was  followed by induction of bilateral renal IRI for 37 minutes and collection 
of blood one day later.  Mice were followed until day 7 after IRI, after which they were sacrificed. 
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7 days on SDS chow, the long-term experiments started with diets given for either 10- or 14 days. At day 
-3 relative to induction of ischemia-reperfusion injury (IRI) the short-term dietary intervention and gene 
expression profiling experiments were started. At day 0, animals used for transcriptomic profiling were 
sacrificed for further analyses. In the other groups, blood collection was followed by induction of bilateral 
renal IRI for 37 minutes and collection of blood one day later. Mice were followed until day 7 after IRI, after 
which they were sacrificed.
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Figure S2. Effects on food intake, body weight and survival by macronutrient free di ts and 
effects on kidney function upon subsequent renal ischemia reperfusion injury.  
 
Figure S2. Effects on food intake, body weight and survival by macronutrient free diets and effects on 
kidney function upon subsequent renal ischemia reperfusion injury. (A) Relative to their control food intake 
during the 7 day acclimatization period, mice consumed (cumulatively during the whole intervention period) 21.7% 
less of the CHO-free diet, 10.1% of the fat-free diet and 32.7% of the protein-free diet. (B) Body weight of mice 
fed a CHO-free diet decreased during the 14-day period with 6.7%, while mice on a 14-day fat-free diet showed 
an increase in body weight with 2.3%. Mice fed a protein-free diet for 10 days lost more than 20% of their body 
weight on day 10. Because of this substantial loss of body weight, the protein-free diet was limited to a period of 
10 days or less in the subsequent ischemia-reperfusion experiments. (C) Mouse mortality rates upon renal 
ischemia-reperfusion injury after both the CHO- and fat-free diet were significantly higher than their PFed controls 
(P<0.05). Mice fed a protein-free diet for 10 days showed a 100% survival following renal IRI. (D) Kidney function 
as determined by serum urea levels on day 1 after induction of renal IRI were significantly worsened in both the 
CHO-free (P<0.05) and fat-free (P<0.05) groups compared to PFed groups. Mice fed a protein-free diet showed 
lower serum urea levels one day after induction of IRI compared with CHO-free (P<0.01), the PFed CHO-free 
(P<0.05), the fat-free (P<0.01) and the PFed fat-free group (P<0.05). ** = P<0.05 compared to AL CHO-free diet 
on day 0. ## = P<0.05 compared to AL fat-free diet on day 0. ^^ = P<0.05 compared to AL protein-free diet on day 
0.  
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Figure S2. Effects on food intake, body weight and survival by macronutrient free diets and effects on kid-
ney function upon subsequent renal ischemia reperfusion injury. (A) Relative to their control food intake 
during the 7 day acclimatization period, mice consumed (cumulatively during the whole intervention pe-
riod) 21.7% less of the CHO-free diet, 10.1% of the fat-free diet and 32.7% of the protein-free diet. (B) Body 
weight of mice fed a CHO-free diet d creas d uring the 14-day period with 6.7%, while mice on a 14-day 
at-free diet showed an incr ase in bodyweight with 2.3%. Mice fed a protein-free diet for 10 days lost mor  
tha  20% of their body weig t on day 10. Because of this substantial loss of body weight, the protein-free 
diet was limited to a period of 10 days or less in the subsequent ischemia-reperfusion experiments. (C) 
Mouse mortality rates upon renal ischemia-reperfusion injury after both the CHO- and fat-free diet were 
significantly higher than their PFed controls (P<0.05). Mice fed a protein-free diet for 10 days showed a 
100% survival following renal IRI. (D) Kidney function as determined by serum urea levels on day 1 after in-
duction of renal IRI were significantly worsened in both the CHO-free (P<0.05) and fat-free (P<0.05) groups 
compared to PFed groups. Mice fed a protein-free diet showed lower serum urea levels one day after induc-
tion of IRI compared with CHO-free (P<0.01), the PFed CHO-free (P<0.05), the fat-free (P<0.01) and the PFed 
fat-free group (P<0.05). ** = P<0.05 compared to AL CHO-free diet on day 0. ## = P<0.05 compared to AL 
fat-free diet on day 0. ^^ = P<0.05 compared to AL protein-free diet on day 0.
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Figure S3. PCA of all probes on the microarray chip. 
 
Figure S3. PCA of all probes on the microarray chip. This unbiased analysis shows the argest source of 
variability,  PC1 is related to the date of hybridization. The 3-day fasting group and their corresponding 
control group were hybridized on a different date than the other groups. This result made the joint analysis of 
all datasets impracticable. PC2 explains only 15% of the variability, and it is related to the dietary 
interventions compared to the control samples. AL SDS (Fast)=  control group of the 3-day fasting mice. AL 
SDS (DR) = control group of the 2 weeks 30% DR mice. Control = control group of the macronutrient-free 
diets. 
 
 
 
 
 
 
 
Figure S3. PCA of all probes on the microarray chip. This unbiased analysis shows the argest source of vari-
ability, PC1 is related to the date of hybridization. The 3-day fasting group and their corresponding control 
group were hybridized on a ifferent date than the other groups. This result made the joint analysis of all 
datasets impracticable. PC2 explains only 15% of the variability, and it is related to the dietary interventions 
compared to the control samples. AL SDS (Fast)= control group of the 3-day fasting mice. AL SDS (DR) = 
control group of the 2 weeks 30% DR mice. Control = control group of the macronutrient-free diets.
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Figure S4. PCR data of mRNA expression levels of genes related to significantly regulated transcription fac-
tors. (A) FOXO1 was significantly higher after all diets except the fat-free diet. (B) FOXO3 showed significant 
up-regulation after all diets except the 2 weeks 30% DR. (C) FOXO4 expression levels were significant higher 
after three days of 30% DR and three days of a CHO-free diet. (D) HNF4a was not significantly regulated 
after any of the dietary interventions. (E) SREBF1 was down-regulated after three days of fasting, while (F) 
SREBF2 was significantly down-regulated after both three days of fasting and a 3-day protein-free diet. 
FOXO = forkhead box O; HNF4a = hepatocyte nuclear factor 4-alpha; SREBF = sterol regulatory element-
binding transcription factor 1. * = P<0.05; ** = P<0.01.
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Figure S5. Representative Western blots of kidney extracts for both phosphorylated (A) and 
total (B) ribosomal protein S6 with β-actin as a loading control used for the relative 
quantification in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S5. Representative Western blots of kidney extracts for both phosphorylated (A) and total (B) 
ribosomal protein S6 with β-actin as a loading control used for the relative quantification in Figure 4. The 
depicted exemplary blots show a full set of kidney extracts from each indicated diet group (lanes 1 – 8) next to a 
marker lane (lane Mr) and a reference sample (lane 9). In total, four such sets of Western blots were generated, 
each with four unique complete series for each diet group. For interblot comparison the exact same amount of the 
reference sample (lane 9) was loaded on each blot. The relative phosphorylation ratios depicted in Figure 4. are 
derived from the quantified signal of the main band in each lane, subtracted with background and corrected for 
both the sample dependent β-actin signal and the blot dependent signal of the reference sample. 
 
Figure S5. Representative Western blots of kidney extracts for both phosphorylated (A) and total (B) ri-
bosomal protein S6 with β-actin as a loading control used for the relative quantifi cation in Figure 4. The 
depicted exemplary blots show a full set of kidney extracts from each indicated diet group (lanes 1 – 8) 
next to a marker lane (lane Mr) and a reference sample (lane 9). In total, four such sets of Western blots were 
generated, each with four unique complete series for each diet group. For interblot comparison the exact 
same amount of the reference sample (lane 9) was loaded on each blot. The relative phosphorylation ratios 
depicted in Figure 4 are derived from the quantifi ed signal of the main band in each lane, subtracted with 
background and corrected for both the sample dependent β-actin signal and the blot dependent signal of 
the reference sample.
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Table S1. Composition and energy content of the individual diets.
Ingredient Control SDS-CRMP Carbohydrate-free Fat-free Protein-free
Crude protein* (%/g)
Casein, lactic (%/g) 20.0
16.4
99.2 31.3 0
 Total kcal/g 3.8 3.3 3.4 3.5 3.8
Protein (g/kg) 179.0 183.5 887.9 280.1 0.0
Carbohydrate (g/kg)  710.0 574.0 1.0 710.0 889.0
Fat (g/kg) 45.0 33.6 45.0 0.0 45.0
Fiber (g/kg) 50.0 24.8 50.0 50.0 50.0
Protein (g%) 17.0 22.0 77.2 24.9 0
Carbohydrate (g%) 67.3 68.9 0.1 63.1 86.2
Fat (g%) 4.3 9.1 3.9 0.0 4.4
Fiber (g%) 4.7 4.2 4.3 4.4 4.8
Protein (kcal/kg) 716 734 3551 1121 0
Carbohydrate (kcal/kg) 2840 2296 4 2840 3556
Fat (kcal/kg) 405 303 405 0 405
Protein (kcal%) 18 22 90 28 0
Carbohydrate (kcal%) 72 69 0 72 90
Fat (kcal%) 10 9 10 0 10
*protein sources: wheat, barley, soya, maize, potato protein
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Table S2. Overview of the dietary interventions, the groups and numbers of mice used for pheno-
typical and transcriptional endpoints.
(A) Overview IRI long-term experiments
Dietary Intervention Model Duration 
(days)
Number 
of mice
Follow-
up (days)
Parameters measured
Control SDS C57BL/6 14 10 7 Survival, body weight, kidney function
Control C57BL/6 14 12 7 Survival, body weight, kidney function
Fat-free C57BL/6 14 6 7 Survival, body weight, kidney function 
Pair-fed fat-free C57BL/6 14 6 7 Survival, body weight, kidney function
Carbohydrate-free C57BL/6 14 6 1 Survival, body weight, kidney function
Pair-fed carbohydrate-free C57BL/6 14 6 7 Survival, body weight, kidney function
Protein-free C57BL/6 10 6 7 Survival, body weight, kidney function
(B) Overview IRI short-term experiments
Dietary Intervention Model Duration 
(days)
Number 
of mice
Follow-
up (days)
Parameters measured
Control C57BL/6 3 4 7 Survival, body weight, kidney function
Protein-free C57BL/6 3 4 7 Survival, body weight, kidney function
AL Control (control to 
3-day 30% DR)
C57BL/6 3 4 7 Survival, body weight, kidney function
3 days 30% DR C57BL/6 3 6 7 Survival, body weight, kidney function
(C) Overview of gene transcription experiments
Dietary Intervention Model Duration 
(days)
Number 
of 
arrays
Follow-
up 
(days)
Parameters measured
Control SDS (control 
2-week 30% DR)
C57BL/6 14 4 0 Gene expression profiling in kidney tissue
2-week 30% DR C57BL/6 14 5 0 Gene expression profiling in kidney tissue
Control SDS (control 
3-day fasting)
C57BL/6 3 5 Gene expression profiling in kidney tissue
3-day fasting C57BL/6 3 4 0 Gene expression profiling in kidney tissue
Control C57BL/6 3 5 0 Gene expression profiling in kidney tissue
Protein-free C57BL/6 3 5 0 Gene expression profiling in kidney tissue
Fat-free C57BL/6 3 4 0 Gene expression profiling in kidney tissue
Carbohydrate-free C57BL/6 3 5 0 Gene expression profiling in kidney tissue
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Table S3. List of genes corresponding to the DEPS found in common between all dietary interven-
tions combined.
Affymetrix ID Entrez Gene ID Symbol Gene Name Log Ratio
1415802_PM_at 20501 SLC16A1
solute carrier family 16 (monocarboxylate 
transporter), member 1 -0,488
1415828_PM_a_at 28146 SERP1
stress-associated endoplasmic reticulum 
protein 1 -0,639
1416414_PM_at 100952 EMILIN1 elastin microfibril interfacer 1 -0,623
1416630_PM_at 15903 ID3
inhibitor of DNA binding 3, dominant 
negative helix-loop-helix protein 1,008
1417150_PM_at 15567 SLC6A4
solute carrier family 6 (neurotransmitter 
transporter), member 4 0,537
1418591_PM_at 58233 DNAJA4
DnaJ (Hsp40) homolog, subfamily A, 
member 4 -0,709
1419040_PM_at 56448 Cyp2d22
cytochrome P450, family 2, subfamily d, 
polypeptide 22 1,033
1422974_PM_at 23959 NT5E 5’-nucleotidase, ecto (CD73) -1,037
1423392_PM_at 29876 CLIC4 chloride intracellular channel 4 -0,782
1423627_PM_at 18104 NQO1 NAD(P)H dehydrogenase, quinone 1 1,024
1424618_PM_at 15445 HPD 4-hydroxyphenylpyruvate dioxygenase 1,064
1424983_PM_a_at 78832 CACUL1 CDK2-associated, cullin domain 1 -0,746
1426568_PM_at 117591 SLC2A9
solute carrier family 2 (facilitated glucose 
transporter), member 9 0,684
1426896_PM_at 59057 ZNF24 zinc finger protein 24 -0,495
1427364_PM_a_at 18263 ODC1 ornithine decarboxylase 1 -0,975
1427931_PM_s_at 216134 PDXK pyridoxal (pyridoxine, vitamin B6) kinase 1,251
1428332_PM_at 216505 PIK3IP1
phosphoinositide-3-kinase interacting 
protein 1 0,828
1433557_PM_at 52609 CBX7 chromobox homolog 7 0,618
1434437_PM_x_at 20135 RRM2 ribonucleotide reductase M2 -0,128
1434974_PM_at 228026 PDK1 pyruvate dehydrogenase kinase, isozyme 1 0,683
1436893_PM_a_at 57438 MARCH7
membrane-associated ring finger (C3HC4) 
7, E3 ubiquitin protein ligase 0,585
1438211_PM_s_at 13170 DBP
D site of albumin promoter (albumin 
D-box) binding protein 1,768
1439797_PM_at 19015 PPARD
peroxisome proliferator-activated receptor 
delta -0,838
1443870_PM_at 239273 ABCC4
ATP-binding cassette, sub-family C (CFTR/
MRP), member 4 1,063
1449183_PM_at 12846 COMT catechol-O-methyltransferase -0,944
1449460_PM_at 142688 ASB13
ankyrin repeat and SOCS box containing 
13 -0,686
1449848_PM_at 14675 GNA14
guanine nucleotide binding protein (G 
protein), alpha 14 -0,832
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Table S3. List of genes corresponding to the DEPS found in common between all dietary interven-
tions combined. (continued)
Affymetrix ID Entrez Gene ID Symbol Gene Name Log Ratio
1451122_PM_at 319554 IDI1
isopentenyl-diphosphate delta isomerase 
1 -1,173
1452264_PM_at 209039 TNS2 tensin 2 0,757
1454709_PM_at 100201 TMEM64 transmembrane protein 64 -0,867
1455293_PM_at 235497 LEO1
LEO1 homolog, Paf1/RNA polymerase II 
complex component -0,727
1455343_PM_at 233765 PLEKHA7
pleckstrin homology domain containing, 
family A member 7 0,922
1455393_PM_at 12870 CP ceruloplasmin (ferroxidase) 1,037
1455490_PM_at 18703 PIGR polymeric immunoglobulin receptor 0,924
1457689_PM_at 319934 SBF2 SET binding factor 2 0,761
1458176_PM_at 18628 PER3 period circadian clock 3 1,072
1460239_PM_at 66109 TSPAN13 tetraspanin 13 -0,925
The Afymmetrix probe sets, their corresponding Entrez Gene ID, symbol, gene name and log ratio are de-
picted in ascending order of the Affymetrix probe set. Only the probe sets with a corresponding gene ID are 
listed, therefore probe sets corresponding to the same gene ID are excluded. Log Ratio = log transformed 
fold change. 
Table S4. Top 10 overrepresented canonical pathways after fasting, dietary restriction and macro-
nutrient free diets individually ranked by their –log P-value.
3-day FASTING
Canonical Pathway P-value Genes Ratio
Superpathway Cholesterol Biosynthesis 3.41E-08 14/87 (16.1%)
Cholesterol Biosynthesis I / II / III 2.18E-06 8/40 (20.0%)
LXR / RXR Activation 2.20E-06 27/139 (19.4%)
NRF2-mediated Oxidative Stress Response 6.27E-06 34/195 (17.4%)
LPS/IL-1 Mediated Inhibition of RXR Function 7.46E-06 39/245 (15.9%)
Acute Phase Response Signaling 7.24E-05 30/181 (16.6%)
GADD45 Signaling 1.25E-04 8/24 (33.3%)
AMPK Signaling 1.25E-04 25/180 (13.9%)
VDR/RXR Activation 2.18E-04 17/88 (19.3%)
Xenobiotic Metabolism Signaling 3.00E-04 42/304 (13.8%)
2-week 30% DR
Canonical Pathway P-value Genes Ratio
Circadian Rhythm Signaling 1.41E-05 6/38 (15.8%)
Aldosterone Signaling Epithelial Cells 3.20E-05 11/168 (6.5%)
Guanosine Nucleotides Degradation II 7.85E-04 3/22 (13.6%)
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Urate Biosynthesis 1.01E-03 3/22 (13.6%)
Phenylalanine Degradation IV 1.27E-03 3/39 (7.7%)
2-ketoglutarate Dehydrogenase Complex 1.48E-03 2/9 (22.2%)
Adenosine Nucleotides Degradation II 1.57E-03 3/26 (11.5%)
NRF2-mediated Oxidative Stress Response 2.39E-03 9/195 (4.6%)
Protein Ubiquitination Pathway 2.63E-03 11/270 (4.1%)
Purine Nucleotides Degradation II 2.71E-03 3/35 (8.6%)
3-day PROTEIN-FREE
Canonical Pathway P-value Genes Ratio
Intrinsic Prothrombin Activation Pathway 5.18E-04 4/37 (10.8%)
Superpathway Cholesterol Biosynthesis 6.79E-04 4/87 (4.6%)
LPS/IL-1 Mediated Inhibition of RXR Function 8.81E-04 10/245 (4.1%)
Mevalonate Pathway I 9.87E-04 3/29 (10.3%)
Creatine-phosphate Biosynthesis 1.77E-03 2/9 (22.2%)
Superpathway of Geranylgeranyl 2.02E-03 3/37 (8.1%)
PXR/RXR Activation 2.12E-03 5/92 (5.4%)
GADD45 Signaling 2.35E-03 3/24 (12.5%)
Tryptophan Degradation 4.84E-03 2/18 (11.1%)
Nicotine Degradation II 9.33E-03 4/85 (4.7%)
3-day CARBOHYDRATE-FREE
Canonical Pathway P-value Genes Ratio
Histamine Degradation 9.52E-05 6/29 (20.7%)
Pyrimidine Deoxygenase De Novo Biosynthesis I 1.57E-04 6/34 (17.6%)
Superpathway of Serine and Glycine Biosynthesis I 2.57E-04 4/18 (22.2%)
Glycolysis I 6.98E-04 7/41 (17.1%)
NRF2-mediated Oxidative Stress Response 8.17E-04 24/195 (12.3%)
Cholesterol Biosynthesis I / II / III 1.04E-03 5/40 (12.5%)
Colanic Acid Building Blocks Biosynthesis 1.52E-03 5/36 (13.9%)
Fatty Acid β-oxidation 1.52E-03 5/21 (23.8%)
Protein Ubiquitination Pathway 1.58E-03 30/270 (11.1%)
Folate Transformations I 1.84E-03 4/32 (12.5%)
3-day 30% DR
Canonical Pathway P-value Genes Ratio
Dopamine Degradation 1.08E-04 5/35 (14.3%)
Aryl Hydrocarbon Receptor Signaling 1.37E-04 9/140 (6.4%)
LPS/IL-1 Mediated Inhibition of RXR Function 2.48E-04 11/221 (5.0%)
PXR/RXR Activation
Circadian Rhythm Signaling
2.63E-04
1.03E-03
6/65 (9.2%)
4/33 (12.1%)
110
Chapter 5
NRF2-mediated Oxidative Stress Response 1.42E-03 9/193 (4.7%)
Tyrosine Degradation I 1.82E-03 2/5 (40.0%)
Histamine Degradation 2.09E-03 3/19 (15.8%)
Noradrenaline and Adrenaline Degradation 2.14E-03 4/40 (10.0%)
Adipogenesis Pathway 2.52E-03 7/134 (5.2%)
Top 10 overrepresented pathways after dietary restriction and macronutrient free diets, with the exception 
of the 3-day fat-free diet that showed no differentially expressed probe sets. Analysis revealed no pathways 
regulated in common between the three protective diets. Furthermore, no pathways were oppositely regu-
lated in the non-protective CHO-free diet. Genes ratio is the number and percentage of genes differentially 
expressed in ratio to the total number of genes involved in the pathway.
Table S5. Top 10 overrepresented canonical pathways after the meta-analysis including fasting, di-
etary restriction and macronutrient free diets ranked by their –log P-value.
Meta-analysis II (Incl. 3-day 30% DR)
Canonical Pathway Pathway Category P-value Genes Ratio Z-score
LPS/IL-1 Mediated Inhibition of RXR 
Function
Nuclear Receptor Signaling 4.68E-05 10/221 (4.5%) N/A
NRF2-mediated Oxidative Stress 
Response
Cellular Stress and Injury 8.92E-05 9/193 (4.7%) N/A
PXR/RXR Activation Nuclear Receptor Signaling 3.59E-04 5/65 (7.7%) N/A
Noradrenaline and Adrenaline 
Degradation
Degradation/Utilization/ 
Assimilation; Hormones
5.25E-04 4.40 (10.0%) N/A
Aryl Hydrocarbon Receptor Signaling
Cell Cycle Regulation; 
Apoptosis; Xenobiotic 
Metabolism, Nuclear Receptor 
Signaling
2.08E-03 6/140 (4.3%) N/A
Superpathway of Cholesterol 
Biosynthesis
Fatty Acids and Lipids 
Biosynthesis, Sterol 
Biosynthesis
2.23E-03 3/28 (10.7%) N/A
Glutathione-mediated Detoxification
Degradation/Utilization/ 
Assimilation; Detoxification
2.47E-03 3/29 (10.3%) N/A
Circadian Rhythm Signaling
Neurotransmitters and Other 
Nervous System Signaling
3.59E-03 3/33 (9.1%) N/A
Retinoate Biosynthesis I
Vitamin (A) Biosynthesis; 
Cofactors, Prosthetic Groups 
and Electron Carriers 
Biosynthesis
3.91E-03 3/34 (8.8%) N/A
Dopamine Degradation
Degradation/Utilization/ 
Assimilation; Amines and 
Polyamines Degradation
4.25E-03 3/35 (8.6%) N/A
The top 10 overrepresented pathways derived from the 279 DEPS in common between 3-days of fasting, 
2 weeks 30% DR, three days of a protein-free and three days of a 30% DR diet. These pathways are mostly 
involved in regulation of nuclear receptor signalling (5 out of 10), biosynthesis signalling (2 out of 10) and 
cellular stress and injury (2 out of 10). 
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Abstract
Ischemia reperfusion injury (IRI) is inevitable during major liver surgery and liver trans-
plantation leading to oxidative stress. Preoperative short-term 30% dietary restriction 
(DR), three days of fasting and three days of a protein-free diet protect against IRI. Here, 
we further disentangled the role of essential amino acids on the effects of DR on liver IRI. 
Male C57BL/6 mice were randomized to preoperative ad libitum control food or 
three days of 30% DR, methionine-free, leucine-free or tryptophan-free diet for three 
days. Liver IRI was induced by partial occlusion of the blood flow (70%) of the liver for 
75 minutes. Food intake and body weight were monitored until postoperative day 1. 
Hepatic damage was measured biochemically and histologically at 6 and 24 hours after 
IRI. After completing each diet, liver gene expression profiles we determined by microar-
ray analysis. All amino acid free diets resulted in body weight loss prior to IRI. Liver IRI 
was already significantly decreased by both the leucine- and tryptophan-free diets at 6 
hours after IRI, and by the methionine-free diet at 24 hours. Microarray analysis showed 
similar transcriptomic responses in all amino acid-free diets, yet with a lower magnitude 
in the methionine-free diet. Detailed analysis of overlapping genes suggested a role for 
pathways involved in nuclear receptor signaling, stress resistance and cell cycle regula-
tion via transcription factors NRF2, FOXM1, SREBF2 and SMARCB1. 
A short-term preoperative tryptophan-free, leucine-free and methionine-free diet 
protect against hepatic IRI similar to a protein-free diet, through a network of pathways 
potentially activated by NRF2, FOXM1, SREBF2 and SMARCB1.
Essential amino acids protects against hepatic ischemia reperfusion injury
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Introduction
Dietary restriction (DR) is defined as a reduction in food intake without malnutrition1. 
Long-term DR is known to extend lifespan1, increase health span2 and improve resis-
tance to multiple stressors1,3 in a wide variety of organisms4-6. Although the effect of 
DR on lifespan in humans is not known, studies show a favorable impact on metabolic 
parameters associated with long-term health7-9. In addition, previous studies showed 
that 2 weeks of 30% DR and three days of fasting increase stress resistance and protect 
against oxidative stress induced by ischemia reperfusion injury (IRI) in mice1,10.  
During major liver surgery and liver transplantation IRI is inevitable and a risk factor for 
complications including primary graft dysfunction and primary non-function, thereby 
causing morbidity and mortality11-13. Cessation of the blood flow (ischemia) leads to 
hypoxia, nutrient deprivation and activation of anaerobic metabolic systems13. Reperfu-
sion of the liver promotes the activation of an inflammatory response, causing further 
cellular damage and the generation of reactive oxygen species13. Therefore, counteract-
ing the adverse effects of IRI could improve the outcome after liver transplantation and 
liver resection. Unfortunately, at this moment no effective treatment for IRI is available. 
Whether the protection by short-term DR is based on a reduction of calories or based 
on the reduction of specific nutrients is not yet completely unraveled. Also, the search 
for the underlying mechanisms of DR is still ongoing. In mice, liquid glucose supple-
mentation did not interfere with the protective effect of 3 days of fasting against renal 
IRI14. In fruit flies, long-term protein restriction contributed more to extension of the life 
span compared to the reduction of carbohydrates or fat15,16. We previously investigated 
the role of specific macronutrients by unrestricted feeding of protein-, carbohydrate-, 
and fat free diets in inducing resistance against renal IRI. We showed that three days 
of a protein- but not a carbohydrate- or a fat-free diet before the induction of renal IRI 
improved survival and kidney function similarly as DR and fasting17. These results point 
towards a role for specific nutrients in the protective effect against renal IRI.
In the present study, we investigated the role of preoperative essential amino acid 
(EAA)-free diets by unrestricted feeding of methionine (Met)-free, leucine (Leu)-free and 
tryptophan (Trp)-free diets in reducing oxidative damage in the liver, and analyzed the 
transcriptomic response of the liver to these diets.  
Material and methods
Animals
Male C57BL/6 (approximately 25 grams) were obtained from Harlan (Horst, the Neth-
erlands). Animals were kept under standard laboratory conditions, and were housed in 
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individually ventilated cages (n = 3 animals/cage). All mice had ad libitum (AL) access to 
food and water (acidified with HCl). All experiments were performed with the approval 
of the appropriate local ethical board.
Diets
Before dietary intervention, all mice were acclimatized during 7 days and fed the 
standard Special Diet Services (SDS) chow. All other diets used for dietary intervention 
were purchased from Research Diets, Inc. (New Brunswick, NJ, USA). The SDS chow was 
used as a control diet for the fasted and 30% dietary restricted mice1. As a control for 
the protein-free and EEA-free diet, a specific control diet was used since this diet has 
the same protein source as the EAA-free diets, including all EAA (Table S1). The protein 
source of the EAA-free diets is derived from a crystalline L-amino acid mixture without 
one of the specific amino acids (Met-free, Leu-free or Trp-free). During the experiment, 
three days 30% DR was used as a negative control group while previous studies showed 
that this dietary intervention did not protect against IRI17. Mice on three days of 30% 
dietary restriction were given 70% of their normal daily intake of the SDS chow. Three 
days of protein-free diet was used as a positive control while this diet protects against 
IRI12. Mice on protein-free, Trp-free, Met-free and Leu-free diets were transferred to clean 
cages with the specific diet given at 4:00 pm. Mice on the control diet were used as the 
control group. Body weight of the mice was recorded daily. An overview of the composi-
tion of the diets used is shown in Table S1.
Hepatic ischemia reperfusion model
Mice were anesthetized by isoflurane/N2/O2 inhalation. To maintain their body tem-
perature mice, were placed on a heating pad. All surgeries were performed between 
9:00 and 1:00 pm. Partial (70%) hepatic IRI was induced by occlusion of the blood flow 
of the left lateral and median liver lobes with a non-traumatic micro vascular clamp for 
75 minutes, which causes ischemia of the liver tissue. After clamp removal, the restora-
tion of blood flow in the liver leads to reperfusion. No mortality was observed associ-
ated with this amount of damage to the liver. After surgery, all mice received 0.5 mL of 
phosphate-buffered saline subcutaneously and were placed under a heating lamp until 
they recovered from anesthesia. Directly after, all mice had free access to SDS chow and 
water.
Hepatocellular injury
Preoperatively fed and fasted mice were euthanized before surgery (baseline), 6 hours 
and 24 hours after reperfusion (n = 5-6 per time point). Serum levels of hepatic dam-
age markers alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT) and 
lactate dehydrogenase (LDH) at the Central Clinical Chemical Laboratory of the Erasmus 
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University Medical Center.  Hemorrhagic necrosis was scored before, and at 6 and 24 
hours after reperfusion (n = 5-6 per time point) in 3 µm thick Hematoxylin and Eosin 
stained liver sections at a magnification of 100x by 2 observers blinded to the treatment. 
Hemorrhagic necrosis was characterized by the loss of the cellular architecture and the 
presence of erythrocytes in necrotic areas. The percentage of hemorrhagic necrosis per 
microscopic field was determined using the following scoring system: 0% (absent), 0% 
to 20% (<20% necrosis per microscopic field), 20% to 40% (20% to <40% necrosis per 
microscopic field) etcetera until 100% necrosis. 
Immunohistochemistry
Frozen liver sections (5 µm) from different time points (baseline, 6 and 24 hours after re-
perfusion) were stained with a monoclonal antibody against neutrophils and visualized 
with an alkaline phosphatase secondary antibody. Per section two observers blinded to 
the treatment counted the number of neutrophils in 10 microscopic fields at magnifica-
tions of 400x.
Microarray analysis
For microarray analysis, mice were either fed the control diet or put on either a protein-
free, Leu-free, Trp-free or Met-free diet for three consecutive days, after which the mice 
were sacrificed. Directly after each intervention, liver samples were taken and snap 
frozen in liquid nitrogen for further analyses. RNA isolation of the liver samples is as 
described previously17,18. RNA quality was tested via the RNA integrity number (RIN, 
range 0-10). All samples used scored a RIN between 7.7 and 9.5. Hybridization to Af-
fymetrix HT MG-430 PM Array Plates was performed at the Microarray Department of the 
University of Amsterdam (the Netherlands), according to Affymetrix protocols and as 
described previously. The procedure for all samples was performed on the same batch. 
Normalization was done using the Robust Multichip Average (RMA) algorithm at the 
website www.arrayanalysis.org. Data output consisted of 45141 probes, whereby more 
probes could present the same Gene ID. 
Statistical Analysis
Data were expressed as mean ± standard error of the mean. Differences in groups were 
analyzed by Mann-Whitney U tests with SPSS (version 21). Differences were considered 
significant at P<0.05. Microarray analyses were performed using the free software 
package R (R foundation), using the Linear Models for Microarray Data (limma) method 
with correction for multiple testing using the false discovery rate (FDR) according to 
Benjamini and Hochberg. Fold changes were expressed as the geometric mean per diet 
group against the corresponding ad libitum fed control group. A FDR <5% with fold 
change ≥1.5 were used as cut-off values for significance. The enrichment factor (EF), 
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defined as the number of times an observation was higher than expected by chance, 
was calculated via the formula: EF=nAB/((nA×nB)/nC), where nA is the number of dif-
ferentially expressed probe sets (DEPS) in experimental group A, nB the number of DEPS 
in experimental group B, nC the number of total genes in the microarray, and nAB the 
number of common DEPS between nA and nB. Functional annotation and analyses were 
performed QIAGEN’s Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, www.
qiagen.com/ingenuity). Subsequent pathway and target categories were generated 
using the QIAGEN’s Ingenuity Target Explorer. The prediction inhibition or activation of 
the upstream transcription regulators are calculated via de statistical z-score based on 
the observed gene expression changes in our dataset. Calculating the z-score reduces 
the chance of significant predictions based on random data (http://ingenuity.force.com/
ipa/articles/Feature_Description/ Upstream-Regulator-Analysis). A z-score ≥ 2 or ≤-2 
was set as significant. 
Results
Single EAA deprivation protects against hepatic IRI 
To disentangle the role of single EAA in the protection against hepatic IRI, mice were ad-
ministered a Met-free, Leu-free or Trp-free diet for three days. The results were compared 
with a control diet and diets that are known to either protect or not protect against IRI17. 
We have demonstrated that three days of a protein-free diet induces protection against 
renal IRI, while others also showed these results in other IRI models, including hepatic 
IRI1. On the contrary, three days of 30% DR does not induce resistance against renal IRI17, 
which makes it a control group for reduced calorie intake and concomitant body weight 
loss observed during feeding of EAA free diets. Mice fed three days of a protein-free 
diet lose on average 9.8% of their body weight, while mice fed the non-protective three 
days of 30% DR showed a similar pattern in body weight loss (Figure 1A). Mice fed a 
single EAA-free also lost body weight: a Met-free diet resulted in 9.5% body weight loss, 
a Leu-free diet 6.2% and a Trp-free diet 8.5% (Figure 1B). Mice fed a protein- or EAA-free 
diet during three days restricted themselves on calorie intake (Figure 1C). Mice fed the 
Met-free diet restricted food intake by 44%, while the Leu-free diet resulted in a restric-
tion of 45%. A Trp-free diet resulted in the smallest decrease in calorie intake, namely an 
average of 9% fewer calories than mice fed a control diet. 
After induction of hepatic IRI, mice on a protein-free diet resumed intake of the control 
food within 24 hours and showed no further weight loss, while ad libitum fed mice or 
mice restricted for 30% during three days lost weight after surgery. Mice fed the EAA-free 
diet resumed food intake postoperatively and stabilized their body weight (Figure 1B).
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Serum levels of liver enzymes ALAT (Figure 2A) and LDH (Figure 2B) were significantly 
lower in the Leu-free and Trp-free groups than in the control group at 6 and 24 hours 
postoperatively. At 24 hours after hepatic IRI, all EAA-free diets showed significantly low-
er liver enzymes (Figure 2AB). Histologic analysis of the livers supports these findings. 
At 6 hours after reperfusion, the percentage of hemorrhagic necrosis was significantly 
lower in the Leu-free and Trp-free diets than in the control group (Figure 2C). At 24 
hours postoperatively, the percentage of necrosis was increased compared to 6 hours, 
but still a significant lower percentage of necrosis was seen in the Leu-free and Met-free 
diet, while the reduction did not reach significance in het Trp-free diet. 
The number of neutrophils, as a marker for the acute inflammatory response in the 
liver, was significantly higher in het Leu-free and Trp-free diets than in the control group 
at 6 hours (Figure 2D), despite the lower percentage of hemorrhagic necrosis. Livers 
from animals fed the non-protective three days of 30% DR showed a significantly in-
creased number of neutrophils, suggesting an ongoing inflammatory response after IRI 
in this group (Figure 2D). 
Taken together, deprivation of essential amino acids methionine, leucine and trypto-
phan for three days induces protection against liver IRI similar to a 3-day protein-free 
Chapter 6: Short-term absence of dietary protein or essential amino acids protects against hepatic 
ischemia-reperfusion injury  
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Figure 1. Body weight and food intake. (A+B) The nutritional interventions started at day -3 and hepatic IRI was 
induced at day 0. During the dietary intervention all mice, except the control chow fed group, showed a decrease 
in body weight. Postoperative day 1, mice fed an essential amino acid (EAA)-free diet lost less body weight 
compared to the control mice. Besides that, the fasted and protein-free mice gained weight. (C) Relative dietary 
energy intake during the 3-day intervention. Mice fed a tryptophan-free consumed on average 9% fewer calories 
than mice fed the control diet. Mice fed a methionine-free diet had 44.2% fewer calories, while mice on a leucine-
free diet consumed 45.2% fewer calories than mice fed the control diet. In comparison, mice fed a protein-free 
diet ate 39.1% fewer calories.  
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diet independent of preoperative body weight loss and voluntary DR. The benefi cial 
eff ects of Leu and Trp are more pronounced at 6 hours after IRI while the eff ects of all 
EAA-free diets are seen at 24 hours postoperatively. 
Transcriptional responses after a methionine-, leucine- and tryptophan-free 
diet are highly overlapping 
To examine transcriptome responses amongst the diff erent EAA-free diets and their 
controls, a principal component analysis (PCA) was made based on all probe sets in 
the microarray data (Figure 3A). In this unbiased PCA plot, PC1 explains 15% and PC2 
explains 13% of the total variance of the probe sets. Examination of the PCA showed 
distinct separation of the mice in the control group and in the Met-free group, with 
uniformity within these groups along PC2. However, the Met-free cluster was grouped 
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Figure 2. Essential amino acid free diets reduce liver injury. (A) Serum concentration of the liver-specifi c 
enzyme alanine aminotransferase (ALAT), indicative of liver damage, were signifi cantly lower levels at 6 
and 24 hours after IRI in mice fed a protein-free or amino acid free diet. (B) Twenty-four hours after IRI, se-
rum concentration of lactate dehydrogenase (LDH), indicative of tissue breakdown, was signifi cant lower in 
mice on a protein-free or amino acid free diet. *P<0.05, **P<0.01 versus the control group at the same time 
point. (C) Six hours post-reperfusion livers from mice fed leucine-free and tryptophan-free diets showed 
less hemorrhagic necrosis compared to the control group. Twenty-four hours post-reperfusion the fasted, 
protein-, leucine- and methionine-free diets induced signifi cantly less damage compared to the control 
group. *P<0.05, **P<0.01 versus the control group. (D) At 24 hours post reperfusion, the protein-free diet 
had a lower number of neutrophils than the control group, while the 30% DR remained with a signifi cantly 
higher neutrophil count. *P<0.05, versus the control group. 
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closely on PC1 with the cluster of control mice. In contrast, the Leu-free and Trp-free 
groups showed a high degree of overlap, differentiating as a whole from the former two 
groups on PC1 and with an intermediate response on PC2 (Figure 3A). A dendogram, 
based on the unbiased hierarchical clustering of all mice, showed two distinct clusters 
of the control group and the Met-free group, which were connected higher up the den-
dogram (Figure 3B). The Leu-free and Trp-free groups had a similar hierarchy, with no 
distinctive clustering between the two groups.
The transcriptomic response was further analyzed by determining the differentially 
expressed probe sets (DEPS) after each dietary intervention compared to the control 
group. The Met-free diet induced the smallest number of DEPS, namely 572 with 348 
up-regulated and 224 down-regulated DEPS. The Leu-free diet resulted in 933 DEPS, of 
which 476 were up-regulated and 457 down-regulated. The Trp-free diet induced 1155 
DEPS of which 579 were up-regulated and 576 were down-regulated. To analyze the 
overlap between the groups, a Venn diagram was made with these DEPS, and 137 genes 
overlapped between all three diets (Figure 3C). The DEPS of the Leu-free and Trp-free 
diets showed the most similarity, with 603 genes present in both diets, comprising 65% 
of the DEPS induced by the Leu-free diet and 52% by the Trp-free diet. Of all differen-
tially regulated genes in common between the Leu-free and Trp-free diets, 99% had the 
same directionality (results not shown). The Met-free induced the highest percentage 
of unique DEPS, namely 334 out of the 573 (58%). However, the directionality pattern 
of all differentially regulated genes reached an 84% agreement between Met-free 
and Leu-free diet and an 86% agreement between Met-free and Trp-free. Despite the 
stronger response induced by the Leu-free and Trp-free diets, there is a high overlap in 
transcriptional responses between all three EAA-free diets.
Essential amino acid-free diets regulate the cellular stress response, nuclear 
signaling and cell cycle  
Subsequent unbiased analysis of the gene expression profiles was performed via 
pathway analysis and upstream transcription factor analysis. Analyses of differen-
tially regulated pathways by the EAA-free diets focused on canonical pathways with a 
positive or negative z-score, which indicates an activation or inhibition of the pathway, 
respectively. Three days of Met-free diet resulted in 11 regulated pathways, of which 
8 activated and 3 inhibited. The most prominent activated pathways were involved in 
cellular stress and injury, cell cycle regulation and growth signaling. Inhibition occurred 
mainly of the nuclear receptor signaling pathway (Table 1A). The Leu-free diet induced 
29 differentially regulated pathways, of which 21 activated and 8 inhibited (Table 1B). 
These pathways represented mainly an activation of the cellular immune response and 
intracellular and second messenger signaling, in combination with an inhibition of 
nuclear receptor signaling and cellular stress and injury. Analysis of the Trp-free diet 
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Figure 3. Principal component analysis and overlapping probe sets. (A) Unbiased principal component analysis 
(PCA) after normalization of all genes in the dataset. A distinct clustering of the control group and the methionine-
free group is seen, with a clear separation of the groups on the principal component (PC) 2 but not on the PC1. 
The leucine-group and tryptophan-free have a highly overlapping clustering, with small intergroup variability. Their 
combined cluster is mainly separated from the control group and the methionine-free group on the PC1. (B) 
Dendogram based on the unbiased hierarchical clustering of all mice. The control group and methionine-free 
group have individual branches, but are connected higher up in the dendogram. The leucine-free and tryptophan-
free group overlap and are intertwined in the dendogram. (C) Veen diagram of the differentially expressed probe 
sets (DEPS) overlapping between the methionine-free, leucine-free and tryptophan-free diets. A total of 137 
genes overlapped between all diets. Of all genes in the leucine-free diet, 64% overlapped with the tryptophan-free 
diet. The methionine-free diet had the highest percentage of unique DEPS, namely 334 out of the 573 (58%). 
Figure 3 Principal component analysis and overlapping probe sets. (A) Unbiased principal component 
analysis (PCA) after normalization of all genes in the dataset. A distinct clustering of the control group and 
the methionine-free group is seen, with a clear separation of the groups on the principal component (PC) 
2 but not on the PC1. The leucine-group and tryptophan-free have a highly overlapping clustering, with
small intergroup variability. Their combined cluster is mainly separated from the control group and the me-
thionine-free group on the PC1. (B) Dendogram based on the unbiased hierarchical clustering of all mice. 
The control group and methionine-free group have individual branches, but are connected higher up in the 
dendogram. The leucine-free and tryptophan-free group overlap and are intertwined in the dendogram. 
(C) Veen diagram of the differentially expressed probe sets (DEPS) overlapping between the methionine-
free, leucine-free and tryptophan-free diets. A total of 137 genes overlapped between all diets. Of all genes 
in the leucine-free diet, 64% overlapped with the tryptophan-free diet. The methionine-free diet had the 
highest percentage of unique DEPS, namely 334 out of the 573 (58%).
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revealed 15 pathways, including 8 activated and 7 inhibited pathways. The activated 
pathways were mostly involved in cellular immune responses and cell cycle regulation, 
while inhibited pathways included nuclear receptor signaling and cancer pathways 
(Table 1C). Comparison of overlapping pathways revealed that 5 out of the 11 pathways 
regulated by the Met-free diet were also regulated by the Leu-free diet, and 4 out of 
the 11 pathways by the Trp-free diet, all with similar directionalities. These overlapping 
pathways were amongst the highest regulated pathways including activation of NRF2-
mediated stress response and G2/M Checkpoint Regulation pathways, and inhibition 
of the LPS/IL-1 mediated inhibition of RXR Function as well as the LXR/RXR activation 
pathway. In addition to the pathways in common between the three EAA-free diets, the 
Leu-free and Trp-free diets had another 4 pathways in common of which 2 had the same 
directionality, namely calcium-induced T-lymphocyte apoptosis and Sphingosine-1-
phosphate signaling. 
Table 1. Overview of the top overrepresented activated and inhibited canonical pathways after each amino 
acid-free diet ranked by their –log P-value.
A. Methionine-free 
Canonical Pathway Pathway Classification P-value Genes Ratio Z-score
LXR/RXR Activation Nuclear Receptor Signaling 3.24E-02 6/121 (5%) -2.236
LPS/IL-1 Mediated Inhibition of RXR 
Function
Nuclear Receptor Signaling 5.61E-10 22/222 (10.0%) -1.897
Antioxidant Action of Vitamin C Cellular Stress and Injury 1.61E-02 6/103 (5.8%) -1.000
PPARa/RXRa Activation Nuclear Receptor Signaling 8.78E-03 9/178 (5.1%) +0.378
eNOS Signaling Cardiovascular Signaling 3.37E-02 7/155 (4.5%) +0.447
ERK5 Signaling Intracellular and Second 
Messenger Signaling
3.53E-02 4/63 (6.3%) +1.000
CNTF Signaling
Cytokine Signaling/ 
Neurotransmitters and Other 
Nervous System Signaling/
Cellular Growth 3.53E-02 4/63 (6.3%) +1.000
UVA-Induced MAPK Signaling Cellular Stress and Injury 1.54E-02 6/102 (5.9%) +1.000
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation
Cell Cycle Regulation 2.68E-03 5/49 (10.2%) +1.342
Melanocyte Development and 
Pigmentation Signaling
Growth Factor Signaling 3.94E-02 5/95 (5.3%) +2.000
NRF2-mediated Oxidative Stress 
Response
Cellular Stress and Injury 1.54E-07 18/193 (9.3%) +2.646
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B. Leucine-free
Canonical Pathway Pathway Classification P-value Genes Ratio Z-score
NRF2-mediated Odixative Stress 
Response
Cellular Stress and Injury 3.46E-05 18/193 (9.3%) +2.309
Calcium-induced T-lymphocyte 
Apoptosis
Apoptosis/Cellular Immune 
Response
1.94E-04 9/66 (13.6%) +1.000
LPS/IL-1 Mediated Inhibition of RXR 
Function
Nuclear Receptor Signaling 2.09E-04 18/222 (8.1%) -0.816
Role of NFAT in Regulation of the 
Immune Response
Intracellular and Second 
Messenger Signaling
6.87E-04 15/185 (8.1%) +1.069
Cholecystokinin/Gastrin-mediated 
Signaling
Neurotransmitters and Other 
Nervous System Signaling
1.18E-03 10/101 (9.9%) +1.265
CD28 Signaling in T Helper Cells Cellular Immune Response 2.61E-03 11/131 (8.4%) +0.447
PKCo Signaling in T Lymphocytes Cellular Immune Response 2.77E-03 11/132 (8.3%) +1.508
Tec Kinase Signaling Intracellular and Second 
Messenger Signaling
6.95E-03 12/170 (7.1%) +0.333
Phospholipase C Signaling Intracellular and Second 
Messenger Signaling
7.42E-03 15/237 (6.3%) +1.291
Thrombin Signaling Cardiovascular Signaling 1.11E-02 13/203 (6.4%) +0.905
LXR/RXR Activation Nuclear Receptor Signaling 1.31E-02 9/121 (7.4%) -1.000
CXCR4 Signaling Cellular Immune Response / 
Cytokine Signaling
1.42E-02 11/165 (6.7%) +0.378
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation
Cell Cycle Regulation 1.76E-02 5/49 (10.2%) +1.000
Production of Nitric Oxide and Reactive 
Oxygen Species in Macrophages
Cellular Immune Response 1.77E-02 12/193 (6.2%) -0.302
PI3K Signaling in B Lymphocytes Cellular Immune Response 1.85E-02 9/128 (7.0%) -0.333
G Beta Gamma Signaling Intracellular and Second 
Messenger Signaling
1.96E-02 7/88 (8.0%) +0.378
Relaxin Signaling Organismal Growth and 
Development / Growth Factor 
Signaling
2.05E-02 10/152 (6.6%) -0.447
Colorectal Cancer Metastasis Signaling Cancer 2.27E-02 14/247 (5.7%) +0.577
Actin Nucleation by ARP-WASP Complex Intracellular and Second 
Messenger Signaling
2.96E-02 5/56 (8.9%) +1.342
Synaptic Long Term Potentiation Neurotransmitters and Other 
Nervous System Signaling
3.36E-02 8/120 (6.7%) +0.707
Dendritic Cell Maturation Cytokine Signaling/ Cellular 
Immune Response 
3.55E-02 11/190 (5.8%) +1.897
ICOS-ICOSL Signaling in T Helper Cells Cellular Immune Response 3.65E-02 8/122 (6.6%) +1.890
Sphingosine-1-phosphate Signaling Intracellular and Second 
Messenger Signaling 
3.81E-02 8/123 (6.5%) +1.414
Macropinocytosis Signaling Cellular Immune Response 4.01E-02 6/81 (7.4%) +1.000
UV-Induced MAPK Signaling Cellular Stress and Injury 4.07E-02 4/42 (9.5%) -1.000
Antioxidant Action of Vitamin C Cellular Stress and Injury 4.14E-02 7/103 (6.8%) -1.000
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B. Leucine-free (continued)
Canonical Pathway Pathway Classification P-value Genes Ratio Z-score
RhoGDI Signaling Intracellular and Second 
Messenger Signaling
4.40E-02 10/173 (5.8%) -0.378
IL-8 Signaling Cytokine Signaling 4.42E-02 11/197 (5.6%) +1.508
ERK5 Signaling Intracellular and Second 
Messenger Signaling
4.58E-02 5/63 (7.9%) +0.447
C. Tryptophan-free 
Canonical Pathway Pathway Classification P-value Genes Ratio Z-score
LPS/IL-1 Mediated Inhibition of RXR 
Function
Nuclear Receptor Signaling 1.25E-05 23/222 (10.4%) -1.667
NRF2-mediated Oxidative Stress 
Response
Cellular Stress and Injury 1.40E-05 21/193 (10.9%) +1.941
Colorectal Cancer Metastasis Signaling Cancer 4.77E-04 21/247 (8.5%) -0.447
Sumoylation Pathway Cellular Stress and Injury/ 
Transcriptional Regulation
9.90E-04 11/96 (11.5%) +0.333
Calcium-induced T Lypmhocyte 
Apoptosis
Apoptosis/Cellular Immune 
Response
3.32E-03 8/66 (12.1%) +1.134
LXR/RXR Activation Nuclear Receptor Signaling 2.11E-03 12/121 (9.9%) -0.447
Wnt/B-catenin Signaling Cancer / Organismal Growth 
and Development
1.20E-02 13/169 (7.7%) -0.333
Cholecystokinin/Gastrin-mediated 
Signaling
Neurotransmitters and Other 
Nervous System Signaling
1.42E-02 9/101 (8.9%) -0.333
MIF Regulation of Innate Immunity Cellular Immune Response 1.85E-02 5/41 (12.2%) +1.342
IGF-1 Signaling Growth Factor Signaling 1.90E-02 9/106 (8.5%) +0.447 
UVC-Induced MAPK Signaling Cellular Stress Injury 2.04E-02 5/42 (11.9%) -1.342
MIF-mediated Glucocorticoid 
Regulation
Cellular Immune Response / 
Nuclear Receptor Signaling
3.47E-02 4/33 (12.1%) +2.000
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation
Cell Cycle Regulation 3.69E-02 5/49 (10.2%) +2.000
Mitotic Roles of Polo-Like Kinase Cell Cycle Regulation 3.81E-02 6/66 (9.1%) -2.000
TWEAK Signaling Apoptosis / Cytokine Signaling 3.82E-02 4/34 (11.8%) -1.000
Sphingosine-1-phosphate Signaling Intracellular and Second 
Messenger Signaling
4.36E-02 9/123 (7.3%) +0.707
Pathways are defined via the canonical pathways as well as the pathway classification. Only pathways with 
a z-score were included. The canonical pathways and pathway category are based on the analyses done 
in Ingenuity and Ingenuity Target Explorer. Genes ratio = the number and percentage of probe sets dif-
ferentially expressed in ratio to the total number of genes involved in the pathway. Z-score = based on the 
observed gene expression changes in the specific array datasets.
Analysis of the upstream transcription factors (TFs) activated or inhibited by the EAA-
free diets resulted in a list of factors depicted in Table S2. The highest activated TF by 
the Met-free diet was NFE2L2, i.e. NRF2, followed by ATF4 and SMARCB1. NFE2L2 and 
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SMARCB1 were also significantly activated by the Leu-free and Trp-free diets, while ATF4 
met a significant z-score in the Trp-free diet and almost significant in the Leu-free diet 
(1.838). The strongest inhibited TF by the Met-free diet was SREBF2, followed by FOXM1 
and MYBL2. Both SREBF2 and FOXM1 were also significantly inhibited by the Leu-free 
and Trp-free diets, while MYBL2 only reached significance in the after the Leu-free 
(-2.000) and not in the Trp-free diet (-1.633) (Table 2). Of the 18 significantly regulated 
TFs by the Met-free diet, 14 and 13 TFs were also regulated by the Leu-free and Trp-free 
diet, respectively. All of these TFs showed the same directionality in all three EAA-free 
diets. 
Table 2. List of significantly up-or down-regulated upstream transcription factors in the liver with corre-
sponding z-scores regulated by all three amino-acid-free diets.
Methionine-
free
Tryptophan-
free
Leucine-free
Upstream 
Regulator
State Z-score P-value Z-score P-value Z-score P-value
NFE2L2 Activated 4.545 6.28E-13 2.975 3.12E-11 2.919 3.92E-07
SMARCB1 Activated 2.026 9.12E-06 2.436 9.74E-04 2.465 2.14E-06
SREBF2 Inhibited -2.804 1.26E-04 -5.540 8.96E-26 -5.159 1.87E-28
FOXM1 Inhibited -2.671 1.66E-04 -3.096 1.76E-05 -2.391 6.91E-06
Upstream regulator analysis of the differentially regulated genes found in common after 3-days of methio-
nine-free, tryptophan-free and leucine-free diet revealed 4 significantly regulated transcription factors , of 
which 2 were activated and 2 were inhibited. 
Discussion
In this study we demonstrated that, in addition to a protein-free diet, a Met-free, a 
Leu-free and a Trp-free diet for three days induce a similar protection against hepatic 
IRI. We show that cellular stress-, nuclear receptor-, and cell cycle regulation pathways 
are regulated by all three EAA-free diets, and that transcription factors NRF2, FOXM1, 
SREBF2 and SMARCB1 may be implicated in orchestrating this response. 
Previously, we have shown that 2 weeks of 30% DR as well as three days of fasting are 
sufficient to induce resistance against hepatic and renal IRI1,10,18. Recently, we and others 
showed that absence of protein is the main contributor to these effects17,19. Here, we 
further dissected the role of essential amino acids, and demonstrated that the absence 
of one single essential amino acid is sufficient to induce the increased stress resistance 
associated with DR leading to protection against hepatic IRI. Mice fed EAA-free diets 
voluntarily restricted food intake by approximately 30%. Since we showed that three 
days of 30% DR without deprivation of EAA is insufficient to induce protection against 
hepatic IRI, the restricted food intake due to EAA-free diets is ruled out as a factor and 
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the absence of EAA during three days is therefore responsible for inducing these ben-
eficial effects. 
All three EAA-free diets induced a similar protective effect, indicative of a common 
denominator of induction of the beneficial response. To extract this denominator, we 
determined mRNA expression profiles of liver tissue following administration of the 
EAA-free diets and performed microarray analyses. These data show that EAA depriva-
tion modifies the transcriptome at three different pathway levels. 
First, cell metabolism is altered as indicated by the nuclear receptor signaling response 
via the activation of the retinol pathway. Nuclear receptors are transcription factors that 
are known to be activated by steroid hormones and lipi-soluble agents, such as the 
retinoid acids (RAs)20. As previously shown21,22, RAs able to induce many of the beneficial 
effects observed after DR. RAs are able to protect from ischemic stroke in the brain and 
have a positive effect on insulin resistance23,24. This activation is in line with our previous 
results, where nuclear receptor signaling activation was proposed as one of the main 
contributors to the beneficial effects of DR against renal IRI17. In our renal IRI model, 
upstream transcription factor FOXO3 was identified as a main player of the activation 
of the nuclear receptor response. FOXO3 was up-regulated after all three EAA-free 
diets, however only reached statistical significance after the Trp-free diet. Besides cell 
metabolism, FOXO3 phosphorylation and activation is at the basis of many processes, 
most importantly stress resistance and autophagy25,26. These data strengthen the role 
of nuclear receptor signaling mediated by FOXO3, however excludes FOXO3 as the only 
contributor for the beneficial effects. For instance, the LXR/RXR pathway has been impli-
cated in the response as well27. The liver X receptor (LXR) is mainly expressed in the liver 
and is an important factor of its lipid metabolism28. However, we found an inhibition 
of this pathway in our EAA-free analysis. The down-regulation of the LXR/RXR pathway 
might in part be a response to the massive down-regulation of SREBF-2 by all EAA-free 
diets, which is a main regulator of the pathway29. Blocking SREBF-2 in a mouse model 
showed to be effective in preventing the development of hepatic steatosis and insulin 
resistance, and might be more important than the activation of the LXR/RXR pathway 
itself27. Our results suggest that inhibition of SREBF-2 might play a role in the protective 
effect on hepatic IRI. Future studies with for instance SREBF-2 -/- mouse models could 
highlight the effects of SREBF-2 deficiency on IRI. 
Second, we found two transcription factors involved with inhibition of cellular prolif-
eration. FOXM1, which increases G2/M DNA damage checkpoint activity30, and SMARCB1 
which inhibits cellular proliferation by mediating between various signaling pathways 
as part of the SWI/SNF complex. In recent work, SMARCB1 has been named often as a 
tumor suppressor via inhibition of cell growth31,32. Inhibition of cell growth is a common 
feature induced by DR regimens. We propose that the evolutionary adaptive response 
to DR that shifts resources from growth (metabolism and temporary withdrawal from 
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the cell cycle) to maintenance occurs already after three days of essential amino acid 
deprivation33. The associated increase in stress resistance is rapidly induced and offers 
robust protection against hepatic IRI. 
Third, all three EAA-free diets induced a strong activation of the NRF2-mediated oxi-
dative stress response, both on transcription factor and pathway level. NRF2 increases 
stress resistance30, and we have already implicated NRF2 in the protection against renal 
IRI after three days of fasting1,17,18. In response to environmental stress, including protein 
deprivation, NRF2 is activated by phosphorylation of eIF2α via Gcn230,34,35 and results in 
the transcription of genes involved in antioxidant defense, reduction of inflammation 
and cell survival. In NRF2 knock-out models, similar effects of dietary restriction on cel-
lular stress injury as in NRF2 proficient models could not be induced30,36. This indicates 
that NRF2 is indeed a major player yet not the only player in the protection against IRI. 
Our results demonstrate that activation of nuclear receptors signaling, inhibition of cel-
lular proliferation and activation of the NRF2-pathway might be the essential package 
required to induce the beneficial effects of hepatic IRI. Validation studies should further 
emphasize on how these regulators induce protection against oxidative stress induced 
by IRI.
Taken together, we report that three essential amino acid-free diets given for three 
days protect against hepatic IRI in a mouse model possibly mediated via transcrip-
tion factors NRF2, FOXM1, SREBF2 and SMARCB1. Further in depth analysis through 
functional and pharmacological modulation of these factors may provide mimetics for 
treatment against ROS-related injury. 
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Table S2. List of significantly up-or down-regulated upstream transcription factors in the liver by a Methio-
nine, Leucine or Tryptophane free diet with the corresponding z-scores
Methionine-free Tryptophan Leucine
Upstream 
Regulator
Gene ratio 
(Log2)
Z-score P-value Z-score P-value Z-score P-value
NFE2L2 0.297 4.545 6.28E-13 2.975 3.12E-11 2.919 3.92E-07
ATF4 0.393 2.911 7.45E-05 2.686 7.60E-09 1.838 2.41E-06
NUPR1 1.593 2.558 8.47E-04 2.846 2.92E-05 1.667 1.06E-05
KMT2D 0.180 2.449 1.15E-01 N/A N/A N/A N/A
CEBPD 0.390 2.194 8.83E-04 1.994 3.42E-01 1.104 1.39E-02
NFKB1 0.007 2.182 1.37E-01 N/A N/A 0.344 7.05E-03
KLF4 0.782 2.110 7.47E-02 1.994 4.08E-01 3.101 3.00E-01
SMARCB1 -0.164 2.026 9.12E-06 2.436 9.74E-04 2.465 2.14E-06
TAF4 0.393 2.000 2.57E-03 N/A N/A N/A N/A
MAFF 1.398 2.000 3.37E-05 N/A N/A N/A N/A
TBX2 0.047 -2.000 6.89E-02 -2.530 7.43E-04 -1.890 1.11E-02
Esrra 0.327 -2.000 4.14E-02 N/A N/A N/A N/A
ATF6 0.216 -2.000 7.27E-03 -0.553 1.78E-05 -1.161 1.15E-04
FOXO1 -0.167 -2.139 9.30E-07 -0.465 1.51E-09 -1.269 6.53E-11
STAT5B 0.123 -2.157 2.12E-02 -0.901 3.17E-04 -1.463 4.42E-02
MYBL2 0.157 -2.236 1.79E-04 -1.633 1.79E-04 -2.000 1.03E-02
FOXM1 -0.080 -2.671 1.66E-04 -3.096 1.76E-5 -2.391 6.91E-06
SREBF2 0.086 -2.804 1.26E-04 -5.540 8.96E-26 -5.159 1.87E-28
Leucine-free Tryptophan Methionine
Upstream 
Regulator
Gene ratio 
(Log2)
Z-score P-value Z-score P-value Z-score P-value
KLF4 0.907 3.101 3.00E-01 1.994 4.08E-01 2.110 7.47E-02
NFE2L2 0.397 2.919 3.92E-07 2.975 3.12E-11 4.545 6.28E-13
KDM5B -0.376 2.739 8.34E-08 2.999 3.88E-07 1.615 1.13E-04
TRIM24 -0.415 2.714 3.19E-04 3.043 1.20E-04 N/A N/A
SMARCB1 -0.126 2.465 2.14E-06 2.436 9.74E-04 2.026 9.12E-06
POU5F1 -0.120 2.234 4.60E-01 -1.103 9.75E-04 N/A N/A
ETS1 0.829 2.198 2.28E-02 N/A N/A N/A N/A
NOTCH1 -0.165 2.137 8.04E-02 0.309 4.59E-02 0.727 9.18E-03
MYBL2 0.097 -2.000 1.03E-02 -1.633 1.79E-04 -2.236 1.79E-04
NFYA -0.197 -2.007 1.27E-11 -0.840 5.51E-12 -0.128 7.02E-06
ARNTL 0.217 -2.180 2.56E-03 -1.539 1.41E-03 N/A N/A
E2F2 -0.287 -2.236 5.13E-03 N/A  N/A N/A N/A
PDX1 0.029 -2.321 1.75E-05 -0.739 6.55E-06 N/A N/A
FOXM1 -0.309 -2.391 6.91E-06 -3.096 1.76E-05 -2.671 1.66E-04
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E2F1 -0.217 -2.480 1.50E-05 -1.068 6.08E-06 -1.564 8.48E-04
MLXIPL -0.039 -2.510 1.27E-09 -2.345 1.35E-07 -0.927 3.18E-03
IRF7 -0.338 -2.599 2.83E-01 -3.088 1.15E-01 N/A N/A
SIRT2 0.113 -2.646 8.82E-07 -2.646 3.30E-06 N/A N/A
PPARGC1B -0.681 -3.396 1.96E-07 -3.248 1.06E-05 -1.980 2.81E-02
SREBF1 -0.534 -4.605 2.68E-24 -4.998 1.55E-23 -1.020 6.88E-05
SREBF2 -0.453 -5.159 1.87E-28 -5.540 9.96E-26 -2.804 1.26E-04
Tryptophan-free Leucine Methionine
Upstream 
Regulator
Gene ratio 
(Log2)
Z-score P-value Z-score P-value Z-score P-value
TRIM24 0.241 3.043 1.20E04 2.714 3.19E-04 N/A N/A
KDM5B -0.602 2.999 3.88E-07 2.739 8.34E-08 1.615 1.13E-04
NFE2L2 0.198 2.975 3.12E-11 2.919 3.92E-07 4.545 6.28E-13
NUPR1 0.772 2.846 2.92E-05 1.667 1.06E-05 2.558 8.47E-04
HTT -0.347 2.784 1.12E-03 N/A N/A N/A 3.16E-04
ATF4 0.317 2.686 7.60E-09 1.838 2.41E-06 2.911 7.54E-05
SMARCB1 0.188 2.436 9.74E-04 2.465 2.14E-06 2.026 9.12E-06
HAND2 0.931 2.224 4.42E-02 N/A N/A N/A N/A
FLI1 0.635 2.150 5.36E-05 1.364 6.55E-05 N/A N/A
FOXO3 -0.209 2.095 2.00E-10 0.448 9.73E-08 0.588 1.75E-06
GATA4 -0.378 2.071 1.12E-01 N/A N/A N/A N/A
TCF3 0.171 2.032 7.48E-05 1.265 9.72E-04 1.890 1.66E-02
IRF5 -0.327 -2.138 5.91E-03 N/A N/A N/A N/A
STAT1 -0.661 -2.145 5.93E-05 -0.540 1.73E-06 -1.706 1.34E-03
MLX -0.124 -2.181 1.20E-09 -1.977 1.09E-07 N/A 7.61E-03
MLXIPL 0.054 -2.345 1.35E-07 -2.510 1.27E-09 -0.927 3.18E-03
MYOD1 0.108 -2.465 1.20E-01 -1.242 1.85E-02 -1.657 5.12E-03
EGR1 -0.180 -2.520 2.14E-03 -1.925 7.99E-04 -1.344 3.23E-02
TBX2 -0.001 -2.530 7.43-04 -1.890 1.11E-02 -2.000 6.89E-02
SIRT2 0.170 -2.646 3.30E-06 -2.646 8.82E-07 N/A N/A
IRF7 -0.349 -3.088 1.15E-01 -2.599 2.83E-01 N/A N/A
FOXM1 -0.181 -3.096 1.76E-05 -2.391 6.91E-06 -2.671 1.66E-04
IRF3 0.254 -3.128 4.08E-03 -1.359 5.45E-04 N/A N/A
PPARGC1B -0.755 -3.248 1.06E-05 -3.396 1.96E-07 -1.980 2.81E-02
SREBF1 -0.247 -4.998 1.55E-23 -4.605 2.68E-04 -1.020 6.88E-05
SREBF2 -0.474 -5.540 8.96E-26 -5.159 1.87E-28 -2.804 1.26E-04
All significantly up-or down-regulated transcription factors (TF) after completion of each diet are shown, 
together with then log-ratio of the gene corresponding to the TF. Of all TF, the z-scores of the other two 
diets are compared and shown in the same table. N/A = not available.
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Abstract
Liver ischemia reperfusion injury (IRI) is inevitable during transplantation and resection, 
and is characterized by hepatocellular injury. Therapeutic strategies to reduce IRI and 
accelerate regeneration could offer major benefits. Mesenchymal stem cells (MSC) are 
reported to have anti-inflammatory and regeneration promoting properties. We inves-
tigated the effect of MSC in a model of combined IRI and partial resection in the mouse. 
Hepatic IRI was induced by occlusion of 70% of the blood flow during 60 minutes, fol-
lowed by 30% hepatectomy. 2x105 MSC or PBS, were infused 2 hours before-, or 1 hour 
after IRI. Six-, 48- and 120 hours post-operatively mice were sacrificed. Liver damage 
was evaluated by liver enzymes, histology and inflammatory markers. Regeneration was 
determined by liver/body weight ratio, proliferating hepatocytes and TGF-b levels. Fate 
of MSC was visualized with 3Dcryo-imaging.
Infusion of 2x105 MSC 2 hours before-, or 1 hour after IRI and resection showed no 
beneficial effects. Tracking revealed that MSC were trapped in the lungs, did not migrate 
to the site of injury and many cells had already disappeared 2 hours after infusion. Based 
on these findings we conclude that intravenously infused MSC disappear rapidly, and 
were unable to induce beneficial effects in a clinically relevant model of IRI and resection. 
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Introduction
The liver has the unique ability of regeneration as a response to liver injury. In healthy 
individuals the liver can compensate an acute loss of 70% and return to its original 
mass within 30 days of resection1. Thanks to this remarkable feature and advances in 
surgical techniques, large (oncologic) liver resections as well as split- and living donor 
liver transplantation are possible. However, in patients with chronic liver diseases, liver 
cirrhosis or malignancies, regeneration of the liver is often compromised due to che-
motherapy2, poor nutritional status3 and the increasing age of patients4. Besides that, 
leaving a smaller fraction of residual liver after resection is a risk factor for postoperative 
morbidity due to hepatic dysfunction and infectious complications5. 
Liver transplantation (LTx) is the only life-saving treatment for end-stage hepatic dis-
eases6 and a treatment for patients with a primary liver tumor or colorectal metastases7-9. 
However, ischemia reperfusion injury (IRI), caused by interruptions of the hepatic blood 
flow, is inevitable during LTx and liver resection. Ischemia is characterized by ATP deple-
tion and activation of anaerobic metabolic pathways, whereas reperfusion activates a 
cascade of pathways that causes further cellular damage and inflammation. IRI leads 
to a decreased regenerative capacity of hepatocytes, tissue necrosis, and apoptosis10,11. 
Liver IRI is the leading cause of hepatocellular injury causing morbidity and mortality 
after LTx and may negatively affect liver regeneration after both post mortal and living 
donor LTx12-14. Taken together, potential therapeutic strategies to reduce hepatic IRI and 
accelerate liver regeneration could offer major benefits in both LTx and resection.
Mesenchymal stem cells (MSC) are able to differentiate into different cell types, secrete 
growth factors, and have immunomodulatory and anti-inflammatory properties15,16. 
Therefore, MSC are considered as a potential therapy to prevent or ameliorate hepatic 
IRI and stimulate liver regeneration.
In rodents, MSC have the potential to reduce hepatic IRI by suppressing oxidative 
stress and inhibiting apoptosis13,17,18. Moreover, MSC improved liver regeneration in a 
resection model13,19,20. However, only few studies investigated the effect of MSC in a 
combined hepatic IRI and partial hepatectomy model19,21-23, while this model is relevant 
for translation to the clinical setting. Results from these studies suggest that MSC have 
beneficial effects on both IRI and regeneration. However, the use of MSC in a large 
animal model showed inconsistent results on IRI24,25. Therefore, it remains unclear if and 
how MSC are able to prevent IRI and/or stimulate regeneration. The purpose of the pres-
ent study is to investigate in a clinically relevant mouse model whether MSC are able 
to reduce hepatic IRI and stimulate liver regeneration after induction of hepatic IRI and 
partial liver resection. 
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Material and methods
Animals
Male C57BL/6 (age 10-12 weeks, ~25 g) were obtained from Harlan, (Horst, the Neth-
erlands). Animals were kept under standard laboratory conditions, and housed in 
individually ventilated cages (n=3 animals/cage). The animals had free access to food 
and water (acidified with HCl). All experiments were performed with the approval of the 
institutional animal welfare committee (Protocol EMC2271).
Mesenchymal stem cell cultures
MSC were isolated from abdominal adipose tissue of C57BL/6 mice. Syngeneic mouse 
MSC were used to avoid xenogeneic and allogeneic responses. The tissue was mechani-
cally disrupted and enzymatically digested with 0.5 mg/mL collagenase type IV (Life 
Technologies, Paisley, UK) in RPMI 1640 Medium with glutaMAX (Life technologies) for 
30 min at 37 C° under continuous shaking. The obtained cell suspension was washed 
and plated in tissue culture flasks in MEM-a with 15% fetal calf serum, and 100U/mL 
pencillin and 100mg/mL streptomycin (1% p/s) (all Invitrogen, Germany). Non-adherent 
cells were removed after 2-3 days and subsequently culture medium was refreshed once 
a week. Plastic adherent cells were removed by trypsinization after reaching 70-80% 
confluency. Cells were maintained at 37°C, 5% CO2, and 95% humidity. MSC of passage 
3-5 were used for experiments. Before intravenous infusion of 2x105 MSC in 200µl PBS, 
cells were filtered through a 40μm sieve. The phenotype of these MSC used in previous 
studies was confirmed as they expressed CD44 and Sca-1, were negative for CD11b and 
CD45, were capable of differentiating into osteoblasts and adipocytes, and had the abil-
ity to inhibit conA stimulated lymphocyte proliferation15.
Surgical model
Mice were anesthetized by isoflurane/O2 inhalation. To maintain their body temperature 
mice were placed on a heating pad. All surgeries were performed between 9:00am and 
1:00pm. After a midline laparotomy, partial hepatic ischemia was induced by occlusion 
of the blood flow of the left lateral and median liver lobes with a non-traumatic micro 
vascular clamp for 60 minutes. The median and lateral lobe (approximately 70% of 
the liver) showed significant discoloration. After clamp removal, restoration of blood 
flow in the ischemic liver lobes causes reperfusion injury. Directly after removing the 
clamp, a partial hepatectomy (PH) was performed by resection of the left lateral liver 
lobe (approximately one-third of the liver). The abdomen was closed in two layers using 
Safil 5-0 (B.Braun, Germany). Mortality associated with this amount of damage to the 
liver was not observed. After surgery all mice received 0.5 mL of phosphate-buffered 
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saline subcutaneously and were placed under a heating lamp until they recovered from 
anesthesia. Directly after surgery, all mice had free access to food and water.
Our pilot study showed that administration of 1x105 MSC or 3x105 was ineffective, or 
showed a trend towards increased injury, respectively (Figure S1). Therefore, we chose 
a cell number of 2x105 MSC as a potentially effective number of cells. We chose a pre-
ischemic time point of administration (2 hours before) and a time point 1 hour after 
ischemia to determine the effect of administration before, and after inducing injury. 
Animals were treated intravenously via the tail vein with 2x105 MSC in 200µl PBS or 
with PBS alone as vehicle control. Seven mice per group were infused 2 hours before 
hepatic IRI and resection, or 1 hour after removing the clamp. They were sacrificed 6 and 
48 hours, and 5 days after surgery. Liver and blood samples were collected for further 
research. Control mice were sacrificed without undergoing any injection or intervention, 
their tissues were used as a baseline for mRNA expression levels. 
Liver/body weight ratio
Mice were weighed daily. The resected liver lobe was weighed after PH. At time of sac-
rifice, livers were removed, and animals and livers were weighed. The liver/body weight 
ratio was calculated as the wet liver weight divided by the total body weight of the 
mouse.
Hepatocellular injury
Blood samples were collected at time of sacrifice 6 hours, 48 hours or 5 days after sur-
gery (n=7 per time point). Sera were analyzed for alanine aminotransferase (ALAT) and 
aspartate aminotransferase (ASAT) levels at the Central Clinical Chemical Laboratory of 
the Erasmus University Medical Center. 
Hemorrhagic necrosis was scored in 3 µm thick paraffin liver sections stained with 
Hematoxylin and Eosin at a magnification of 100x by 2 independent observers blinded 
to the treatment (n=5 per time point). Hemorrhagic necrosis was characterized by the 
loss of the cellular architecture and the presence of erythrocytes in necrotic areas. The 
percentage of hemorrhagic necrosis per microscopic field was scored with the follow-
ing scoring system: 0%, 1% to 20% (≤20% necrosis per microscopic field), 21% to ≤40% 
necrosis per microscopic field, 41% to ≤60% necrosis per microscopic field, 61% to ≤80% 
necrosis per microscopic field and 81% to 99% necrosis per microscopic field and 100% 
necrosis. 
Immunohistochemistry
Frozen (5 µm) liver sections from mice infused with PBS or MSC and sacrificed 6 hours, 48 
hours or 5 days after reperfusion and resection were stained with monoclonal antibod-
ies against proliferating cell nuclear antigen (PCNA) (Abcam, UK). They were visualized 
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with a horseradish peroxidase-conjugated secondary antibody (DAKO, Belgium). In 8 
microscopic fields per section, the number of positive cells was counted by two observ-
ers (TS, SvD) blinded to the treatment at magnifications of 200 to 400x.
Quantitative RT-PCR 
Total RNA was extracted from frozen liver tissue using Trizol reagent (Invitrogen, Breda, 
the Netherlands), purified by a DNase treatment (RQ1 RNase-Free DNase; Promega 
Benelux B.V., Leiden, the Netherlands), and reverse transcribed to complementary DNA 
using random hexameter primers and Superscript II RT (both from Invitrogen, Breda, 
the Netherlands) according to manufactures instructions. Quantitative real-time PCR 
was performed using a MyiQ single-color Real-Time PCR Detection System with SYBR 
Green incorporation (both from Bio-Rad Laboratories B.V., Veenendaal, the Netherlands; 
primer sequences are available upon request). 
B2M and HPRT were used as housekeeping genes, IL-6 and TNF-α were used as genes 
indicative for inflammation. To assess cytoprotection we measured HO-1 and IL-10 as an 
anti-inflammatory genes. 
TGF-β was used as a marker for regeneration. Primers used to amplify the genes of 
interest were obtained from Sigma, the Netherlands. The relative expression was calcu-
lated as 2 –(ΔCt sample – ΔCt control), corrected for expression levels in healthy control animals. 
Mice without any infusion and surgery were used as healthy controls. Each sample was 
tested at least in duplicate. 
MSC tracking by 3D cryo-imaging
One batch of MSC was labeled with fluorescent Qtracker 605 beads according the manu-
facturer’s description (stains viable MSC; Life Technologies, Grand Island, NY, USA). 2x105 
labeled MSC were infused in the tail vein directly after hepatic IRI. Two hours after the 
induction of IRI the mouse was sacrificed by isoflurane overdose and the whole mouse 
was snap frozen in Tissue-Tec O.C.T. Compound (Sakura Finetek Europe B.V., Alphen 
aan den Rijn, the Netherlands). 3D anatomical and molecular fluorescence videos were 
generated by CryoViztm (BioInVision, Mayfield village, OH, USA), allowing the detection 
of single labeled cells.
Statistical Analysis
Data were expressed as mean ± standard error of the mean. Differences between groups 
were analyzed by Mann-Whitney U tests using SPSS (version 21). Differences were con-
sidered significant at P values less than 0.05. 
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Results
Effect of mesenchymal stem cells on liver damage
Liver damage was evaluated by measuring serum transaminases and histological dam-
age. 6 hours after reperfusion and partial hepatectomy (PH), serum ALAT (7400±1392 
U/L) and ASAT (7529±1202 U/L) levels were significantly lower in mice infused with MSC 
2 hours before IRI and PH compared with their PBS controls (ALAT 13271±1644 U/L) 
(ASAT 13207±1131 U/L) (P=0.015; Figure 1A) (P=0.005, Figure 1B). Mice infused with 
MSC 1 hour after reperfusion and PH showed no significant difference compared with 
their PBS control group (Figure 1A, 1B). 48 hours after reperfusion and PH, there were 
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Figure 1. Hepatocellulair injury. (A) Six hours after IRI and PH, the serum ALAT concentration was significantly 
lower in mice treated with MSC 2 hours before hepatic IRI and PH compared to their PBS control. (B) Serum 
ASAT concentration, six hours after reperfusion, was significantly lower in mice treated with MSC 2 hours before 
IRI and PH compared to their PBS controls. (C) Forty-eight hours after IRI and PH there were no significant 
differences in serum ALAT levels between mice treated with MSC or PBS. (D) Serum ASAT concentrations 
showed no significant differences forty-eight hours after IRI and PH between mice infused with MSC or PBS. (E) 
Forty-eight hours after IRI and PH, livers from mice treated with MSC showed no differences in amount of 
necrosis compared to their PBS controls. The data are expressed as means ± SEM, ((*P<0.05) vs their PBS 
controls).    
 
 
 
 
 
 
 
Figure 1. Hepatocellulair injury. (A) Six hours after IRI and PH, the serum ALAT concentration was signifi-
cantly lower in mice treated with MSC 2 hours before hepatic IRI and PH compared to their PBS control. (B) 
Serum ASAT concentration, six hours after reperfusion, was significantly lower in mice treated with MSC 2 
hours before IRI and PH compared to their PBS controls. (C) Forty-eight hours after IRI and PH there were 
no significant differences in serum ALAT levels between mice treated with MSC or PBS. (D) Serum ASAT 
concentrations showed no significant differences forty-eight hours after IRI and PH between mice infused 
with MSC or PBS. (E) Forty-eight hours after IRI and PH, livers from mice treated with MSC showed no dif-
ferences in amount of necrosis compared to their PBS controls. The data ar  express d as means ± SEM, 
((*P<0.05) vs th ir PBS controls). 
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no significant differences in transaminases between mice infused with MSC 2 hours be-
fore or 1 hour after reperfusion and PH compared to the mice infused with PBS (Figure 
1C, 1D). Histological examination of livers 48 hours after reperfusion and PH (Figure 1E) 
revealed no significant differences in amount of hemorrhagic necrosis between mice 
treated with MSC compared to controls. 
Effect of mesenchymal stem cells on inflammation
We investigated the effect of MSC on the inflammation induced by IRI by measuring the 
expression levels of IL-6 and TNF-α compared with the PBS treated controls. Six hours 
after reperfusion and PH, there were no significant differences in expression levels of 
IL-6 between both groups. However, 48 hours after reperfusion expression levels of IL-6 
were significantly lower in mice treated with MSC 2 hours before surgery compared to 
their PBS controls (P=0.013). Mice treated with MSC 1 hour after surgery showed no 
differences (Figure 2A). TNF-α did not show significant differences in expression levels 
after reperfusion and PH in mice infused with MSC or PBS (Figure 2B). 
In response to hepatic IRI, the cytoprotective gene HO-1 is up-regulated in an attempt 
to protect the liver against antioxidants. In previous studies, we found that up-regulation 
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Figure 2. (Anti)-inflammatory- and cytoprotective response. (A) mRNA levels of inflammatory marker IL-6 showed 
no differences six hours after reperfusion. Forty-eight hours after reperfusion mice treated with MSC 2 hours 
before IRI and PH showed significant lower expression levels of IL-6 compared to PBS treated mice. (B) 
Inflammatory markers TNF-α showed no significant difference after reperfusion. (C) Cytoprotective gene HO-1 
showed no significant differences between mice treated with MSC or PBS at both time points. (D) Anti-
inflammatory gene IL-10 showed no significant differences between MSC or PBS treated mice. The data are 
expressed as means ± SEM, (*P<0.05) vs their PBS controls).    
 
Figure 2. (Anti)-inflammatory- and cytoprotective response. (A) mRNA levels of inflammatory marker IL-6 
showed no differences six hours after reperfusion. Forty-eight hours after reperfusion mice treated with 
MSC 2 hours before IRI and PH showed significant lower expression levels of IL-6 compared to PBS treated 
mice. (B) Inflammatory markers TNF-α showed no significant difference after reperfusion. (C) Cytoprotec-
tive gene HO-1 showed no significant differences between mice treated with MSC or PBS at both time 
points. (D) Anti-inflammatory gene IL-10 showed no significant differences between MSC or PBS treated 
mice. The data are expressed as means ± SEM, (*P<0.05) vs their PBS controls). 
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of HO-1 was associated with reduced the liver damage26. In the present study, infusion 
of MSC had no effect on the expression of HO-1 compared to their PBS control group 
(Figure 2C). Anti-inflammatory gene IL-10, showed no differences between mice treated 
with MSC compared to their PBS controls after both time points (Figure 2D). 
Effect of mesenchymal stem cells on liver regeneration
The remarkable capacity of the liver to regenerate is important for the postoperative 
liver function and is influenced by hepatic IRI. We determined liver/body weight ratios 
5 days after hepatic IRI and PH of mice infused with MSC 2 hours before- or 1 hour after 
hepatic IRI and PH, compared with their PBS controls. There were no significant differ-
ences in liver weight/total body weight ratios between mice treated with MSC or their 
PBS controls (Figure 3A). Next we investigated hepatocyte proliferation with a PCNA 
staining (Figure 3B). 
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Figure 3. Liver regeneration. (A) Liver/body weight ratio 5 days after IRI and PH showed no significant dif-
ferences between MSC or PBS treated mice. (B) After 6 and 48 hours after IRI and PH the numbers of PCNA 
positive cells were not significantly different. (C) Regeneration marker TGF-β showed significantly higher 
expression levels forty-eight hours after reperfusion in mice treated with PBS 2 hours before IRI and PH. The 
data are expressed as means ± SEM, ((*P<0.05) vs their PBS controls). 
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Six hours after hepatic IRI and PH, there was no signifi cant diff erence between mice 
infused with MSC or PBS. Forty-eight hours after IRI and PH, the PCNA index peaked 
but there were no signifi cant diff erences between the MSC and the PBS groups. Trans-
forming growth factor beta (TGF-β) is a protein involved in the termination response of 
liver regeneration27. Six hours after IRI and PH, there were no diff erences between the 
MSC infused mice and their PBS controls. Forty-eight hours after IRI and PH expression 
levels of TGF-β were signifi cantly lower in mice infused with MSC 2 hours before surgery 
compared to their PBS controls (P=0.025), mice infused with MSC 1 hour after surgery 
showed no signifi cant diff erences (Figure 3C).
Fate of intravenously infused mesenchymal stem cells
Using CryoVize whole body imaging, MSC can be detected at single cell level and quanti-
fi ed. Luk et al. (unpublished data) showed by CryoViz imaging that intravenously infused 
MSC disappear for over 90% within 24 hours after infusion in a healthy mouse but also 
in a mouse with renal IRI and did not migrate to the damaged organ. We infused 2x105 
labeled MSC directly after the induction of hepatic IRI. Two hours after IRI the mouse 
was sacrifi ced and the MSC were traced. By far, most cells were found in the lungs (45 
584 cells), in the damaged liver 3693 cells were present. A few cells were found in other 
organs and 1218 cells were found in the rest of the mouse. These data show that MSC 
infused intravenously 2 hours before hepatic IRI are trapped in the lungs, and do not 
migrate to the injured liver (Figure 4). Importantly, 2 hours after infusion of 2x105 MSC 
only 50 607 MSC were found, indicating that many of the infused cells disappeared 
within 2 hours. 
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Figure 4. In vivo cryo imaging of labeled MSC. (A) MSC labeled with Qtracker605, which stains live cells, infused 
directly after-, and imaged 2 hours after hepatic IRI are present in the lungs and not in the damaged liver. (B) 
Number of detected MSC 2 hours after hepatic IRI, many of the live MSC are trapped in the lungs, but the 
majority of infused cells cannot be detected, suggesting that these cells are dead.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. In vivo cryo imaging of labeled MSC. (A) MSC labeled with Qtracker605, which stains live cells, 
infused directly after-, and imaged 2 hours after hepatic IRI are present in the lungs and not in the damaged 
liver. (B) Number of detected MSC 2 hours after hepatic IRI, many of the live MSC are trapped in the lungs, 
but the majority of infused cells cannot be detected, sugges ing that these cells are ead. 
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Discussion
Combined IRI and inadequate tissue regeneration are major causes of morbidity and 
mortality after LTx and liver resection12,13,28. Animal models showed beneficial effects of 
MSC therapy on repair of injured organs and are able to ameliorate inflammatory pro-
cesses13,29-31. However, the role of MSC therapy in a clinically relevant model of combined 
hepatic IRI and partial liver resection remains to be established. 
In the present study we demonstrated that infusion of 2x105 MSC 2 hours before 
hepatic IRI and PH significantly decreased ASAT and ALAT levels compared to their PBS 
controls six hours after IRI and PH, but did not decrease the amount of IRI induced hem-
orrhagic necrosis. In addition, MSC infused before or after hepatic IRI and PH showed 
no beneficial effect on liver damage or regeneration. Although the kinetics of markers 
of injury and inflammation after IRI, and proliferation and termination after resection 
are relatively well known, their behavior following combined IRI and resection is less 
clear32,33. 
Serum transaminase levels were significantly lower at 6 hours after IRI and PH in mice 
that were infused with MSC 2 hours before surgery. Intra-hepatic mRNA IL-6 and TNF-α 
levels did not provide consistent results. Cytoprotective gene HO-1 showed a trend to-
wards higher levels of expression in mice treated with MSC 1 hour after surgery, whereas 
IL-10 did not. Despite the significant differences in transaminases between MSC and PBS 
treated mice, the amount of liver necrosis at 48 hours after surgery, which can be con-
sidered the gold standard to measure hepatocellular injury, did not differ between PBS 
treated controls and any of the MSC treated groups. These data show that MSC infusion 
may have modulated the early inflammatory response, but had no effect on IRI induced 
liver damage. 
Liver regeneration as assessed by liver/body weight ratio was not significantly dif-
ferent between groups, although there was a trend towards a higher ratio in the MSC 
treated animals. However, this is not supported by numbers of proliferating cells and 
TGF-β expression at 48 hours after IRI. However, 48 hours after IRI and PH, TGF-β ex-
pression attained significant higher levels in the PBS infused mice before IRI and PH 
compared to MSC treated mice. On the one hand, this might be explained by the role of 
TGF-β as a key mediator of tissue fibrosis34-36. Rats treated with hepatocyte growth factor 
(HGF)–expressing MSC after small-for-size liver transplantation showed a decrease in 
hepatic fibrosis compared to rats treated with PBS37. In this model, a suppressed produc-
tion of TGF-β is correlated with decreased fibrosis. Suggesting that the balance between 
TGF-β and HGF plays a critical role in the recovery or fibrogenesis of the injured tissues. 
On the other hand, higher levels of proliferation and TGF-β in control mice in our study 
may also suggest a more rapid regenerative response in the absence of MSC.
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Our findings are in contradiction with the results of Saidi et al.23. Using a mouse model 
with 60 minutes of partial IRI with 70% hepatectomy, mice were treated with 1-2 million 
human adipose-derived MSC that were administered intravenously 30 minutes before 
ischemia. Mice treated with MSC showed improved survival, lower levels of ALAT and 
serum IL-6, and increased numbers of PCNA positive cells. Labelled MSC were localised 
in the liver for 9 days. 
How MSC exert their effect is still matter of debate. Using 3D cryo-imaging, we were 
able to show that intravenously infused MSC are exclusively trapped in the lungs, do 
not migrate to the injured liver, and that many infused cells have disappeared from the 
body 2 hours after infusion. These data support recent findings that infused MSC do not 
migrate to sites of injury, but are trapped in microcapillary networks, have a short lifes-
pan, and exert their action via paracrine mechanisms15,19,38-41. MSC have been observed 
in liver, spleen23,42,43 and injured organs26,40,42 after intravenous infusion. The viability of 
these cells is not well known, and it has been suggested that they may represent dead 
or phagocytosed MSC. Despite the hypothesis that the detected MSC are dead, a variety 
of animal models showed beneficial effects of MSC13,23,28,43,44 lending further support to 
the notion that delivery of MSC to the injured organ is not required for their beneficial 
effects16,41. 
In our study robust beneficial effects of MSC on liver injury and regeneration are 
lacking while in other studies they have been shown to be effective in ameliorating 
hepatic IRI and promote liver regeneration20,23,27,28,43,44. The variable outcomes in animal 
studies have many reasons. The number of MSC is a critical factor, yet differs between 
studies, with reported numbers between 1-3 million MSC in rats and 0.5-2 million MSC 
in mice13,22,23,38,45. We used 2x105 MSC since higher numbers of cells induced liver dam-
age (Figure S1). The route of administration, which can be local via the portal vein13, 
or systemic via the tail vein,21 might play an important role in the outcome after MSC 
infusion. Since it is now known that MSC do not migrate beyond the lungs after intra-
venous infusion, the systemic route may not be the best route for MSC administration. 
MSC delivered via the portal vein were detected in the liver until post-operative day 7. 
However, the effect on liver damage and regeneration was comparable to infusion of 
MSC via the tail vein13. Also, the timing of MSC administration might play an important 
role in the outcome after IRI and PH. 
Intravenous infusion of 2x105 MSC 2 hours before- or 1 hour after partial IRI and 30% 
PH did not ameliorate liver damage or improve regeneration. Using 3D cryo-imaging, 
we showed that many of the infused MSC disappear within 2 hours and that the remain-
ing cells are trapped in the lungs and do not migrate towards the damaged liver. More 
research is needed to the sources of these inconsistent results to improve the reliability 
of MSC therapy and get closer to translation to the clinical arena. 
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Supplementary data
Chapter 7: Fate and effect of intravenously infused mesenchymal stem cells in 
a mouse model of hepatic ischemia reperfusion injury and resection 
Figure S1. Hepatocellular injury after infusion of PBS, 1x105 or 3x105 MSC directly after IRI and 
PH. 
 
Figure S1. Hepatocellular injury after infusion of PBS, 1x105 or 3x105 MSC directly after IRI and PH. (A) Six 
hours after IRI and PH serum ALAT levels showed no significant differences between PBS, 1x105 or 3x105 MSC 
infused mice. Forty-eight hours after IRI and PH, mice infused with 3x105 MSC showed significant higher serum 
levels of ALAT compared to the PBS and 1x105 MSC treated mice. (B) Mice infused with 3x105 MSC showed 
significant higher serum ASAT levels six hours after IRI and PH compared with mice infused with 1x105 MSC. 
Forty-eight hours after IRI and PH mice treated with 3x105 MSC showed significant higher levels of ASAT 
compared to PBS treated mice. (C) Forty-eight hours after IRI and PH there was no difference in percentage of 
necrosis in liver tissue between mice infused with PBS, 1x105 or 3x105 MSC. However, mice infused with 3x105 
MSC show a trend towards higher percentage of necrosis compared to PBS treated mice. (D) The number of 
PCNA positive cells was not significantly different. However, mice treated with 3x105 MSC might show a trend 
towards higher number of proliferating cells compared to PBS treated mice. These data suggest that there is 
more liver damage in mice treated with 3x105 MSC, and hence a stronger regenerative response. The data are 
expressed as means ± SEM, ((*P<0.05) vs PBS or 1x105 MSC infused mice).    
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Figure S1. Hepatocellular injury after infusion of PBS, 1x105 or 3x105 MSC directly after IRI and PH. (A) Six 
hours after IRI and PH serum ALAT levels showed no significant differences between PBS, 1x105 or 3x105 
MSC infused mice. Forty-eight hours after IRI and PH, mice infused with 3x105 MSC showed significant 
higher serum levels of ALAT compared to the PBS and 1x105 MSC treated mice. (B) Mice infused with 3x105 
MSC showed significant higher serum ASAT levels six hours after IRI and PH compared with mice infused 
with 1x105 MSC. Forty-eight hours after IRI and PH mice treated with 3x105 MSC showed significant higher 
levels of ASAT compared to PBS treated mice. (C) Forty-eight hours after IRI and PH there was no difference 
in percentage of necrosis in liver tissue between mice infused with PBS, 1x105 or 3x105 MSC. However, mice 
infused with 3x105 MSC show a trend owards higher percentage of necrosis compar d to PBS tr ated mice.
(D) The umber of PCNA positive cells was not significantly different. However, mice treated with 3x105 
MSC might show a trend towards higher number of proliferating cells compared to PBS treated mice. These 
data suggest that there is more liver damage in mice treated with 3x105 MSC, and hence a stronger regen-
erative response. The data are expressed as means ± SEM, ((*P<0.05) vs PBS or 1x105 MSC infused mice).
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Abstract
Aortic aneurysm formation is associated with defective extracellular matrix remodeling, 
in which Fibulin-4 plays an important role. During the open repair of pararenal aortic 
aneurysms, renal ischemia reperfusion injury (IRI) is inevitable and causes acute kidney 
injury and morbidity. Preoperative fasting is a powerful way to increase resistance 
against IRI. Therefore we investigated the effect of fasting on IRI in heterozygous Fibu-
lin-4 (Fibulin-4+/R) mice, which are predisposed to develop aortic aneurysms. 
Wild type (WT) and Fibulin-4+/R mice were fed ad libitum or were fasted for 2 days 
before the induction of renal IRI. Six hours, one day or six months postoperatively serum 
urea levels, renal histology, matrix metalloproteinase activity and mRNA expression 
levels of inflammatory and injury genes were used to determine kidney function and 
damage.
Two days of fasting improved survival the first week after renal IRI in WT mice compared 
to ad libitum fed mice. Remarkably, AL fed Fibulin-4+/R mice already showed improved 
survival and kidney function compared to AL fed WT mice, which could not be further 
improved by fasting. However, six months after renal IRI fasted WT and Fibulin-4+/R 
mice showed improved survival, kidney function and morphology compared to AL fed 
mice. Moreover, fasted Fibulin-4+/R mice showed reduced apoptotic cells in the kidney 
together with increased expression levels of matrix metalloprotease activity, indicative 
of increased matrix remodeling in the kidney. 
Mice predisposed to developing aortic aneurysms are protected against the short-
term-, but not long-term consequences of renal IRI. Preoperative fasting protects against 
renal IRI and prevents deterioration of kidney function and morphology. These data 
suggest that preoperative fasting may decrease renal damage in patients undergoing 
open abdominal aneurysm repair.
Fasting protects Fibulin-4 mice against chronic ischemia reperfusion injury
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Introduction 
Pararenal aortic aneurysms (PRAAs) are characterized by the absence of normal aorta 
structure between the upper extent of the aneurysm and the renal arteries or extent to 
the renal arteries, and cover 8-20% of the abdominal aortic aneurysms (AAAs)1,2. Stan-
dard endovascular aneurysm repair (EVAR) is feasible in most cases of AAAs and reduces 
morbidity and mortality3. However, the feasibility of standard EVAR in patients with 
PRAAs is limited by strict anatomical requirements, high costs, and lengthy manufactur-
ing lead-times2,3. Therefore, open repair of PRAAs is still used on one in five patients4,5.
The development of aortic aneurysms is associated with extrinsic or intrinsic defects 
of the blood vessel wall6. AAAs show destructive extracellular matrix (ECM) remodeling, 
apoptosis of smooth muscle cells, and inflammatory cell infiltration. Besides gender, 
age, and lifestyle-related risk factors, there is evidence that genetic determinants play a 
role in the development of AAAs7. Fibulin-4 is an elastic fiber-associated glycoprotein in-
volved in stabilizing the organization of ECM structures and plays a role in elasticity and 
integrity8-10. Mice without expression of Fibulin-4 (Fibulin-4-/-) display embryonic death 
due to aortic rupture8,9. In a Fibulin-4 knockdown mouse model, mice homozygous for 
the Fibulin-4 reduced expression allele (Fibulin-4R/R) have a 4-fold reduced Fibulin-4 
expression. These mice show disorganized elastic fiber networks and may die suddenly 
of cardiovascular complications before reaching weaning age8,11. Heterozygous mice 
(Fibulin-4+/R) have a 2-fold reduced Fibulin-4 expression, which results in clear aberra-
tions in elastin formation with occasionally small aneurysm formation and may therefore 
provide invaluable information regarding the early onset of aortic degeneration and the 
effect of stressors on blood vessel walls 
Renal ischemia-reperfusion injury (IRI) is an inevitable consequence of open surgical 
PRAA repair. Ischemia is caused by interruption of the renal blood flow and is associ-
ated with a drop in oxygen and nutrient concentration, which causes accumulation of 
metabolic waste products12. Reperfusion of the kidney activates an inflammatory re-
sponse, triggers apoptotic cell death and results in reactive oxygen species formation13. 
IRI is a risk factor for acute kidney injury that can lead to dialysis and is associated with 
prolonged hospitalization and risk to develop chronic deterioration of kidney function14. 
Previous studies in mice showed that preoperative fasting protects against renal IRI15,16. 
Here, we used the Fibulin-4+/R mouse to explore the effect of oxidative stress induced by 
IRI on kidney damage directly after surgery and in the long-term. In addition, we studied 
the effect of preoperative fasting in Fibulin-4+/R mice after inducing renal IRI on survival, 
kidney function and morphology.
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Material and methods
Mouse model
Heterozygous Fibulin-4 mutant mice (Fibulin-4+/R) were generated as described previ-
ously11. Male wild type and Fibulin-4+/R mice aged 8-10 weeks were used for the experi-
ments. The mice were housed in individually ventilated cages (2-3 animals/cage) under 
standard conditions. Mice were earmarked and genotyped 4 weeks after birth to avoid 
stress-related vascular injury. Animals were housed at the Animal Resource Centre (Eras-
mus University Medical Centre), which operates in compliance with the “Animal Welfare 
Act” of the Dutch government, using the “Guide for the Care and Use of Laboratory 
Animals” as its standard. As required by Dutch law, formal permission to generate and 
use genetically modified animals was obtained from the responsible local and national 
authorities. An independent Animal Ethics Committee of the Erasmus Medical Center 
(Stichting DEC Consult) approved these studies (permit number 105-12-16), in accor-
dance with national and international guidelines. 
Experimental design
At the start of the experiment, wild type (WT) mice and heterozygous Fibulin-4 mutant 
(Fibulin-4+/R) mice were randomly divided into two different groups, ad libitum (AL) fed 
or 2 days of fasting. All mice were transferred to clean cages at 4:00 pm. The AL fed mice 
had free access to food and water. Two days before surgery, mice in the fasted groups 
did not receive any food but had AL access to water. Despite significant weight loss 
as a result of fasting, no morbidity or mortality was observed as a function of fasting 
alone. Mouse body weight as well as food intake was recorded daily. Following induc-
tion of renal IRI, mice with symptoms indicative of irreversible acute kidney injury were 
sacrificed. AL fed and fasted mice were euthanized before surgery (3-5 per group), six 
hours (4-6 per group), 24 hours (3-7 per group) 7 days (8-12 per group) and 6 months 
(5-7 per group) after renal IRI mice were sacrificed to collect blood, and kidney tissue 
(Table S1A). At 6 months the aorta was dissected from the heart until the bifurcation for 
further analysis (Table S1B).
Renal ischemia reperfusion injury
Surgeries were performed between 9:00 am and 1:00 pm. Mice were anesthetized by 
isoflurane inhalation (5% isoflurane initially and then 2-2.5% with oxygen for mainte-
nance), and placed on heating pads of 37°C to maintain body temperature until recov-
ery from anesthesia. Following a midline abdominal incision, the left and right renal 
pedicles were localized and dissected from the surrounding fat, and a non-traumatic 
micro-vascular clamp was placed across the vessels. After inspection for signs of isch-
emia (purple coloration of kidneys), the incision was covered with a phosphate buffered 
Fasting protects Fibulin-4 mice against chronic ischemia reperfusion injury
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saline (PBS) soaked cotton and aluminum foil to maintain body temperature. In the 
short-term experiments, kidneys underwent 37 minutes of ischemia. In previous stud-
ies15 we consistently found mortality of approximately 80% due to acute kidney failure 
following 37 min warm ischemia, making it difficult to study the long-term consequences 
of IRI. To circumvent this problem, in the long-term experiments, kidneys underwent 30 
minutes of ischemia. With this amount of damage survival rates are higher, allowing 
following these animals beyond the first postoperative days. After clamp removal, the 
abdomen was closed in two layers using Vicryl 4-0 sutures. All mice received 0.5 mL PBS 
subcutaneously immediately after surgery for the fluid balance. Mice were placed under 
a heating lamp until recovered from anesthesia. Directly after surgery all animals had AL 
access to food and water15. 
Kidney function
Kidney function, as assessed by serum urea concentrations, was determined using the 
Quantichromä Urea Assay Kit (DIUR-500) (BioAssay Systems, Hayward, USA) following 
the manufactures instructions.
Histopathological analysis
Kidneys were harvested, fixed for 24 hours in formalin and embedded in paraffin. Three-
micrometer thick sections were cut and stained with periodic acid Schiff (PAS) staining. 
The percentage of damaged tubules in the corticomedullary junction was scored using 
a five-point scale according the following criteria: tubular dilatation, cast deposition, 
brush border loss, and necrosis in 10 randomly chosen, non-overlapping fields with 
x400 magnification. Lesions were scaled from 0 to 5: 0 is normal, 1 is mild, 2 is moderate, 
3 is severe, 4 very severe and 5 is extensive damage17. 
In kidneys harvested six months after renal IRI an additional Sirius Red staining was 
performed to determine the amount of interstitial fibrosis. A renal pathologist (MCG) 
blinded for genotype and intervention used the Banff classification18 to determine 
interstitial fibrosis in the cortex: 0 (< 5% fibrosis), 1 (6-25% fibrosis), 2 (26-50% fibrosis) 
and 3 (>50% fibrosis). 
TUNEL staining
Kidney specimens were fixed overnight in 10% buffered formalin, paraffin-embedded, 
sectioned at 5 micrometer, and mounted on Superfrost Plus slides. Paraffin sections 
were employed for TdT-mediated dUTP Nick-End Labeling (TUNEL) assay using a com-
mercial kit (Apoptag Plus Peroxidase in situ apoptosis detection kit, Millipore). Sections 
were deparaffinized and incubated as described by the manufacturer. Kidney sections 
were scanned with the Nanozoomer-XR (Hamamatsu Photonics, NanoZoomer-XR), after 
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which TUNEL positive cells were counted in 3 slides per animal, and corrected for kidney 
area. 
Molecular imaging for MMP activation
We used vascular fluorescent mediated tomography (FMT) imaging with near-infrared 
fluorescent protease activatable probes as previously described8,19. FMT imaging was 
performed using an FMT 2500 system (Perkin Elmer, Inc.) at 680/700 nm excitation and 
emission wavelengths, 24 hours after tail vein injection of 2 nmol per 25 g bodyweight 
of the MMPSenseTM680 near-infrared fluorescent probe (Perkin Elmer, Inc.), mice were 
imaged in a portable animal imaging cassette between optically translucent windows. 
The FMT 2500 quantitative tomography software was then used to calculate 3D fluoro-
chrome concentration distribution of the fluorescent signal. After fluorescence imaging, 
kidneys were harvested and fluorescence was quantified using the FMT 2500 or Odyssey 
imaging systems (LI-COR Inc.). Near-infrared images were obtained in the 700-nm chan-
nel. 
Quantitative RT-PCR 
Total RNA was extracted from frozen liver tissue using Trizol reagent (Invitrogen, Breda, 
the Netherlands), followed by a DNase treatment (RQ1 RNase-Free DNase; Promega 
Benelux B.V., Leiden, the Netherlands), and reverse transcribed to complementary DNA 
using random hexamer primers and Superscript II RT (both from Invitrogen, Breda, the 
Netherlands) according to manufacturer’s instructions. Quantitative real-time PCR was 
performed using a MyiQ single-color Real-Time PCR Detection System with SYBR Green 
incorporation (both from Bio-Rad Laboratories B.V., Veenendaal, the Netherlands; primer 
sequences are available upon request). As a housekeeping gene we used B2M. Besides 
that, we measured gene expression levels of inflammatory marker IL-6, cytoprotective 
gene HO-1 and kidney injury molecule-1 (Kim-1). The Dixons Q test was used to elimi-
nate the outliers. The relative expression was calculated as 2 –(ΔCt sample – ΔCt control), corrected 
for expression levels in healthy wild type control animals. Each sample was tested at 
least in duplicate. 
Statistical analysis 
Data were expressed as mean ± standard error of the mean. Differences in groups were 
analyzed by Mann-Whitney U test. Differences in survival rates were analyzed by Log-
rank test using SPSSv21. Differences were considered significant at P values less≤ 0.05. 
Fasting protects Fibulin-4 mice against chronic ischemia reperfusion injury
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Results
Baseline diff erences in kidney functional parameters between Fibulin-4+/R and 
WT mice
At baseline, before the induction of renal IRI, serum urea levels were similar between 
diets and genotypes (Figure 1A). Also, overall kidney pathology was similar between 
the two genotypes. However, tubular injury seemed slightly increased in kidneys of AL 
fed Fibulin-4+/R mice compared to AL fed WT but did not reached signifi cant diff erences 
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Figure 1. Baseline kidney injury parameters diff er between AL-fed Fibulin-4+/R and WT mice. (A) At 
baseline, serum urea levels showed no diff erences between genotypes or diets. (B) AL-fed Fibulin-4+/R kid-
neys showed slightly increased tubular injury compared to WT, which was not observed in Fibulin-4+/R mice 
after fasting. (C) At baseline, in AL-fed Fibulin-4+/R mice Kim-1 expression levels were higher compared to 
AL-fed WT mice, which was signifi cantly reduced in fasted Fibulin-4+/R mice (*p=0.034). (D) Infl ammatory 
gene IL-6 is up-regulated in AL-fed Fibulin-4+/R compared WT kidneys (#P=0.025) which was signifi cantly 
reduced after fasting in both WT (*p=0.014) and Fibulin-4+/R kidneys (**P=0.034).
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(Figure 1B). As additional measure of renal injury, mRNA expression levels of kidney 
injury molecule-1 (Kim-1) were used. Already at baseline, Kim-1 levels were increased in 
AL fed Fibulin-4+/R compared to WT mice, which could be significantly reduced by fasting 
(Figure 1C). Similarly, before induction of renal IRI, mRNA expression levels of inflam-
matory gene IL-6 seemed increased in AL-fed Fibulin-4+/R mice, which was significantly 
decreased after fasting in both WT and Fibulin-4+/R mice (Figure 1D). Taken together, 
it seems that at baseline AL fed Fibulin-4+/R mice have a slight increase in kidney injury 
parameters, which can be significantly reversed by fasting.
AL fed Fibulin-4+/R animals are protected against renal IRI compared to WT 
controls
During the 2 days of fasting, WT and Fibulin-4+/R mice lost significant weight (Figure 2A), 
while AL fed mice maintained their body weight (WT p<0.01; Fibulin-4+/R p=0.025). One 
day after induction of renal IRI, fasted mice showed an increased body weight. Interest-
ingly, while AL fed WT mice had lower body weights compared to AL fed Fibulin-4+/R mice 
(**p=0.046). Directly after renal IRI, fasted WT and Fibulin-4+/R mice started eating which 
resulted in a higher postoperative calorie intake compared to their AL fed controls (Fig-
ure 2B). After induction of renal IRI, many AL fed WT mice had to be sacrificed due to 
signs indicative of irreversible kidney injury within seven days (Figure 2C). In contrast, 
67% of AL fed Fibulin-4 mice survived 7 days after IRI ($p=0.001). Whereas fasted WT 
mice showed no signs of morbidity and all survived (**p<0.001 compared to AL fed WT), 
fasting did not further increase the survival of Fibulin-4+/R animals. Serum urea levels 
at 48 hours (Figure 2D) were consistent with survival data. Serum urea levels in AL fed 
WT mice were significantly higher compared to fasted WT mice (*p=0.004) and AL fed 
Fibulin-4+/R mice (#p=0.044). In agreement with the survival rates, no differences were 
found in serum urea levels between AL fed or fasted Fibulin-4+/R mice (Figure 2D). Tu-
bular injury was determined in kidneys harvested 24 hours after renal IRI. Kidneys from 
AL fed WT and Fibulin-4+/R mice showed widespread tubular necrosis, tubular dilatation 
and brush border loss, while fasted WT and Fibulin-4+/R mice showed less tubular injury 
(p=0.018 in both cases) (Figure 2E and F). In summary, although Fibulin-4+/R mice seem 
to have somewhat increased kidney injury parameters at baseline, they show increased 
survival after 37 minutes of renal IRI, which could not be further increased by fasting. 
Six hours after renal IRI, Kim-1 expression was strongly increased compared to baseline 
levels, with a trend towards lower levels in fasted WT and Fibulin-4+/R mice (Figure 3A). 
One day after renal IRI, Kim-1 expression was further increased with no significant dif-
ference between AL fed and fasted WT mice. However, AL fed Fibulin-4+/R mice showed 
significant lower expression levels of Kim-1 compared to AL fed WT mice (p<0.01) and 
fasted Fibulin-4+/R mice (p<0.01) (Figure 3B). Six hours after renal IRI, IL-6 levels were 
strongly increased in AL fed WT and Fibulin-4+/R mice, which was significantly reduced 
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Figure 2. Short-term outcome after 37 minutes IRI in WT and Fibulin-4+/R mice. (A) During the dietary 
intervention, fasted mice had a signifi cantly lower body weight compared to AL fed WT (*p<0.01) and 
Fibulin-4+/R mice (#p=0.025). After renal IRI (t=0 in the graph), fasted mice gained weight, while AL fed 
mice lost weight. At day 1 after IRI, AL fed WT mice had a signifi cantly lower body weight compared to 
fasted WT (*p<0.01) and AL fed Fibulin-4+/R mice (**p=0.046). (B) At postoperative day 1, fasted WT and 
Fibulin-4+/R mice had a higher calorie intake compared to their AL fed controls (*p=0.004 and **p=0.001, 
respectively). (C) Seven days after the induction of renal ischemia none of the AL fed WT mice survived, 
whereas AL fed Fibulin-4+/R mice showed a signifi cantly higher survival rate of 66.7% ($p<0.01). One week 
after renal IRI, all 2-day fasted WT mice survived (**p<0.001 compared to AL-fed WT) and 81.8% of the 2-day 
fasted Fibulin-4+/R mice survived (not signifi cant compared to AL fed Fibulin-4+/R). (D) AL fed Fibulin-4+/R 
mice showed signifi cant lower serum urea levels compared to AL fed WT mice (#p=0.044) 48 hours after IRI. 
Two days of fasting signifi cantly lowered the serum urea levels in WT mice (*p=0.004), but in the Fibulin-4+/R 
fasting did not result in further decrease of serum urea levels. (E, F) Kidneys from AL fed mice showed wide-
spread tubular necrosis, tubular dilatation and brush border loss, 24 hours after IRI. Fasting signifi cantly 
reduced tubular injury in both WT and Fibulin-4+/R mice (*p=0.018; #p=0.018).
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by fasting in Fibulin-4+/R mice (*p=0.025) (Figure 3C and D). The levels were returning to 
baseline 24 hours after IRI. 
Fasting improves long-term survival, postoperative recovery and kidney 
function in WT and Fibulin-4+/R mice
As we observed differences between WT and Fibulin-4+/R mice in kidney injury param-
eters and short-term survival after 37 minutes of renal IRI, we wondered how this would 
affect long-term kidney function. To study these long-term effects, we used a milder 
model of renal IRI (30 minutes of ischemia), allowing more animals to survive the injury 
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Figure 3. Renal injury and inflammatory response after renal IRI. (A) Six hours after renal IRI, Kim-1 RNA 
expression levels showed no differences between AL fed and fasted mice. (B) AL fed Fibulin-4+/R mice showed 
significantly lower Kim-1 RNA expression levels compared to AL fed WT mice 24 hours after IRI (#p<0.01). These 
levels were significantly reduced in 2-day fasted Fibulin-4+/R mice (*p<0.01). (C) Six hours after renal IRI there 
were no significant differences in IL-6 RNA expression levels between the different experimental groups. (D) 
Twenty-four hours after renal IRI AL fed Fibulin-4+/R mice showed an up-regulation of IL-6, which was significantly 
reduced by fasting (*p=0.025). 
 
 
 
 
 
 
 
 
 
Figure 3. Renal injury and inflammatory response after renal IRI. (A) Six hours after renal IRI, Kim-1 
RNA expression levels showed no differences between AL fed and fasted mice. (B) AL fed Fibulin-4+/R mice 
showed significantly lower Kim-1 RNA expression levels compared to AL fed WT mice 24 hours after IRI 
(#p<0.01). These levels were sig ificantly reduced in 2-day fasted Fibulin-4+/R mice (*p<0.01). (C) Six hours 
after renal IRI there were no significant differences in IL-6 RNA expression levels between the different ex-
perimental groups. (D) Twenty-four hours after renal IRI AL fed Fibulin-4+/R mice showed an up-regulation 
of IL-6, which was significantly reduced by fasting (*p=0.025).
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and to be examined at 6 months of age. During the dietary intervention, similar to the 
previous experiment, mice lost around 10% of their body weight and had a significantly 
lower body weight compared to their AL controls (p<0.01) (Figure 4A). One day after 
surgery, fasted WT and Fibulin-4+/R mice increased their body weight, while the AL fed 
WT and Fibulin-4+/R mice lost weight. Also, at postoperative day 1, fasted WT and Fibulin-
4+/R mice ate significant more calories compared to the AL fed WT and Fibulin-4+/R mice, 
which is in correlation with their body weight (p<0.01) (Figure 4B). Six months after 
the induction of renal IRI there was no significant difference in body weight between 
fasted or AL fed WT and Fibulin-4+/R mice (data not shown). Comparable to 37 minutes 
of renal IRI, at postoperative day 7 more AL fed Fibulin-4+/R were alive than AL fed WT 
animals (70% versus 60%) (Figure S1). After 6 months, all fasted WT and Fibulin-4+/R 
mice were alive, whereas 60% of the AL fed WT and Fibulin-4+/R mice were deceased 
(Figure S1). Serum urea levels were used as an indicator of kidney function and 48 hours 
after renal IRI, and showed no significant differences (Figure 4C). At 6 months after IRI, 
fasted WT and Fibulin-4+/R mice showed significantly lower tubular injury score (p<0.01) 
and a reduction in number of apoptotic cells compared to their AL fed controls (Figure 
4D,E,G). In addition, Sirius red staining showed significantly less fibrosis in the renal 
cortex of fasted WT and Fibulin-4+/R mice (p<0.05) (Figure 4F,H), compared to Al fed 
controls. Interestingly, only 2 days of fasting has significant effects on kidney injury, even 
after 6 months. 
Fasting results in lower MMP expression in Fibulin-4+/R kidneys 6 months after 
the induction of renal IRI
Microscopically, AL fed WT and Fibulin-4+/R kidneys showed increased tubular injury 
and interstitial fibrosis (Figure 4F, Figure 4H), and macroscopically these kidneys were 
smaller, dystrophic and some developed renal cysts (data not shown). Since these 
parameters were significantly reduced after fasting, this seemed a long-term effect of 
renal IRI. We therefore next examined the potential long-term impact of IRI on matrix 
remodeling in the kidney, by determining matrix metalloprotease activity (Figure 5A). 
In control age matched controls, no significant differences between the different 
genotypes or diets in matrix metalloproteinases activity were found (Figure 5B). Kidneys 
from WT mice did not show any differences between AL fed or fasted mice 6 months 
after IRI (Figure 5C). In fasted Fibulin-4+/R mice, however, MMP activity was significantly 
higher than in AL fed animals (p=0.011). This increase in MMP activity did not correlate 
to the degree of fibrosis in the kidney as determined in Sirius Red stained sections in 
Figure 4E (data not shown). These data might indicate, that in Fibulin-4+/R kidneys, fast-
ing induces long-term matrix remodeling after renal IRI. 
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Figure 4. Fasting improves postoperative recovery, kidney function and long-term survival in WT 
and Fibulin-4+/R mice
Fasting protects Fibulin-4 mice against chronic ischemia reperfusion injury
167
← Figure 4. Fasting improves postoperative recovery, kidney function and long-term survival in WT 
and Fibulin-4+/R mice continued (A) After 2 days of fasting, the body weight of WT and Fibulin-4+/R mice 
strongly decreased compared to the AL fed mice (*p<0.01). However, after the induction of renal IRI, body 
weight of the fasted mice increased rapidly, around 13%, whereas the AL fed mice lost 9% of their body 
weight (*p<0.01). Postoperative day 7 showed no diff erences between the body weights of fasted or AL fed 
WT and Fibulin-4+/R mice. (B) Directly after surgery, fasted WT and Fibulin-4+/R mice started eating, which 
resulted in a higher calorie intake compared to their AL fed controls (*p<0.01). (C) No signifi cant diff erences 
in serum urea levels were observed between fasted and AL fed WT and Fibulin-4+/R mice 48 hours after renal 
IRI. Remarkably, after 6 months serum urea levels were signifi cantly lower in fasted mice compared to their 
AL fed controls (*p<0.01). (D) Two days of fasting resulted in signifi cantly less tubular injury in both WT and 
Fibulin-4+/R kidneys compared to their AL fed controls (WT *p<0.01;Fibulin-4+/R #p<0.01). (E, F) Similarly, 
two days of fasting resulted in signifi cantly less interstitial fi brosis in both WT and Fibulin-4+/R kidneys com-
pared to their AL fed controls (*p<0.05; #p<0.05), and less apoptosis. (G,H) Representative histological PAS 
and Sirius Red stained sections from AL fed and fasted WT and Fibulin-4+/R mice. 
Figure 4. Fasting improves postoperative recovery, kidney function and long-term survival in WT and 
Fibulin-4+/R mice (A) After 2 days of fasting, the body weight of WT and Fibulin-4+/R mice strongly decreased 
compared to the AL fed mice (*p<0.01). However, after the induction of renal IRI, body weight of the fasted mice 
increased rapidly, around 13%, whereas the AL fed mice lost 9% of their body weight (*p<0.01). Postoperative 
day 7 showed no differences between the body weights of fasted or AL fed WT and Fibulin-4+/R mice. (B) Directly 
after surgery, fasted WT and Fibulin-4+/R mice started eating, which resulted in a higher calorie intake compared 
to their AL fed controls (*p<0.01). (C) No significant differences in serum urea levels were observed between 
fasted and AL fed WT and Fibulin-4+/R mice 48 hours after renal IRI. Remarkably, after 6 months serum urea 
levels were significantly lower in fasted mice compared to their AL fed controls (*p<0.01). (D) Two days of fasting 
resulted in significantly less tubular injury in both WT and Fibulin-4+/R kidneys compared to their AL fed controls 
(WT *p<0.01;Fibulin-4+/R #p<0.01). (E, F) Similarly, two days of fasting resulted in significantly less interstitial 
fibrosis in both WT and Fibulin-4+/R kidneys compared to their AL fed controls (*p; #p<0.05), and less apoptosis. 
(G,H) Representative histological PAS and Sirius Red stained sections from AL fed and fasted WT and Fibulin-
4+/R mice.  
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Figure 5. Fasting results in lower MMP expression in Fibulin-4+/R kidneys 6 months after the induction of 
renal IRI. (A) Ex vivo fluorescent images of AL fed and fasted WT and Fibulin-4+/R mice after injection of the MMP 
probe, 6 months after IRI. (B) Control mice showed no significant differences between genotypes, or diet in MMP 
expression after IRI. (C) Six months after renal IRI, WT mice showed no differences in MMP expression levels 
between AL fed or fasted mice. However, fasted Fibulin-4+/R mice had significant lower levels of MMP compared 
to AL fed Fibulin-4+/R mice (#p=0.011).  
 
Figure 5. Fasting results in lower MMP expression in Fibulin-4+/R kidneys 6 months after the induc-
tion of renal IRI. (A) Ex vivo fl uorescent images of AL fed and fasted WT and Fibulin-4+/R mice after injection 
of the MMP probe, 6 months after IRI. (B) Control mice showed no signifi cant diff erences between geno-
typ , or die  in MMP expression after IRI. (C) Six months after renal IRI, WT mi  showed no diff ere c s in 
MMP expression levels between AL fed or fasted mice. However, fasted Fibulin-4+/R mice had signifi cant 
lower levels of MMP compared to AL fed Fibulin-4+/R mice (#p=0.011). 
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Discussion 
Despite the reduction in morbidity and mortality after the use of standard EVAR, still 
one in five patients undergo open repair of aneurysms, especially patients with PRAAs4,5. 
During open repair of PRAAs renal IRI is inevitable and a major risk factor for acute kid-
ney injury, which causes morbidity and mortality14. Another factor in the development 
and outcome of aortic aneurysms in patients might be genetic determinants. In the 
present study, we used the Fibulin-4+/R mouse model with a 2-fold reduced Fibulin-4 
expression. These mice match those patients with sporadic and barely detectable forms 
of aneurysms, which might make them more vulnerable to a worse postoperative out-
come. Previous studies showed that preoperative fasting improved survival and kidney 
function one week after renal IRI15. However, the beneficial effects of preoperative fast-
ing on renal IRI in mice prone to develop aneurysms, and in the long-term, are unknown. 
Interestingly, before the induction of renal IRI, Fibulin-4+/R mice showed signs of 
increased kidney injury compared to WT mice. In agreement with previous studies15,16, 
our study showed the same beneficial effect of preoperative fasting on renal IRI in WT 
mice. Fasting reduced injury and inflammation of the kidney and improved survival, 
kidney function and postoperative recovery compared to AL fed WT mice. In contrast 
to what we expected, Fibulin-4+/R mice were protected against renal IRI compared to WT 
mice, and fasting could therefore not further improve outcome following injury on the 
short-term. These data would imply that the mild kidney injury in Fibulin-4+/R mice in-
duces an increased resistance against oxidative damage. Although counterintuitive, we 
previously showed that mice harboring a genetic defect in a gene involved in the repair 
of DNA damage also showed increased resistance against renal IRI20. This phenotype 
has been interpreted as an adaptive response to unrepaired endogenous DNA damage 
engaged to protect from further oxidative injury21. A prediction of this interpretation is 
that the low grade kidney injury in Fibulin-4+/R mice, most probably due to mild extracel-
lular matrix degeneration observed in these animals8, induces a similar response which 
renders them resistant to acute oxidative stress. In the long-term no differences were 
observed in survival between ad libitum fed WT and Fibulin-4+/R mice, suggesting that 
the potential survival response is only effective in reducing acute damage. Remarkably, 
even six months after the induction of renal IRI, 2 days of preoperative fasting proved 
beneficial in both WT as well as Fibulin-4+/R mice; all fasted mice were alive compared to 
only 60% of the AL fed mice. Moreover, fasting also prevented kidney injury induced by 
renal IRI. Fasted WT and Fibulin-4+/R mice showed lower serum urea levels compared to 
their AL fed controls. Kidneys from AL fed Fibulin-4+/R mice were small, dystrophic and 
some developed renal cysts, but none of these abnormalities were seen in kidneys from 
fasted Fibulin-4+/R or WT mice. In addition, kidney sections from fasted mice showed less 
tubular injury, less apoptosis and less fibrosis compared to AL fed controls. 
Fasting protects Fibulin-4 mice against chronic ischemia reperfusion injury
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MMPs are responsible for extracellular matrix remodeling; they directly activate 
cytokines, chemokines, growth factors and other proteases22,23. Previously we showed 
that in Fibulin-4+/R and Fibulin-4R/R mice MMP expression levels were up-regulated in the 
aorta even before the aneurysm actually was formed8. Therefore, we were curious to 
determine the expression levels of MMP in the kidneys six months after renal IRI. The 
AL fed or fasted WT mice did not show any differences in MMP expression levels. In 
contrast, fasted Fibulin-4+/R mice had increased MMP expression levels compared to AL 
fed Fibulin-4+/R mice. MMPs have been shown to be involved in acute and chronic renal 
injury and might play a role in tubular atrophy and fibrosis24. Besides that, after renal IRI 
MMP expression levels increased suggesting that MMPs may regulate the inflammatory 
response25. In a MMP-2-deficient mouse model the degree of tubular injury, necrosis, 
apoptosis and renal dysfunction was markedly less compared to wild type mice22. 
Therefore, inhibition of MMPs might protect against kidney injury, which has created 
interest in MMP inhibitors as drugs to reduce acute kidney injury23,24,26. However, recent 
studies highlighted the beneficial role of MMPs in tissue remodeling and recovery after 
IRI27,28. Kaneko et al.29 demonstrated that after renal IRI MMP-2 expression increased in 
the medulla on day 7-14 and the damaged tubules recovered within 14 days. The lack of 
MMP-2 expression resulted in impaired recovery of the damaged tubules, which might 
be due to the suppression of proliferation, migration and differentiation of regenerated 
tubular epithelial cells29. The conflicting roles of MMP expression suggest a different role 
for the different MMPs in the acute and recovery phase after IRI. In literature increased 
expression of MMPs is related to renal fibrosis30. However, in fasted Fibulin-4+/R mice 
MMP expression is up-regulated six months after renal IRI while there is significant less 
renal fibrosis compared to AL fed mice. This suggests that in the kinetics of remodeling 
in the injured kidney differ between Fibulin-4+/R and wildtype mice.
In summary, two days of preoperative fasting improved kidney function and also 
prevented the deterioration of kidney function and morphology, up to six months after 
renal IRI. Despite the 2-fold reduction in Fibulin-4, these mice seem protected against 
the acute injury induced by renal IRI. However, in the long-term pre-operative fasting 
does protect against kidney injury induced by renal IRI. Moreover, in Fibulin-4+/R mice, 
increased MMP activity after pre-operative fasting may be indicative of another protec-
tive mechanism aimed at remodeling of the kidney matrix to reduce kidney injury. These 
data suggest that although patients with a (familiar) history of aneurysms might not 
be more vulnerable to renal IRI, preoperative fasting could benefit these patients by 
reducing renal injury after IRI, especially in the long-term.
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Figure S1. AL fed WT and Fibulin-4+/R mice had a survival of 60% within the 6 months after renal IRI, while 
fasted WT and Fibulin-4+/R mice showed a survival of 100%.
Table S1. Overview of the experimental design 
(A) Overview short-term experiments
Dietary 
intervention
Genotype Surgical 
intervention
Follow-up Parameters measured
Ad libitum Wild type 37min IRI Baseline, 6 hrs,  
24 hrs or 7 days
Body weight, food intake, kidney function, 
histology, gene expressions and survival. 
Ad libitum Fibulin-4+/R 37min IRI Baseline, 6 hrs,  
24 hrs or 7 days
Body weight, food intake, kidney function, 
histology, gene expressions and survival. 
2 day fasted Wild type 37min IRI Baseline, 6 hrs,  
24 hrs or 7 days
Body weight, food intake, kidney function, 
histology, gene expressions and survival. 
2 day fasted Fibulin-4+/R 37min IRI Baseline, 6 hrs, 
24 hrs or 7 days
Body weight, food intake, kidney function, 
histology, gene expressions and survival. 
Fasting protects Fibulin-4 mice against chronic ischemia reperfusion injury
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(B) Overview long-term experiments
Dietary 
intervention
Genotype Surgical 
intervention
Follow-up Parameters measured
Ad libitum Wild type 30min IRI 7 days or 6 
months
Survival, body weight, food intake, kidney 
function (48hrs), histology, MMP expression 
kidney and aorta. 
Ad libitum Fibulin-4+/R 30min IRI 7 days or 6 
months
Survival, body weight, food intake, kidney 
function (48hrs), histology, MMP expression 
kidney and aorta. 
2 day fasted Wild type 30min IRI 7 days or 6 
months
Survival, body weight, food intake, kidney 
function (48hrs), histology, MMP expression 
kidney and aorta. 
2 day fasted Fibulin-4+/R 30min IRI 7 days or 6 
months
Survival, body weight, food intake, kidney 
function (48hrs), histology, MMP expression 
kidney and aorta. 
Ad libitum Wild type Control 7 days or 6 
months
Survival, body weight, food intake, kidney 
function (48hrs), histology, MMP expression 
kidney and aorta. 
Ad libitum Fibulin-4+/R Control 7 days or 6 
months
Survival, body weight, food intake, kidney 
function (48hrs), histology, MMP expression 
kidney and aorta. 
2 day fasted Wild type Control 7 days or 6 
months
Survival, body weight, food intake, kidney 
function (48hrs), histology, MMP expression 
kidney and aorta. 
2 day fasted Fibulin-4+/R Control 7 days or 6 
months
Survival, body weight, food intake, kidney 
function (48hrs), histology, MMP expression 
kidney and aorta. 
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Summary and discussion
Organ transplantation is the treatment of choice for patients with end-stage organ 
failure and offers the best chance on long-term survival and improvement of quality 
of life1. However, transplantation is facing a shortage of donor organs which limits its 
widespread use2. The increasing gap between availability of donor organs and demand 
has contributed to the expansion of the donor pool. Nowadays not only Donation after 
Brain Death (DBD) donors and living donors are being used, but also Donation after 
Circulatory Death (DCD) donors and extended criteria donors.
Another limitation of organ transplantation is the development of ischemia reperfu-
sion injury (IRI) during transplantation. IRI is inevitable during transplantation and has 
major consequences for graft- and patient survival3-6. Although DCD kidney donation 
has increased the number of donor kidneys with 30% in some programs, this comes 
with a disadvantage7. DCD donors and extended criteria donors are more vulnerable 
to IRI since the organs suffer from prolonged warm ischemia time, increased donor age 
or comorbidity of the donor8. Therefore prevention or reduction of IRI could improve 
graft survival and decrease patient morbidity. Unfortunately, at this moment there is no 
therapy available to reduce or ameliorate IRI. 
The overall aims of this thesis were to: 1) examine gene expression profiles of living-, 
DBD- and DCD donor organs in relation to transplant outcome, and 2) to determine if 
preconditioning strategies such as dietary preconditioning or the use of mesenchymal 
stem cells could be used as a therapeutic approach to ameliorate IRI. 
In chapter 2 we reviewed the literature on experimental and clinical studies on dietary 
preconditioning, preservation, ischemic pre- and post-conditioning, cell therapy, phar-
macological treatment and microRNA therapy as intervention strategies to reduce renal 
IRI. These therapies to reduce renal IRI can be implemented in both donor and recipient, 
and before, during and after transplantation. Studying renal IRI is complex, coping with 
translational difficulties, and multifactorial pathophysiological mechanisms. Experimen-
tal research has contributed to the development of strategies to prevent or ameliorate 
IRI. However, despite these advances in animal studies, only few animal data are finding 
their way into the clinic and improve transplant outcome9. 
Due to the increasing gap between organ demand and supply, different donor types 
are being used. Kidneys from living donors are exposed to minimal warm and cold isch-
emia times, which results in a superior long-term graft survival compared to DBD- and 
DCD donor grafts. DBD kidneys are affected by the changes in hormonal and circulatory 
state, which contribute to organ damage and decreased post-transplant function and 
graft survival compared to living donors10,11. Kidneys from DCD donors suffer from pro-
longed warm ischemia times, which increases the incidence of delayed graft function. 
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Despite the higher incidence of delayed graft function in DCD kidneys compared to 
DBD kidneys, graft survival is similar12. The pathophysiology of DBD donors is relatively 
well established, and strategies to optimize donor organs are emerging13. In contrast, 
experimental studies on the changes that occur in DCD donor organs are sparse14. 
In chapter 3, expression levels of genes indicative of inflammation, cytoprotection and 
injury at the time of kidney retrieval, after clinically relevant cold ischemia times, and 
over a time-course during cold storage are compared between living donors, DBD- and 
DCD donors in a rat model.
The most striking finding in our study is the difference between DBD- and DCD 
donors in renal transcription of pro-inflammatory genes. Compared to kidneys after 
living donation, IL-1b, IL-6, TNF-a, MCP-1, TLR4, P-selectin and E-selectin were massively 
up-regulated in DBD kidneys, and only moderately increased in DCD kidneys. The high 
levels of pro-inflammatory and injury genes in DBD donors are in contrast with the 
high clinical incidence of delayed graft function in DCD- compared to DBD donors. 
Human DCD donors may suffer from other injuries, which influence the inflammatory 
response and might play an important role in the incidence of DGF and post-transplant 
outcome15. Besides that, the absence of huge inflammatory changes in our study could 
be an explanation why the impact of DGF is reduced in DCD kidneys. 
A significant increase in the expression of injury markers Kim-1, and p21, and the 
cytoprotective gene HO-1 accompanied the up-regulation of pro-inflammatory genes. 
In living donors, up-regulation of HO-1 expression had a protective effect on renal IRI16. 
In contrast, the increased levels of HO-1 in DBD kidneys did not prevent renal damage17. 
This suggests that DBD causes renal damage to such an extent that the increased ex-
pression of HO-1 is insufficient to ameliorate the damage, and therefore may be viewed 
as a marker of injury17. After clinically relevant cold ischemia times, the gene expression 
profiles remained stable. However, in both post-mortem donors the average number of 
apoptotic cells increased between retrieval and 18 hours of cold storage. 
In conclusion, we show a massive up-regulation of inflammatory, cytoprotective, and 
injury genes in DBD kidneys, but not in LD- or DCD kidneys at the time of graft retrieval, 
which remains stable during cold preservation. These results may imply why delayed 
graft function in DCD kidneys does not have the deleterious effect it has on DBD kidneys 
and lend further support to the anti-inflammatory treatment of DBD donors. 
After finding the remarkable differences in expression levels of inflammatory, cytopro-
tective and injury genes between DBD- and DCD kidneys, we wondered if these differ-
ences were organ specific. In chapter 4, we compared gene expression profiles in rat 
livers from living donors, DBD- and DCD donors at the time of retrieval, after clinically 
cold ischemia times, and over a time-course during cold storage. 
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As mentioned before, living donors experience minimal warm and cold ischemia 
times18, and DBD donors suffer from physiological perturbations that influence post-
transplant outcome11. Organs from DCD donors are exposed to a period of hypotension, 
hypoxia and prolonged warm ischemia time, which affects early graft function and 
survival19. DCD Livers have an almost 11 times increased risk of developing ischemic 
type biliary lesions and 1.85 higher risk of graft loss, compared to DBD donors19,20. 
After retrieval, early mediators of inflammation MCP-1, HMGB1 and TLR4 were in-
creased in DCD livers, whereas a massive up-regulation of pro-inflammatory genes IL-6, 
IL-1b, TNF-a, P-selectin and E-selectin was seen in DBD livers, but not in living donor 
livers. Cytoprotective gene HO-1 was increased in both post-mortem groups. Despite 
the lower expression of inflammatory genes in DCD- compared to DBD livers, the 
outcome after DCD liver transplantation are inferior21. The prolonged warm ischemia 
time in DCD livers might be the reason why HMGB1, marker of overall graft damage, is 
up-regulated directly after retrieval. Besides that, MCP-1 is considered an early mediator 
of inflammation and in human high levels of MCP-1 early after transplantation are as-
sociated with poor early graft function after transplantation22 and it has been suggested 
that MCP-1 contributes to the development of biliary atresia23. After cold ischemia, DCD 
livers showed increased levels of MCP-1, TLR4 and HMGB1, whereas expression of pro-
inflammatory genes in DBD livers remained high. During 12 hours of cold storage, mRNA 
gene expression profiles remain stable in LD livers, while DBD- and DCD livers show mild 
changes in expression of Hif-1a, Bcl-2 and HMGB1. DCD livers showed a significantly 
higher number of early apoptotic cells compared to DBD livers directly after retrieval. 
These numbers do not change during cold preservation. The higher number of apop-
totic cells might explain why DCD livers have a worse outcome after transplantation, 
despite the lower expression of inflammatory genes. Our study shows a differential gene 
expression profile between livers retrieved from DBD- versus DCD donors. This suggests 
that the kinetics of injury and inflammatory processes might be different between 
DBD- and DCD donors. These differences may be relevant for more effective and early 
treatment in the recipient.
Long-term dietary restriction (DR) is defined as a reduction in food intake without caus-
ing malnutrition. DR is known to extend lifespan, increase health and improve stress 
resistance in different organisms24. Previously we showed that 2 and 4 weeks of 30% 
preoperative DR as well as three days of fasting decreased morbidity and mortality and 
improved kidney function in a murine renal IRI model24. Whether this protection is based 
on the reduction in calories or the source of those calories is unclear. In chapter 5, we 
investigated the role of specific macronutrients by unrestricted feeding of protein-, 
carbohydrate (CHO)-, and fat-free diets in inducing resistance against renal IRI. 
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We showed that the absence of protein for three days is sufficient to induce resistance 
against renal IRI, while a carbohydrate- and fat-free diet did not protect against renal 
IRI. In order to elucidate the mechanisms underlying these beneficial effects we pro-
duced gene expression datasets of diets proven to be either protective or not protective 
against renal IRI. We compared mRNA transcriptional profiles of kidneys from mice after 
2 weeks of 30% DR, three days of fasting, or three days of a protein-free-, CHO-free-, or 
fat-free diet, before inducing renal IRI. Gene expression profiles of the non-protective 
CHO-free diet showed a striking overlap with gene expression profiles of the protec-
tive diets. This could either indicate that overlapping pathways are not involved in the 
induction of protection against renal IRI, or that they require additional changes in other 
pathways to induce this effect. To identify upstream regulators of these pathways, we 
determined the most differentially regulated transcription factors in all protective diets, 
which were FOXO3, HNF4A, HMGA1 and HSF1. These were not regulated in the non-
protective CHO-free diet. Directly or indirectly these transcription factors are involved 
in stress resistance pathways25. Various pathways are proposed to be involved in the 
protective response against renal IRI generated by dietary interventions. The eukaryotic 
translation factor 2α (eIF2α) signaling pathway, in which eIF2α is phosphorylated by the 
general control nonderepressible 2 (Gcn2) kinase, might be one of them26. However, the 
role of this pathway is subject of debate27. In our study, up-regulation of eIF2α occurred 
in 3-day fasted mice only. 
The nutrient sensing pathway mammalian target of Rapamycine (mTOR) mediates 
between growth factors, hormones and nutrients to regulate essential cellular func-
tions. Inhibition of the mTOR pathway increases lifespan in various animal species26. We 
found a down-regulation of mTOR after 2 weeks of 30% DR and after three days of a 
protein-free diet. An up-regulation of mTOR was seen in the non-protective CHO-free 
diet and after three days of 30% DR. In contrast, MTORC1, which is a part of mTOR, was 
down-regulated after three days of fasting. However, more research is warranted to 
further elucidate the role of these transcription factors and pathways in the induction 
of acute stress resistance by short-term DR, which may ultimately lead to a therapeutic 
strategy in humans. 
In mice, two weeks of 30% DR and three days of fasting does not only protect against 
renal-, but also against hepatic IRI. We showed that three days of a preoperative protein-
free diet induces resistance against renal IRI (chapter 5). Since recent literature suggests 
that the beneficial effect of long-term DR on lifespan is induced by the absence of 
essential amino acids28,29, in chapter 6, we studied the effect of essential amino acid 
(EAA)-free diets on hepatic IRI and aimed to find the mechanisms underlying the protec-
tive effects. Three days before inducing partial hepatic IRI, mice received a methionine 
(Met)-, a leucine (Leu)- or a tryptophan (Trp)-free diet. We showed that all three EAA-free 
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diets protected against IRI. However, a Met-free diet has a more gradual response than 
a Leu- and Trp-free diet, with both the Leu- and Trp-free diets showing a protective 
response that is activated faster after surgery than the Met-free diet. During microarray 
analysis these differences also come forward, since the transcriptomic response of a 
Met-free diet was of a lower magnitude than that of the Leu- and Trp-free diets. Since the 
Met-free diet resulted in the smallest number of differentially pathways and transcrip-
tion factors, the analysis could be narrowed down to the results revealed by Met-free 
diet. Detailed analysis of overlapping genes suggested a role for pathways involved in 
nuclear receptor signaling, stress resistance and cell cycle regulation. The transcription 
factors involved are NRF2, FOXM1, SREBF2 and SMARCB1. Further in depth analysis via 
functional and pharmacological modulation of these factors may provide mimetics for 
treatment against ROS-related injury. 
The liver has the unique ability of regeneration as a response to liver injury. Thanks to 
this remarkable feature and advances in surgical techniques, large liver resections as 
well as split- and living donor liver transplantation are possible. During liver transplan-
tation and liver resection IRI is inevitable. Liver IRI leads to a decreased regenerative 
capacity of hepatocytes, tissue necrosis, and apoptosis6. IRI is a major cause of morbidity 
and mortality after liver transplantation and liver resection30. Therapies that are able to 
reduce hepatic IRI and promote liver regeneration could offer major benefits in both 
liver transplantation and resection. Mesenchymal stem cells (MSC) are able to differenti-
ate into cell types other than their tissue of origin, secrete growth factors that stimulate 
other cells, and have immunomodulatory and anti-inflammatory properties31. Because 
of these characteristics, MSC are considered as a potential therapy to prevent or amelio-
rate hepatic IRI and stimulate liver regeneration. 
In chapter 7, we investigated whether MSC are able to reduce hepatic IRI and stimulate 
liver regeneration in a combined hepatic IRI and partial hepatectomy (PH) model in the 
mouse. Intravenous infusion of 2x105 MSC 2 hours before hepatic IRI and PH significantly 
decreased ASAT and ALAT levels compared to their PBS controls six hours after IRI and 
PH, but did not decrease the amount of hemorrhagic necrosis. In addition, MSC infused 
before or after hepatic IRI and PH showed no beneficial effect on liver damage and 
regeneration. Besides that, MSC infusion had no beneficial effect on liver regeneration, 
although there was a trend towards a higher liver/body weight ratio in the MSC treated 
animals. This is supported by a trend towards more proliferating hepatocytes and higher 
TFG-β expression 48 hours after IRI and PH. 3D cryo-imaging showed that intravenously 
infused MSC do not migrate to the damaged organ but are trapped in microcappillary 
networks and have a short lifespan. 
In conclusion, intravenous infusion of 2x105 MSC 2 hours before- or 1 hour after IRI 
and partial PH showed no beneficial effect on liver damage or regeneration. Many of 
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the infused MSC are trapped in the lungs, disappear within 2 hours and do not migrate 
towards the damaged liver. 
Pararenal aortic aneurysms (PRAAs) are characterized by the absence of normal aorta 
structure between the upper extent of the aneurysm and the renal arteries, or extent 
to the renal arteries. The feasibility of standard endovascular aneurysm repair (EVAR) 
in patients with PRAAs is limited by strict anatomical requirements and high costs. Still 
one in five patients with PRAAs are undergoing an open repair, which leads to renal 
ischemia reperfusion injury (IRI), which may cause acute kidney injury. The development 
of aortic aneurysms is associated with extrinsic or intrinsic defects of the blood vessel 
wall. Aneurysms show destructive extracellular matrix remodeling, apoptosis of smooth 
muscle cells, and inflammatory cell infiltration. 
Fibulin-4 is an elastic fiber-associated glycoprotein involved in stabilizing the orga-
nization of extracellular matrix structures and plays a role in elasticity and integrity. A 
reduction in Fibulin-4 expression leads to the early onset of aortic degeneration. The 
heterozygous Fibulin-4 mouse model (Fibulin-4+/R) has a 2-fold reduction in Fibulin-4 
expression, which results in clear aberrations in elastin formation with occasionally small 
aneurysm formation. In Chapter 8 we used this mouse model to explore the effect of 
Fibulin-4 deficiency on renal IRI directly after surgery and in the long-term. Besides that, 
we studied the effect of preoperative fasting on renal IRI in Fibulin-4+/R and wild type 
(WT) control mice. Mice were fed ad libitum or fasted for 2 days before the induction of 
renal IRI, and animals were monitored six hours, one day or six months postoperatively. 
Interestingly, before the induction of renal IRI, Fibulin-4+/R mice showed signs of de-
creased kidney function compared to WT mice. As previously described, fasted WT mice 
showed improved survival, kidney function and postoperative recovery compared to AL 
fed WT mice. In contrast, Fibulin-4+/R mice were protected against renal IRI compared to 
WT mice, and fasting could not further improve the outcome. These data might imply 
that mild kidney injury present at baseline in Fibulin-4+/R mice increased resistance 
against oxidative damage. In the long-term no differences were observed in survival 
between ad libitum (AL) fed WT and Fibulin-4+/R mice, suggesting that the potential 
survival response is only effective in reducing acute damage. Six months after renal 
IRI preoperative fasting improved survival in both WT and Fibulin-4+/R mice; all fasted 
mice were alive compared to only 60% of the AL fed mice. Besides that, fasting reduced 
kidney injury as indicated by lower serum urea levels compared to their AL fed controls. 
Kidneys from AL fed Fibulin-4+/R mice were small, dystrophic and some developed re-
nal cysts, while none of the abnormalities were seen in fasted Fibulin-4+/R or WT mice. 
Kidney sections from fasted mice showed less tubular injury, less apoptosis and less 
fibrosis compared to AL fed controls. Matrix Metalloproteinases (MMPs) are responsible 
for extracellular matrix remodeling and directly activate cytokines, chemokines and 
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growth factors. Fasted Fibulin-4+/R mice showed increased expression levels of MMPs 
compared to AL fed Fibulin-4+/R mice. MMPs have been shown to be involved in acute 
and chronic renal injury and might play a role in tubular atrophy and fibrosis. However, 
in fasted Fibulin-4+/R mice MMP expression levels are up-regulated while there is signifi-
cant less renal fibrosis compared to AL fed mice. This suggests a different role for MMPs 
in the acute and recovery phases after IRI. 
In conclusion, mice predisposed to developing aortic aneurysms are protected against 
the short-term-, but not long-term consequences of renal IRI. Preoperative fasting pro-
tects against renal IRI and prevents deterioration of kidney function and morphology. 
These data suggest that preoperative fasting may decrease renal damage in patients 
undergoing open abdominal aneurysm repair.
Future directions
In this thesis we showed that dietary preconditioning with a preoperative 3-day 
protein-free or essential amino acid free diet protects against renal and hepatic ischemia 
reperfusion injury (IRI). These data have contributed to our understanding of a specific 
role for macro- and micronutrients in inducing acute stress resistance. Three days of a 
preoperative protein-free diet, a methionine-, leucine- or tryptophan-free diet protects 
against IRI due to the deficiency of the specific nutrient and not due to the reduction in 
calories. However, translation of these results to the clinic may be challenging due to the 
disparities between experimental animals and humans. 
In our animal experiments, inbred, young, healthy males were used. This is obviously 
not representative for the patients undergoing transplantation and experience IRI. Gen-
der, old age, overweight, comorbidities and the use of medication are variable factors 
that can interfere with the outcome of dietary preconditioning or other therapies that 
might be able to ameliorate IRI. Jongbloed et al.32 showed that preoperative fasting also 
protects both male and female aged-overweight mice against renal IRI. These findings 
suggest a general protective response induced by dietary preconditioning against IRI re-
gardless of age and gender. However, other studies suggest that the benefits of protein 
restriction are age-dependent or at least are affected by age33,34.
Dietary preconditioning is applied before ischemia, which makes translation difficult 
since in the human setting, treatment before ischemia would imply treatment of the 
donor. This raises not only feasibility issues but also ethical concerns in DBD- and DCD 
donors35. In living donors, the donor must give full consent and treatment should not 
interfere with the donor’s health. Ginhoven et al.36 investigated whether a preoperative 
dietary restriction (DR) regimen is feasible in living kidney donors and explored the ef-
fects of DR on both the donor and recipient. Of the living kidney donors, 94% adhered 
184
Chapter 9
to a preoperative reduction in caloric intake. There were no differences in postoperative 
wellbeing, appetite and ability to perform daily tasks between the preoperative DR or 
control donors. Serum creatinine levels at post-operative day one and after a month 
showed no difference between kidneys from the DR donors or control donors. They 
concluded that dietary preconditioning is feasible and safe in living kidney donors, but 
that the dietary regimen that was used induced no major beneficial effects. 
The treatment of DBD- or DCD donors is not only difficult due to the ethical concerns. 
Our studies suggest that the kinetics of injury and inflammatory processes might be 
different between the different donor types. Organs from living donors have a supe-
rior long-term outcome compared to organs from DBD- and DCD donors and express 
low levels of inflammatory genes. DBD donor kidneys and livers showed massive up-
regulation of inflammatory and injury genes while DCD donor organs showed only mild 
changes. In DBD donors IL-1β, IL-6, TNF-α, MCP-1, P-selectin and E-selectin were mas-
sively up-regulated immediately after retrieval combined with the increased expression 
of injury markers Kim-1 and p21. DCD donors showed only a mild up-regulation of these 
pro-inflammatory or injury genes. These differences may be relevant for tailor made 
therapy as a more effective treatment of the recipient based on donor type. Recipients 
receiving a DBD donor organ could be treated with anti-inflammatory therapies like 
methylprednisolone37 and dopamine13 to reduce the inflammatory response. In contrast, 
the treatment of DCD donor organs is mainly focused on reducing IRI by using machine 
perfusion or normothermic regional perfusion during abdominal organ retrieval to 
improve the outcome after transplantation38. In the future, treatment of both donor and 
recipient should be based on donor type to improve transplant outcome.
The mechanisms underlying the beneficial effects of dietary preconditioning on IRI 
are still a subject of investigation while various pathways, factors and genes have been 
proposed to play a central role in the protective effects25. We analyzed the transcriptome 
of kidneys and livers after feeding diets proven to be either protective or not protective 
against IRI. Transcription factors differentially regulated in kidneys after 2 weeks of 30% 
DR, three days of fasting and three days of protein-free diet, but not in the non-protective 
carbohydrate-free diet, were FOXO3, HNF4A and HMGA1. 
Phosphorylation of FOXO3 via the c-Jun N-terminal kinase (JNK)-pathway results in 
nuclear inclusion and activation, and regulates various processes involved in cellular 
stress resistance, biosynthesis, cell cycle regulation, apoptosis and autophagy39. The 
FOXO family interacts with retinoid metabolism via RXR, and is based on a co-stimulation 
of FOXO with PPAR. This forms a PPAR;RXR complex40. An indirect relation between FOXO 
and RXR can be established via HMGA1. The most important link between FOXO, RXR 
and HMGA1 is insulin signaling, because all factors are suggested to be regulators of 
the insulin-receptor signaling system. The beneficial effects of DR have been repeatedly 
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linked to the improvement of insulin sensitivity, and the link between FOXO, RXR and 
HMGA1 and insulin deserves further consideration41,42.
HNF4A plays a role in the development as well as metabolism of mainly the liver and 
kidney43,44. Up-regulation of HNF4A usually depends on the presence of low levels of 
stress, causing an interesting phenomenon called hormesis. Hormesis is a beneficial 
biological response to a low dose of stressors which leads to strong adaptive changes 
and alter signal transduction, transcription and translation45. The activity of HNF4A is in-
directly regulated by insulin through the action of FOXO145. Activation of HNF4A results 
in inhibition of metabolic factors like the mammalian target of Rapamycine (mTOR)46 
and SREBF. This leads to down-regulation of the metabolism, and might improve stress 
resistance. 
Our meta-analysis of pathways and transcriptions factors in kidneys indicates that 
30% DR, 3-day fasting and three days of a protein-free diet have a significant overlap in 
expressed genes and pathways, which are involved in stress resistance. Unfortunately, at 
this moment the transcription factors are not linked to one single pathway. 
After finding that three days of protein-free diet had the same robust protective effect 
on IRI, we investigated the role of single essential amino acid deficiency on hepatic IRI. 
Our results showed that all three investigated EAA-free diets protect against hepatic 
IRI. Our analysis showed that single EAA deprivation modifies the protective response 
at different levels. In line with previous results47, all three EAA-free diets induced up-
regulation of FOXO3, which is seen as one of the main contributors to the beneficial 
effects of dietary restriction on IRI39. 
Besides that, the EAA-free diets showed inhibition of the LXR/RXR pathway while via 
another pathway RXR was activated, showing an opposite effect. This might be part of 
a response tot the massive down-regulation of SREBF-2, as seen in all EAA-free diets, 
which is a main regulator of the LXR/RXR pathway48. When cellular sterol levels are low 
SREBF-2 is down-regulated, which leads to reduced LXR activity. Studies in mice showed 
that blocking SREBF-2 would be effective in preventing the development of hepatic ste-
atosis and insulin resistance49. Our studies suggest that inhibition of SREBF-2 might play 
a role in the protective effect on hepatic IRI. It would be interesting to induce hepatic IRI 
in a SREBF-2-/- mouse model, to see the effect on organ function and survival.
Another effect of EAA deprivation is inhibition of the cell cycle leading to regulation 
of the transcription factors FOXM1. FOXM1 is associated with cell proliferation and is 
only expressed in proliferating cells50. In cancer cells, FOXM1 is highly expressed and 
associated with cell proliferation and protect tumor cells against oxidative stress51,52. 
Therefore, inhibition of FOXM1 is a possible agent target in tumor therapy, since inhibi-
tion of FOXM1 dysregulates the G2/M cell phase division and might make tumor cells 
more vulnerable for oxidative stress51. Contradictory to the result we show, a knockdown 
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for FOXM1 made human stem cells more vulnerable for oxidative stress53. Therefore the 
role of FOXM1 in protection or inducing oxidative stress is not clear and shows conflict-
ing results. 
All three EAA-free diets induced a strong activation of NRF2, both on pathway- and 
on transcriptional level. NRF2 is a well-known factor in DR, IRI and stress-resistance45. 
We showed that NRF2 plays an important role in the protective effect against renal 
IRI in young male mice after DR as well as in aged obese mice following three days of 
fasting24,32,47. NRF2 is activated by phosphorylation of eIF2α, a pathway recently impli-
cated in the protection against IRI45. However, in our meta-analysis of the EAA-free diets, 
GCN2 and other target genes of the eIF2α pathway such as mTOR were not expressed. 
Phosphorylation of eIF2α via GCN2 contributes to the response seen by amino acid 
deprivation54,55. Besides that, GCN2 activation might be able to inhibit mTOR. Recently 
Harputlugil et al.56 showed that the protective effect of protein restriction is not based 
on activation of GCN2 but activation of mTOR repressor tuberous sclerosis complex 
(TSC). Activation of TSC improved insulin sensitivity prior to ischemia, increased survival 
and reduced apoptosis after reperfusion. Future studies should determine the roles 
of macro- and micronutrients on the transcription factors and pathways in protection 
against IRI.
We also studied the use of MSC as a therapeutic approach to reduce hepatic IRI and 
improve liver regeneration. The effects of MSC therapy are influenced by many variables 
like cell number, route of administration, time of infusion and the use of different animal 
models. This results in different outcomes after using MSC as a therapy in IRI and liver 
regeneration57-61. How MSC exert their therapeutic effects is not clear. Do MSC migrate 
to the damaged organ or do MSC have an immunomodulatory or regenerative effect? 
We showed that MSC disappear within 2 hours after intravenous infusion, which sug-
gests that MSC have immunomodulatory effects. MSC are able to inhibit lymphocyte 
proliferation and induce regulatory T and B cells62. Clinical trials showed that the use of 
MSC in humans is safe63-65. However, before MSC can be used as a therapy to reduce IRI 
and improve regeneration more research in large animal models and humans is needed. 
Research should be focused on the numbers of cells needed for a therapeutical effect, 
the route of administration and the exact time of infusion of the MSC. 
As mentioned before, preoperative fasting protects against renal and hepatic IRI in a 
healthy mouse model. We were curious if preoperative fasting also protects against renal 
IRI in a Fibulin-4 deficient mouse model. Heterozygous mice (Fibulin-4+/R) have a 2-fold 
reduced Fibulin-4 expression, which results in clear aberrations in elastin formation with 
occasionally small aneurysm formation and may therefore provide invaluable informa-
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tion regarding the early onset of aortic degeneration and the effect of stressors on blood 
vessel walls. Before the induction of renal IRI, Fibulin-4+/R mice showed signs of increased 
kidney injury compared to WT mice. Previous studies24,47,66 showed that preoperative 
fasting protects against renal IRI. However, Fibulin-4+/R mice were protected against 
short-term renal IRI and preoperative fasting could not improve this outcome. Two days 
of preoperative fasting improved kidney function and morphology in Fibulin-4+/R mice 
up to six months after renal IRI. These results suggest that patients with a history of 
aneurysms might not be more vulnerable to renal IRI and preoperative fasting could 
benefit these patients by reducing renal injury after IRI especially in the long-term.
In our heterozygote Fibulin-4+/R mouse model we studied the effect of renal IRI on 
kidney injury but we did not investigated if IRI induced the development of aneurysms 
and if preoperative fasting effects the formation of aneurysms. This could be relevant 
for patients with a (familiar) history of aneurysms. The expression of Fibulin-4 in human 
aortic walls of aortic dissection was decreased67. 
Conclusion
We found that DBD- and DCD donation induces a different inflammatory response and 
might need different therapeutical strategies to optimize donor quality. Besides that, 
we showed that a short-term protein-free or EAA-free diet protects against IRI in both 
kidney and liver. We attempted to unravel the underlying mechanisms of these protec-
tive diets, and found overlapping transcription factors and pathways that are possibly 
implicated in the protective response. More research is warranted to further elucidate 
the mechanisms underlying the protection of IRI by dietary preconditioning, which may 
ultimately lead to ‘dietary restriction mimetic’ therapeutic strategies that exploit the 
benefits of dietary restriction in humans. 
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Orgaantransplantatie biedt de beste kans op verbetering van kwaliteit van leven en 
overleving bij patiënten met eindstadium orgaanfalen. Helaas wordt het succes van 
deze behandeling overschaduwd door het tekort aan donororganen. Het aantal patiën-
ten op de wachtlijst voor een donororgaan neemt toe, terwijl het aanbod van donoror-
ganen achterblijft. Het is dan ook noodzakelijk dat meer mensen in aanmerking komen 
als orgaandonor. Dit betekent dat er niet alleen organen van levende en hersendode 
donoren gebruikt worden, maar soms ook van hartdode donoren en donoren die bui-
ten de ‘normale’ strikte regels vallen. Donoren die buiten de normale regels vallen zijn 
ouder dan 60 jaar of tussen de 50-59 jaar met 2 of meer van de volgende risicofactoren; 
hypertensie, serum kreatinine levels hoger dan 1.5mg/dL of overlijden ten gevolgen van 
een cerebrovasculaire oorzaak 
Het succes van orgaantransplantatie wordt beperkt door het optreden van ischemie-
reperfusie (I/R) schade tijdens de transplantatie. Tijdens ischemie is er spraken van 
zuurstoftekort, een gebrek aan voedingsstoffen en een opstapeling van afvalstoffen. 
Reperfusie is het herstellen van de bloedtoevoer waarbij zuurstofradicalen vrij komen. 
I/R schade heeft grote gevolgen voor de kwaliteit en levensduur van het donororgaan, 
en daarmee ook voor de overleving van de patiënt. Op dit moment is er geen behande-
ling of methode beschikbaar om I/R schade te voorkomen of te verminderen. 
In dit proefschrift hebben wij onderzocht of het pre-conditioneren van het donororgaan 
door middel van diëten of stamcellen bescherming biedt tegen I/R schade. Daarnaast 
hebben wij de genexpressie profielen van organen afkomstig van de verschillende 
donortypen (levende, hersendode en hartdode donoren) in kaart gebracht. 
In hoofdstuk 2 geven wij een overzicht van experimentele en klinische studies waarin 
verschillende manieren zijn onderzocht om I/R schade van de donornier te vermind-
eren of te voorkomen. Pre-conditionering met behulp van een dieet, preservatie van 
het orgaan, ischemische pre- en post-conditionering, celtherapie, medicamenteuze 
behandeling en het gebruik van microRNAs zijn onderzocht als mogelijke behandeling 
om renale I/R schade te voorkomen of te verminderen. Deze behandelingen, met als 
doel I/R schade van de donornier te verminderen, kunnen plaatsvinden in de donor én 
de ontvanger voor, tijdens of na transplantatie. Ondanks de veelbelovende resultaten 
in diermodellen, is het vertalen van deze resultaten naar de kliniek moeizaam. Het 
mechanisme onderliggend aan I/R schade is niet volledig bekend. Het ontrafelen van dit 
mechanisme kan nieuwe aangrijpingspunten in de behandeling van I/R schade aan het 
licht brengen. Daarnaast moet met het oog op klinische toepasbaarheid de interven-
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ties die succesvol lijken in  diermodellen vertaald worden naar de humane setting met 
behulp van randomized controlled trials. 
Genexpressie in verschillende type donoren
De toenemende vraag naar donororganen en het achterblijvende aanbod heeft ervoor 
gezorgd dat er verschillende typen donoren gebruikt worden. Nieren van levende 
donoren worden blootgesteld aan minimale warme en koude ischemie tijden, wat re-
sulteert in de meest optimale kwaliteit van de donornier vergeleken met hersendode en 
hartdode donornieren. Nieren van hersendode donoren ondergaan hemodynamische 
en hormonale veranderingen wat leidt tot orgaanschade, verminderde postopera-
tieve nierfunctie en verkorte levensduur van het transplantaat vergeleken met nieren 
afkomstig van levende donoren. Hartdode donornieren hebben een langere warme 
ischemie tijd en een hogere incidentie van delayed graft function (DGF). Ondanks de 
hogere incidentie van DGF vergeleken met de donornieren van hersendode donoren, is 
de levensduur van de nier gelijk. De pathofysiologie van hersendode donoren is goed 
in kaart gebracht en mogelijke behandelingen om de kwaliteit van de donororganen 
te verbeteren dienen zich aan. Als het om hartdode donoren gaat is er echter weinig 
informatie betreffende de pathofysiologie. In hoofdstuk 3, vergelijken we de mRNA 
expressie van genen representatief voor inflammatie, schade en bescherming tijdens 
uitname, na klinisch relevante koude ischemie tijden en gedurende koude opslag tus-
sen levende, hersendode en hartdode donornieren in een rat model. 
Opvallend in onze studie is het verschil in expressie van inflammatoire genen tussen 
hersendode en hartdode donoren. Expressie van de inflammatoire genen IL-1b, IL-6, TNF-
a, MCP-1, TLR4, P-selectin en E-selectin was sterk verhoogd in hersendode donornieren, 
terwijl in hartdode donornieren deze genen in mindere mate waren verhoogd. Ondanks 
de sterk verhoogde expressie van inflammatoire genen in hersendode donornieren, is 
de incidentie van DGF hoger in hartdode donornieren terwijl de uiteindelijkel evensduur 
van de donornier gelijk is. Mogelijk spelen andere factoren hierbij een rol. Naast een 
stijging van de expressie van inflammatoire genen, vonden wij dat ook de markers voor 
schade, Kim-1 en p21, verhoogd waren net als het beschermende gen HO-1. In levende 
donoren was een verhoogde expressie van HO-1 geassocieerd met een beschermend 
effect op renale I/R schade. De verhoogde expressie van HO-1 in hersendode donor-
nieren, was echter niet in staat de I/R schade te beperken. Hersendode donornieren 
lopen waarschijnlijk zodanig veel schade op, dat verhoogde expressie van HO-1 niet 
voldoende is om nierschade te reduceren. De hoogte van HO-1 lijkt wel indicatief voor 
de mate van schade. Na koude ischemie, blijven de gen expressie levels stabiel in alle 
donortypen. Desondanks, neemt in zowel hersendode als hartdode donornieren, het 
aantal apoptotische cellen toe ten opzichte van het aantal apoptotische cellen aanwezig 
bij uitname van het donororgaan.
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Concluderend, laten wij zien dat in nieren die afkomstig zijn van een hersendode 
donor, de expressie van inflammatoire, schade-geassocieerde en beschermende genen 
enorm verhoogd is vergeleken met levende en hartdode donornieren. Deze gen expres-
sie blijft stabiel tijdens en na koude preservatie. Deze resultaten suggereren dat DGF in 
nieren van hartdode donoren minder schadelijk is, dan DGF in hersendode donoren. In 
hersendode donoren kan anti-inflammatoire therapie mogelijk een behandelmethode 
zijn om de orgaankwaliteit te optimaliseren.
Na de opvallende verschillen tussen de expressie levels van inflammatoire, bescher-
mende en schade markers tussen hersendode en hartdode donornieren, vroegen wij 
ons af of deze bevindingen orgaan specifiek zijn. Daarom hebben wij in hoofdstuk 4, de 
genexpressie profielen onderzocht in donorlevers afkomstig van levende, hersendode 
en hartdode ratten op het moment van uitname, na klinisch relevante koude ischemie 
tijden en gedurende koude preservatie. Levers van hartdode donoren hebben een 11 
keer hogere kans op het ontwikkelen van ischemische galweg schade en een 1.85 keer 
hogere kans op orgaan falen ten opzichten van hersendode donoren. 
Direct na uitname van levers afkomstig van hersendode donoren waren de inflam-
matoire genen IL-6, IL-1b, TNF-a, P-selectin en E-selectin sterk verhoogd, terwijl in 
hartdode donorlevers de vroege markers voor inflammatie, MCP-1, HMGB1 en TLR4 
verhoogd waren. De donorlevers afkomstig van levende donoren lieten géén verhoging 
zien van de inflammatoire genen. Ondanks de lagere expressie waarden van inflam-
matoire genen in hartdode versus hersendode leverdonoren, was de postoperatieve 
uitkomst van hartdode donorlevers slechter. De langdurige warme ischemie waaraan 
hartdode donorlevers worden blootgesteld is mogelijk de reden waarom HMGB1, een 
marker voor algemene orgaanschade, verhoogd is direct na uitname van de lever. 
Daarnaast wordt MCP-1 gezien als een vroege inflammatoire marker en zijn verhoogde 
MCP-1 waarden in patiënten postoperatief geassocieerd met een slechte orgaanfunctie. 
Daarnaast draagt MCP-1 mogelijk bij aan de ontwikkeling van galgangatresie. Na koude 
ischemie bleven de vroege inflammatoire markers MCP-1, TLR4 en HMGB1 verhoogd 
in hartdode donorlevers terwijl in hersendode donorlevers de inflammatoire genen 
verhoogd bleven. Tijdens de 12 uur durende koude preservatie bleven de mRNA expres-
sie levels stabiel in levende donorlevers terwijl in hersendode en hartdode donorlevers 
subtiele veranderingen in expressie van Hif-1a, Bcl-2 en HMGB1 plaatsvond. Hartdode 
donorlevers hadden een significant hoger aantal apoptotische cellen vergeleken met 
hersendode levers direct na uitname. Tijdens koude preservatie veranderde het aantal 
apoptotische cellen niet. Het hoge aantal apoptotische cellen in hartdode donorlevers 
is mogelijk een verklaring voor de slechtere postoperatieve uitkomst ondanks de lage 
expressie van de inflammatoire genen. Onze studie laat zien dat in levers afkomstig van 
hersendode en hartdode donoren de genexpressie profielen anders zijn. Dit suggereert 
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dat het onderliggende schade inducerende mechanisme in hersendode en hartdode 
donoren verschillend is. Deze uitkomsten zijn relevant voor een effectievere behande-
ling van de ontvanger aangepast aan donortype.
Nutritionele preconditionering
Dieet restrictie (DR) is een reductie in voedselinname zonder dat er sprake is van onder-
voeding. Van langdurige DR is het bekend dat het, in verschillende soorten organismen, 
een toename geeft van de levensverwachting, verbetering van de gezondheid en 
verhoogde resistentie tegen schade veroorzaakt door zuurstofradicalen. Omdat renale 
I/R schade in belangrijke mate wordt veroorzaakt door zuurstofradicalen hebben wij 
onderzocht of DR hiertegen kan beschermen. In voorgaande onderzoeken hebben wij 
laten zien dat kortdurende DR voor inductie van I/R schade, namelijk 2 en 4 weken 30% 
DR, en 3 dagen vasten, de nierfunctie verbetert en de morbiditeit en mortaliteit in een 
muismodel van renale I/R schade vermindert. Of deze bescherming gebaseerd is op de 
reductie in het aantal calorieën of de bron van de calorieën is onduidelijk. In hoofdstuk 
5 onderzoeken wij of een eiwit-, koolhydraat- of vetvrij dieet bescherming biedt tegen 
renale I/R schade. 
Zowel een preoperatief eiwitvrij dieet gedurende 3 dagen, 30% DR en 3 dagen vasten 
bieden bescherming tegen renale I/R schade, terwijl een koolhydraat- en vetvrij dieet 
geen bescherming bieden tegen renale I/R schade. De beschermende diëten laten 
een significante overlap zien tussen de mRNA transcriptie profielen en mechanismen, 
welke mogelijk een rol spelen in de bescherming tegen oxidatieve schade die ontstaat 
na renale I/R schade. Een meta-analyse van transcriptie factoren laat zien dat in de 
beschermende diëten de expressie van in elk geval vier transcriptie factoren verhoogd 
is (FOXO3, HNF4A, HMGA1 en HSF1), welke op hun beurt verschillende mechanismen 
kunnen activeren die een rol spelen bij de bescherming tegen oxidatieve schade. In de 
literatuur is een link tussen deze transcriptiefactoren en mechanismen betrokken bij 
stress resistentie gemaakt. Echter, meer onderzoek is nodig om een volledig beeld te 
krijgen van de onderliggende mechanismen die een rol spelen bij het beschermende 
effect van pre-conditionering middels DR, vasten of een eiwitvrij dieet met als ultiem 
doel het ontwikkelen van een behandeling om I/R schade te voorkomen/verminderen 
in het menselijk lichaam.
In muizen biedt preoperatief 2 weken 30% DR of 3 dagen vasten niet alleen bescherming 
tegen renale I/R schade maar ook tegen I/R schade van de lever. Wij hebben laten zien 
dat een preoperatief eiwitvrij dieet gedurende 3 dagen bescherming biedt tegen renale 
I/R schade (hoofdstuk 5). In hoofdstuk 6 bestuderen wij het effect van een preoperatief 
essentieel aminozuur (EAA) vrij dieet op hepatische I/R schade en hebben wij getracht 
het specifieke onderliggende mechanisme van bescherming in kaart te brengen. Drie 
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dagen voor het induceren van hepatische I/R schade kregen muizen een methionine 
(Met)-, leucine (Leu)- of tryptofaan (Trp) vrij dieet. Alle drie de EAA-vrije diëten lieten 
minder leverschade zien na het induceren van I/R schade vergeleken met muizen die 
een normaal dieet kregen. Opvallend is dat een Met-vrij dieet een meer geleidelijke 
respons liet zien en een Leu- en Trp-vrij dieet direct een beschermend effect lieten zien. 
Deze verschillen zijn ook zichtbaar in de microarray analyse, waarbij de respons op het 
Met-vrije dieet minder sterk was ten op zichten van de respons op zowel het Leu- als 
het Trp-vrije dieet. Het Met-vrije dieet heeft invloed op het minste aantal transcriptie 
factoren, de microarray analyse kon op deze manier versmald worden. Uit deze analyse 
komen een aantal overlappende transcriptiefactoren naar voren zoals NRF2, FOXM1, 
SREBF2 en SMARCB1. Helaas hebben deze transcriptie factoren invloed op meerdere 
mechanismen en is er niet één overkoepelend mechanisme. Er is meer onderzoek nodig 
naar het exacte onderliggende mechanisme om in de toekomst een behandeling te 
vinden die mensen bescherming biedt tegen I/R schade.
Het effect van mesenchymale stamcellen 
De lever heeft als unieke eigenschap dat het in staat is te regenereren na schade. Dankzij 
deze eigenschap en verbeterde chirurgische technieken, zijn leverresectie en -transplan-
tatie middels een levende donor mogelijk. Tijdens leverresectie en –transplantatie is I/R 
schade niet te voorkomen. Hepatische I/R schade vermindert de regeneratieve functie 
van de hepatocyten en kan leiden tot necrose en apoptose. I/R schade is een risicofac-
tor voor een verhoogde morbiditeit en mortaliteit na levertransplantatie en -resectie. 
Therapieën die in staat zijn I/R schade te verminderen kunnen bijdragen aan een betere 
postoperatieve uitkomst. Mesenchymale stamcellen (MSC) zijn in staat te differentiëren 
in verschillende celtypen, scheiden groeifactoren uit en hebben immunomodulatoire 
en anti-inflammatoire eigenschappen. Dankzij deze eigenschappen worden MSC als 
mogelijke behandeling gezien om I/R schade te voorkomen of te verminderen en re-
generatie te stimuleren. 
In hoofdstuk 7 hebben wij in de muis onderzocht of na een combinatie van hepati-
sche I/R schade en partiële hepatectomie (PH), MSC in staat zijn I/R schade te vermin-
deren en regeneratie te bevorderen. Intraveneuze toediening van 2x105 MSC 2 uur voor 
inductie van hepatische I/R schade en PH resulteerde, 6 uur postoperatief, in significant 
lagere ASAT en ALAT waarden vergeleken met de onbehandelde controle groep. Echter, 
intraveneuze toediening van MSC voor of na I/R schade en PH liet geen reductie zien van 
de hoeveelheid levernecrose. Ook werd er geen effect gezien van MSC op regeneratie. 
Door middel van 3D cryo-imaging laten wij zien dat intraveneus toegediende MSC niet 
naar de plek van leverschade migreren maar vastlopen in de microcapillairen van de 
longen, en een korte levensduur hebben. Mochten MSC een effect hebben dan is het 
een paracrien effect aangezien MSC niet migreren naar de plek van schade.
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Intraveneuze toediening van 2x105 MSC 2 uur voor of 1 uur na I/R schade en PH laat 
geen beschermend effect zien op I/R schade en/of lever regeneratie. Daarnaast migre-
ren intraveneus toegediende MSC niet naar de lever maar lopen vast in de microcapil-
lairen van de longen en verdwijnen binnen 2 uur. Om MSC in de toekomst als potentiele 
behandeling te gebruiken is onderzoek nodig naar de variabelen die van invloed zijn op 
de werking van MSC en de betrouwbaarheid hiervan.
Heterozygote Fibuline-4 muis
Aneurysmata van de aorta ontstaan onder andere door een defect in de extracellulaire 
matrix. Fibuline-4 is een glycoproteine dat zorgt voor stabiliteit en structuur van de 
extracellulaire matrix en speelt een belangrijke rol in de elasticiteit van de vaatwand. 
Defecten in Fibuline-4 kunnen dan ook zorgen voor aneurysmavorming. Een muis die 
homozygoot is voor een mutatie in het Fibuline-4 gen, heeft een Fibuline-4 expressie 
die vier keer lager is dan die van wild type muizen. Deze muizen laten een chaotisch 
netwerk zien van elastische vezels in de vaatwand, krijgen een sterk verwijde en 
stijve aortawand, en overlijden aan cardiovasculaire complicaties voor het bereiken 
van de volwassen leeftijd. Heterozygote Fibuline-4 (Fibulin-4+/R) muizen hebben een 
tweemaal lagere expressie van Fibuline-4, dat zich kan uiten in het ontstaan van kleine 
aneurysmata op latere leeftijd. Dit muismodel biedt daardoor de mogelijkheid om het 
effect van oxidatieve stress te onderzoeken op de vaatwand en de gevolgen hiervan 
op orgaanfunctie. Bij 8-20% van de aneurysmata zijn de nierarteriën betrokken en is 
endovasculaire behandeling geen optie. Hierdoor ondergaat 1 op de 5 patiënten met 
een pararenaal aneurysma een open chirurgische behandeling. Patiënten met een ver-
minderde Fibuline-4 expressie hebben mogelijk een verhoogd risico op een slechtere 
postoperatieve uitkomst wat zich kan uiten in een verminderde nierfunctie. 
Renale I/R schade is onvermijdelijk bij de open behandeling van pararenale aneu-
rysmata en is een risicofactor voor het ontwikkelen van acuut nierfalen. Voorgaande 
studies hebben laten zien dat preoperatief vasten een beschermend effect heeft op 
renale I/R schade. Vanwege deze redenen gebruiken wij in hoofdstuk 8 het Fibuline-4+/R 
muismodel, om te zien of een reductie in Fibuline-4 expressie invloed heeft op de mate 
van I/R schade op korte en lange termijn. Daarnaast onderzochten wij  het effect van 
preoperatief vasten in Fibuline-4+/R muizen. Vasten verbeterde de survival, nierfunctie en 
het postoperatieve herstel vergeleken met wild type ad libitum (AL) gevoerde muizen. 
Opvallend was dat AL gevoerde Fibuline-4+/R muizen beschermd waren tegen renale I/R 
schade vergeleken met wild type muizen, en dat preoperatief vasten geen additioneel 
verbeterend effect had op I/R schade. 
Zes maanden na het induceren van renale I/R schade waren de wild type 
en Fibuline-4+/R muizen die gevast hadden allemaal nog in leven, vergeleken met 60% 
van de normaal gevoerde muizen. De gevaste wild type en Fibuline-4+/R muizen hebben 
Nederlandse samenvatting
201
lagere serum ureum waarden vergeleken met hun AL controles. Daarnaast zijn de nieren 
van AL gevoede Fibuline-4+/R muizen kleiner, dystrofisch en een aantal van hen laat (nier)
cysten zien. Geen van deze afwijkingen werd gezien in nieren van gevaste wild type of 
Fibuline-4+/R muizen. Histologie liet significant minder tubulaire schade en fibrose zien 
in nieren afkomstig van gevaste wild type en Fibuline-4+/R muizen. 
Matrix Metalloproteinases (MMPs) zijn verantwoordelijk voor het herstructureren van 
de extracellulaire matrix. Ze activeren onder andere cytokines, chemokines en groei-
factoren. Zes maanden na het induceren van renale I/R schade was de MMP expressie 
in gevaste Fibuline-4+/R muizen verhoogd vergeleken met AL gevoerde Fibuline-4+/R 
muizen. In wild type AL gevoerde of gevaste muizen was er geen significant verschil 
in MMP expressie. In de literatuur is de rol van MMPs tegenstrijdig, dit suggereert dat 
MMPs in de acute fase na I/R schade mogelijk een andere rol spelen dan op de lange 
termijn. Een verhoogde MMP expressie is gerelateerd aan renale fibrose. Wij laten zien 
dat gevaste Fibuline-4+/R muizen een verhoogde MMP expressie hebben en significant 
minder fibrose hebben vergeleken met AL gevoerde Fibuline-4+/R muizen. Mogelijk 
speelt over-expressie van MMP in de herstelfase een rol in de regeneratie van de be-
schadigde nier. 
Concluderend verbeterde, 2 dagen preoperatief vasten de nierfunctie op korte en 
lange termijn in wild type muizen. Ondanks de verminderde expressie van Fibuline-4, 
waren Fibuline-4+/R muizen beschermd tegen renale I/R schade en ontstonden er geen 
aneurysmata. Deze resultaten suggereren dat patiënten met een familiaire voorgeschie-
denis van aneurysmata geen verhoogd risico hebben op een ernstiger beloop na renale 
I/R schade, terwijl preoperatief vasten de mate van I/R schade kan reduceren.
Conclusie
In organen van hersendode en hartdode donoren is sprake van een verschillend inflam-
matoir proces. Mogelijk zijn hierdoor de therapeutische behandelingen om de donor 
kwaliteit te optimaliseren verschillend. 
Daarnaast hebben wij aangetoond dat een preoperatief eiwitvrij dieet gedurende 3 
dagen bescherming biedt tegen zowel renale als hepatische I/R schade. Doormiddel 
van microarray analyses hebben wij getracht het onderliggende mechanismen te on-
trafelen. De verschillende beschermende diëten laten een overlap zien in een aantal 
transcriptiefactoren en meerdere mechanismen die mogelijk betrokken zijn bij het 
beschermende effect. Meer onderzoek is nodig om het onderliggende mechanisme in 
kaart te brengen, wat uiteindelijk kan leiden tot een behandeling in de kliniek. 
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Dankwoord
Het heeft ‘even’ geduurd maar het is eindelijk zo ver, mijn proefschrift is af! Dit proef-
schrift is tot stand gekomen door de steun, betrokkenheid en inzet van velen. Een aantal 
mensen wil ik in het bijzonder bedanken.
Mijn promotor, beste prof. dr. J.N.M. IJzermans, na het doen van mijn keuzeonderzoek 
als onderdeel van de studie geneeskunde kreeg ik de kans om als promovenda aan de 
slag te gaan bij de afdeling Heelkunde. Dankzij de vrijheid en het vertrouwen dat ik 
kreeg kon ik de eerste twee jaar van mijn promotieonderzoek combineren met wed-
strijdroeien, het beste van twee werelden, waarvoor veel dank!
Mijn copromotor, dr. R.W.F. de Bruin, beste Ron, hartelijk dank voor jouw begeleiding 
tijdens de eindeloze experimenten, de bemoedigende woorden tijdens tegenslagen 
en je oneindige geduld. Dat laatste is zeker niet mijn beste eigenschap en tijdens mijn 
promotietraject flink op de proef gesteld. Desondanks had jij er altijd vertrouwen in dat 
het ‘ooit’ goed zou komen, gelukkig had je gelijk en is het dan eindelijk zo ver! 
Dr. M. Hoogduijn, beste Martin, het kweken van mesenchymale stamcellen bleek een 
uitdaging. Gelukkig was jij, samen met jouw team, bereid om te helpen. Hartelijk dank 
voor de prettige samenwerking, je hulp bij het schrijven van het artikel en je deelname 
in de commissie. 
Dr. J. Essers, beste Jeroen, hartelijk dank voor de samenwerking tussen onze beide 
laboratoria. Jouw kritische vragen zijn van groot belang geweest bij het uitvoeren van 
de experimenten en het schrijven van het artikel. Bedankt voor je deelname in de com-
missie.
Dr. M.E.T. Dolle, beste Martijn, de microarray analyses en bijbehorende fenotypische 
data zijn de meest bediscussieerde onderdelen van mijn proefschrift. Inmiddels is er een 
mooie publicatie uit voortgekomen. Heel erg bedankt voor alle hulp en je deelname in 
de commissie. Ik wil ook alle betrokkenen van het RIVM bedanken voor alle hulp.
Ik wil prof. dr. H.J. Metselaar, prof. dr. C.C. Baan en prof. dr. H.G.D. Leuvenink hartelijk dan-
ken voor het beoordelen van mijn proefschrift en voor hen deelname in de oppositie. 
Dr. I. van der Pluijm, beste Ingrid, het leek zo simpel om preoperatief vasten en renale 
ischemie-reperfusie schade toe te passen in heterozygote Fibuline-4 muizen. Toch bleek 
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dit nog veel voeten in aarde te hebben.  Bedankt voor het laagdrempelige overleg, je kri-
tische blik, hulp bij het analyseren van de vele data en het schrijven van het manuscript. 
Alle overige co-auteurs van de publicaties in dit proefschrift: veel dank voor jullie bij-
drage en kritische blik.
Ik wil alle collega’s van het laboratorium voor Experimentele Chirurgie bedanken voor de 
gezellige tijd, hulp bij het brainstormen en uitvoeren van de experimenten. Daarnaast 
wil ik alle collega’s bedanken die de afgelopen jaren op  kamer Ee-173 hebben gezeten!
Mariëlle, bedankt voor de begeleiding tijdens mijn keuzeonderzoek, dit is de basis ge-
weest voor mijn promotie!  Met name ben ik dankbaar voor de tip om alle data netjes te 
ordenen, hierdoor kan ik zelfs van de eerste experimenten alle data terugvinden!
Sandra, vanaf het eerste moment heb jij mij geholpen met het uitvoeren van alle experi-
menten. Mijn ambitieuze, strakke planningen zag jij als een uitdaging. Samen lukte het 
ons altijd alles binnen de tijd af te krijgen! Heel veel dank voor al je hulp en gezelligheid! 
Gisela, jij kwam bij ons op het lab werken toen ik eigenlijk al ‘klaar was’, echter moest er 
zo nu en dan toch nog iets aanvullends gedaan worden en het liefst snel. Bedankt voor 
je hulp in de laatste fase van mijn promotietraject. 
Sander en Eline, vanaf het begin mijn partners in crime op ‘Labje #1’. Ik wil jullie vooral 
bedanken voor het lachen! Sander, jouw zomerse hitjes en relaxte humeur waren een 
(welkome) afleiding. Eline, ons gezamenlijke doel om Sander met regelmaat voor de gek 
te houden zorgde altijd voor een boel voorpret! Veel succes met jullie  carrière. 
Franny, eindelijk is het af! De twee stukken die wij samen hebben geschreven zijn denk 
ik de meest besproken (hoofdpijn) stukken van mijn boekje. Het leek soms of er nooit 
een eind aan zou komen; hier wat toevoegen, daar weer wat af, nieuwe analyses, ga 
zo maar door. Mede dankzij jouw doorzettingsvermogen is het toch gelukt! Heel veel 
succes met het afronden van je promotie onderzoek!   
Maren, mijn allerliefste roomie, zonder jou als paranimf zou mijn promotie niet compleet 
zijn. Als huisgenoten begonnen en als soulmates geëindigd! De vele koppen koffie, al-
coholische versnaperingen, urenlange gesprekken en bovenal het lachen samen (helaas 
snapt niet iedereen onze humor) zijn mij zeer dierbaar. Ik hoop op nog vele jaren lachen 
samen. Er bestaat geen twijfel dat jij jouw promotieonderzoek bij de MDL tot een goed 
einde gaat brengen en een fantastische MDL-arts zal worden! 
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Christa, lief vriendinnetje, wie had ooit gedacht dat je van ‘korfbal vriendinnetje’ naar 
paranimf zou promoveren?! Ondanks dat je geen idee had wat een paranimf was, zei 
je zonder enige twijfel JA! Ruim 20 jaar kennen wij elkaar, partners in crime op de mid-
delbare school, tijdens schoolfeesten en later in Rotterdam! Jouw optimisme, relative-
ringsvermogen, kracht en humor zijn heerlijk! Met jou wil ik nog lang ‘viben’ en Berlijn 
onveilig maken!
Lieve meiden, mijn tweede familie, het is eindelijk zover: we kunnen aan de champagne! 
Sinds de middelbare school zijn jullie mijn trouwste vriendinnen. Lief en leed delen 
wij inmiddels ruim 15 jaar met elkaar. De afgelopen jaren zijn mijn frustraties omtrent 
onderzoek met regelmaat besproken tijdens de borrel. Ik ben ontzettend trots dat ik 
het eindresultaat met jullie mag delen en dat jullie een keer op mijn kosten kunnen 
borrelen! Op naar meer herinneringen, avonturen en dansjes!
Lief broertje, lieve Rein, ‘waarom doe je iets wat je niet leuk vindt’, waren jouw woorden 
tijdens mijn klaagzang over onderzoek. Jouw nuchtere kijk op dingen is voor mij als 
control freak soms lastig te volgen. Jouw (Rotterdamse) uitspraken, belevenissen en 
humor zijn bij ons thuis legendarisch en zorgen met regelmaat voor buikpijn van het 
lachen. Ik ben trots op jou als grote, kleine broer! 
Lieve paps en mams, één ding is zeker, zonder jullie onvoorwaardelijke liefde en steun 
zou dit boekje er niet zijn. Ik weet niet wie er meer opgelucht is dat het af is, jullie of ik. 
Niet alleen tijdens mijn studie en onderzoek maar ook langs de roeibaan waren jullie 
mijn trouwste supporters. Paps, onze fietstripjes blijven voor mij het hoogtepunt van 
het jaar, hoe gaaf dat wij dit samen delen! Gezellige gesprekken, scheldend een berg op 
fietsen (ik dan) en heel veel lachen! Ik kijk uit naar onze volgende uitdaging! 
Mams, jij ben oprecht de allerliefste moeder ooit, niks is te gek voor jou. Bevriezen in 
Boston omdat ik in de sneeuw moet roeien, de auto overvol laden met Ikea spullen of 
last minute mee willen eten, alles kan! Lieve ouders, dankzij jullie liefdevolle opvoeding, 
arbeidsethos en no-nonsens instelling ben ik zo ver gekomen! Bedankt voor al jullie 
hulp en steun de afgelopen tijd! Ik ben zo ontzettend trots op jullie! 
Allerliefste Hugo, eindelijk is het veel besproken boekje af! Ik wil je heel erg bedanken 
voor je eeuwige geduld, relativeringsvermogen en bovenal je steun. Letterlijk en figuur-
lijk hou jij mij uit de wind. Met jou deel ik mijn passie voor sport kijken en zelf sporten, 
voor ons is de Tour de France kijken een full time job. Ik ben benieuwd welke sportieve 
uitdaging je nu weer aan gaat, jij kan alles! Het leven met jou samen is zoveel leuker! 
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Tanja Charlotte Saat werd geboren op 1 juli 1988 te Rotterdam, Nederland. In 2006 
slaagde zij voor haar VWO-eindexamen aan het Emmauscollege te Rotterdam. Via de 
Decentrale Selectie werd zij toegelaten tot de studie geneeskunde aan de Erasmus 
Universiteit in Rotterdam. Na het behalen van haar Doctoraal in 2010, begon zij als 
onderzoeker aan haar promotieonderzoek bij de afdeling experimentele chirurgie aan 
de Erasmus Universiteit te Rotterdam onder leiding van prof. J.N.M. IJzermans en dr. 
R.W.F. de Bruin. Tijdens haar studie werd zij lid bij de Algemene Rotterdamse Studenten 
Roeivereniging Skadi waar haar passie voor roeien ontstond. Zij ging wedstrijdroeien en 
heeft dit fanatiek gedaan tijdens haar studie en eerste jaren van haar promotieonder-
zoek. De liefde voor sport kijken en zelf sporten is blijven bestaan.
In augustus 2014, na drie maanden reizen door China, Tibet en Nepal, ging zij verder 
met de studie geneeskunde en begon zij aan haar coschappen. Haar oudste coschap 
heeft zij bij de chirurgie in het Maasstad gevolgd, haar keuze-coschap op de Maag-, 
Darm-, Leverafdeling in het Erasmus MC. Na het behalen van haar artsexamen in 2016 
is zij begonnen als ANIOS bij de Interne geneeskunde in het Franciscus Gasthuis. Zij wil 
uiteindelijk graag Maag-, Darm-, Leverarts worden.
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Name PhD student:  Tanja Charlotte Saat 
PhD period:   November 2010 – December 2013
Erasmus MC Department: Surgery  Promotor: Prof. dr. J.N.M. IJzermans
Research School: Molecular Medicine Co-promotor: Dr. R.W.F. de Bruin
1. PhD training
Year Workload (ECTS)
General courses
- Laboratory animal science 2011 5.7
- Biomedical English Writing (short) 2011 2.0
- Basic introduction course on SPSS 2011 1.0
Seminars and workshops
- Photoshop and Illustrator CS4 workshop 2011 0.3
- Presenting Skills for Scientists 2011 1.0
Presentations
- National conferences 2010 1.0
2011 4.0
2012 2.0
2013 2.0
2014 1.0
- International conferences 2011 1.0
2013 7.0
2. Teaching activities
- Supervising Bachelor thesis (Higher Laboratory education) 2013 5.0
- Supervising Bachelor thesis (Higher Laboratory education) 2013 5.0
- Supervising Bachelor thesis (Higher Laboratory education) 2014 5.0
